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Recent advances in the area of nanotechnology have led to interesting applications of 
nanomaterials in medicine, especially in the areas of imaging and treatment. This thesis 
presents the development of two molecularly imprinted polymers (MIPs) based on the 
same fluorescent functional monomer. One MIP, prepared in the bulk format, is 
investigated for its ability to detect tamoxifen and its metabolites. The other MIP 
synthesised in the nanogel format, holds the potential to be used as pH-responsive drug 
delivery system.  
Four objectives were identified within this project. The first was the design and synthesis 
of fluorescent functional monomer. Two coumarin derivatives carrying a polymerisable 
unit, for covalent bonding within the polymer, and a carboxylic moiety, for interaction 
site with the template, were synthesised and characterised. However, only one of them 
(the VCC: 6-vynilcoumarin-4-carboxylic acid) showed high fluorescent yield and was 
selected as functional monomer. The second objective involved the development of a 
detection system based on bulk MIP containing the VCC fluorescent monomer. This 
system proved effective in generating a detectable signal upon binding the analytes. The 
signal was observed as a quenching of the polymer fluorescence and it was proportional 
to the amount of target molecules detected. The third objective was the preparation of 
tamoxifen-imprinted nanogels for potential application in the drug delivery field. The 
optimisation of the procedure gave a set of NIP/MIP with the desired solubility, particle 
size and fluorescence emission. These nanogels were then employed in the last objective, 
which involved the toxicity study and evaluation of the drug loading on of transgenic line 
of zebrafish. The nanogels were non-toxic at the tested concentrations and the presence 
of tamoxifen was confirmed. 
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°C = Celsius degree 
13C = carbon, isotope 13 in NMR 
1H = proton in NMR 
4-OHT = 4-Hydroxytamoxifen 
ACN = acetonitrile 
AIBN = azobisisobutyronitrile 
CLO = clomiphene 
CM = monomer concentration 
COSY = correlation Spectroscopy 
DCM = dichloromethane 
DDS = drug delivery system 
DLS = dynamic light scattering 
DMF = dimethylformamide 
DMSO = dimethylsulfoxide 
dpf = days post fertilisation 
EBA = N,N' - ethylenebis(acrylamide) 
eq = equivalents 
EtOAc = ethyl Acetate 
FM = functional monomer 
FM-PX = nanogels formulations, where 
X is the number of the preparation 
GC-MS = gas chromatography-mass 
spectrometry  
HCl = hydrochloric acid  
hpf = hours post fertilisation 
HPLC = high Performance Liquid 
Chromatography 
JH-H = vicinal proton coupling constant  
KDa = kilo Dalton 
LC-MS = liquid chromatography-mass 
spectrometry   
MBA = N,N'-methylenebis(acrylamide) 
MeOH = methanol 
MIP = molecularly imprinted polymer 
mmol = millimoles 
mol = moles 
N2 = nitrogen gas 
NaHCO3 = sodium bicarbonate 
NIP = non-imprinted polymer 
NIPAM = N-isopropylacrylamide  
nm = nanomoles 
NMR = nuclear magnetic resonance  
NP = nanoparticle 
PBS = phosphate buffer solution 
PFA = paraformaldehyde  
ppm = parts per million 
QDs = quantum dots 
Rf = retention factor 
SPE = solid-phase extraction  
T = template  
TAM = tamoxifen 
TCA = 7- acrylamidecoumarin-4-
trifluoromethyl 
TLC = thin layer chromatography 
THF = tetrahydrofuran 
UV-Vis = ultraviolet-visible radiation  
v/v = volume/volume 
VCC = 6-vynilcoumarin-4-carboxylic 
acid 
w/v = weight/volume 
XL = cross-linker 
λ = wavelength 
λexc or λem = excitation/emission 
wavelength  
μM = micromolar 
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1.1. Nanomaterials in medicine  
Nanotechnology is the branch of technology that studies materials with length size 
between 1-100nm, defined as “nanomaterials”. 1 Nanotechnology is currently in its most 
flourishing period and it is considered one of the most innovative and cutting-edge 
fields of science. The spotlight is on nanomaterials and their unique features, which are 
very different from the bulk systems due to their small size. 2 Nanomaterials and their 
applications have revolutionised a wide range of fields including physics, chemistry, 
engineering and medicine. 3 In particular, nanomaterials applied in medicine have seen a 
rapid growth in the last few decades, covering a multitude of different areas. For 
example, nanomaterials can be engineered in order to enhance tissue repair and enable 
the body to heal itself, thus being largely useful in regenerative medicine. 4-6  
Nanomaterials are also used to a great extent in diagnostic imaging, contributing to an 
increase in the resolution and sensitivity compared to traditional techniques (i.e. 
magnetic resonance imaging, ultra-sounds, positron-emission tomography).7 
Furthermore, nanosystems play an important part in the study of human biochemical 
processes in vivo, allowing an early detection of disease and the monitoring of their 
different stages. 8-10  
Nanosized materials find application also in immunotherapy, which is a cancer 
treatment aiming to improve the natural defence of the body and activating its immune 
response. Nanoparticles were successfully used to develop an antigen-capturing system, 
which demonstrated an enhanced response rate of the therapy and improved the efficacy 
of the treatment. 11  
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Although nanomaterials have many medical applications, there two areas that have 
particularly benefitted from the development of such materials: sensing 12 and smart 
delivery systems. 13 Therapeutic drugs monitoring (TDM) is one of the many interesting 
use of nanomaterials in sensing. 14 TDM involves the active evaluation of the drug 
concentration in patients’ organic fluids to assess the pharmacokinetics of the 
administrated drug. Amongst a number of advantages, TDM implements a personalised 
medicine approach, which is tailored to meet the different needs of each patients, 
adjusting the dosage of the therapy or intervening medically if required.   
Molecular recognition, in terms of specificity and high binding ability is the key 
requirement for the successful application of nanomaterials in medicine. Amongst the 
different approaches utilised for the generation of high molecular recognition, molecular 
imprinting has attracted a large volume of research, as evidenced by the number of 
publications in the literature on this topic, with more than 1500 papers published over 
the last two years. 15  
1.2. Molecular imprinting approach 
Molecular imprinting is a particularly useful process for developing materials with high 
recognition properties and selectivity. Using a template-casting technique the functional 
monomers interact with the template molecule, forming a pre-polymerisation complex. 
The polymerisation then occurs in the presence of the initiator and the cross-linker. The 
polymers obtained with this procedure are called molecularly imprinted polymers 
(MIPs). When the template is removed, 3D cavities, complementary in shape and 
functionalities to the template, are left in the matrix (figure 1.1) and are able to 
selectively recognise and rebind the target analyte. 16  
  




Figure 1.1. Representation of the molecular imprinting process. It starts with the formation of a pre-
polymerisation template-monomer complex, which polymerises in the presence of cross-linker and 
initiator. The cavities can then rebind the template.  
Three main approaches to successful imprinting have been investigated over the years, 
namely covalent, non-covalent and semi-covalent. 17 These relate to the different type of 
interactions taking place between the template (T) and functional monomer (FM) and 
are often chosen according to the application of the MIPs. In the first approach, covalent 
bonds occur between the functional monomer and the template before the 
polymerisation process. Although the polymer, produced with this process, is more 
stable and has exact stoichiometry between FM and T, it has slow kinetics, both in the 
formation and in the cleavage of the bond. Therefore, the reversibility of the system is 
limited as well as its applications, especially when fast equilibrium is required. In the 
non-covalent approach the interactions between the FM and the T occur through non-
covalent bonds, namely hydrogen bonding or electrostatic interactions. This way the 
template extraction and the equilibration are favourite and more rapid. However, the 
ability of template re-uptake is limited, as 85% of the cavities shrink and loose their 
selectivity. 18 Whereas, the semi-covalent approach involves the formation of covalent 
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the polymer re-binds the analyte. This procedure combines the high stability of the 
covalent interaction between the FM and T with the reversibility and rapid equilibration 
of the non-covalent interactions. Due to the different interactions involved, every 
approach requires a specific ratio of T to FM in order to ensure the best results of 
imprinting in the final polymer. Typically, the ratio used in covalent and semi-covalent 
approaches is 1:1 or 1:2 T to FM. The non-covalent procedure requires higher ratios, 
typically 1:4 - 1:8, to push the equilibrium towards the formation of the complex, 
though there is a substantial risk to form non-specific binding sites. Nevertheless, the 
appropriate ratio depends on the complexity of the template and the affinity between the 
functional monomer and the template. Another option is the stoichiometric/non-
covalent interactions, which is achieved when the pre-polymerisation complex is strong 
enough and involves high association constants. 18 This way it is possible to combine 
the fast rebinding kinetics, characteristic of the non-covalent/non-stoichiometric 
procedure, with the high stability and accessibility of the cavities, typical of the covalent 
approach, without the aforementioned disadvantages involved in the two procedures. 
Therefore, the key step to having polymers with high selectivity is to use strong and 
defined interactions in the pre-polymerisable complex.  
Literature offers many examples of the range of applications of MIPs. 19, 20 In particular, 
the use of MIPs as sensor 21, 22 and drug delivery system 23 has seen a significant growth 
in the last few years. For instance, MIPs were used to replace the antibodies in ELISA 
tests (enzyme-linked immunosorbent assay) to overcome the disadvantages of using 
antibodies, such as the related high costs and poor stability. 24 The assay employing MIP 
nanoparticles showed lower detection limit than the ELISA equivalent, detecting the 
analyte in real samples with mean accuracy of 98%. Moreover, such device was stable 
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to high temperature overtime and also versatile, as it was employed for detection of a 
variety of analytes, including drugs and toxins.  
Ton et al. reported another noteworthy example of MIP used as sensor for herbicides 
and mycotoxins. 25 The group developed a disposable evanescent wave fibre optic 
sensor in which the polystyrene waveguide was coated with MIP, specific for the 
selected analytes. The MIPs were also equipped with a fluorophore that provided 
fluorescence enhancement upon binding of the analytes. Such sensors showed detection 
of analytes in the order of nM or μM, and were proposed as screening tools for fast and 
on-site monitoring of herbicides and mycotoxins in environmental or food samples.  
In the literature there are also very good reports on the applications of MIP in drug 
delivery. 26 For example the use of MIPs for ocular delivery is a very fascinating one. 
MIPs contributed to overcome issues linked to the ocular protective mechanisms and 
high lachrymal turnover, which reduces the bioavailability of the already available 
ophthalmic medications. Imprinted hydrogels have been developed for uses as soft 
contact lenses that offer a sustained drug release. 27 Such MIPs, characterised by a low 
content of cross-linker in order to ensure transparency and flexibility to the system, 
have the potential to improve the treatments of ocular diseases enhancing the efficacy 
and efficiency of the lenses. 
1.2.1. Format of molecularly imprinted polymers  
Molecularly imprinted polymers can be prepared in a variety of formats that provide 
different characteristics and properties of the matrices. The choice of format and method 
of preparation, therefore, is strongly dependent on the final applications of the MIPs. 
Common formats are nano- or micro-beads, thin films, membranes, gels or bulk 
polymers, all of which can be obtained by controlling different parameters. 28 
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Chronologically, the first format of MIP ever proposed was in the format of bulk 
polymer. In his first work on molecular imprinting published in 1973, Wulff describes 
the formation of an imprinted organic bulk polymer able to separate a racemic 
mixture.29 Within the following 10 years after Wulff’s first paper, the number of groups 
who contributed to the innovation of this field grew considerably. In 1978 Shea and 
Thompson published their first work in which the two presented a bulk polymer able to 
achieve stereo-specific reactions. 30 In 1997 Damen and Neckers developed a highly 
cross-linked styrene-divinylbenzene copolymer prepared in the bulk format, which was 
able to recognize stereoisomers. 31 Mosbach’s group gave great impact to MIP synthesis 
and application when, in 1981, they introduced molecular imprinting in synthetic bulk 
MIP with non-covalent interactions. 32  
The bulk preparation consists on the synthesis of a polymer monolith, which is then 
crushed and grounded, following by sieving of the particles into the desired size ranges. 
The preparation of bulk polymers is time-consuming and more than 50% of the polymer 
is wasted in the process of grinding and sieving, however this method is the most 
straightforward and widely used. 33, 34 Bulk polymerization requires fewer optimization 
steps compared to other methods, it is fast and simple to set up and the resulting 
monoliths are easy to handle. 20, 35 Bulk polymers are still the most preferred matrices 
for sensing applications. In 2016, Hu et al. presented a sensor based on bulk MIP 
integrated with silver nanoparticles. The sensor was able to specifically separate and 
detects trace level of melamine in tap water and milk samples in 18 min and 25 min, 
respectively. 36 A few months later Ji et al. published a study, which described the 
synthesis of molecularly imprinted polymers for the recognition of glycosides in 
aqueous media characterized by excellent hydrophilicity. 37 
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Another common format for imprinted polymers is nanogels. Nanogels are defined as 
intra-molecularly cross-linked polymeric particles, which are able to swell or aggregate 
according to the solvent used. Nanogels form three-dimensional network in which at 
least one dimension is in the nanometre size (between 1 and 100nm). 38 These materials 
combine the advantages of the polymeric nanoparticles, such as physical stability, and 
ease of surface modification, 39 together with the typical features of the hydrogels of 
swelling, biocompatibility and low surface tension. 40 Such characteristics have attracted 
considerable interest towards the use of nanogels and their applications have covered a 
large variety of topics, from imaging, 41 41b to sensing 42 43 and also coating. 44 Nanogels 
pose also as very promising drug delivery systems (DDS). In fact, some of their features 
are compatible with those of the ideal DDS such as: high loading capacities of the 
swollen network without involving chemical reactions, thus reducing the amount of 
carrier required and protecting the drug activity; ease control of the particle size in order 
to obtain nanogels small enough to be able to reach the small capillary vessels and 
penetrate the tissues; and the possibility to acquire a controlled and sustained release of 
the therapeutic at the target site. 45 Nanogels have been employed as DDS in vivo and in 
human clinical trial since the early 2000s, showing encouraging results. Shimizu et al. 
applied cholesterol-bearing pullulan (CHP)-based nanogels to administration in vivo of 
anti-cancer interleukin-12 (IL-12), using murine model. Preliminary studies in vivo 
demonstrated that, although the IL-12 resulted in a complete remission of the cancer, it 
showed systemic toxicity and short half-life. Nevertheless, the incorporation of 
recombinant IL-12 within CHP nanogels allowed the administration of the drug in a 
reduced dose so to minimise its toxic effect, while obtaining a suppression of the 
tumour growth in the animal. 46 CHP nanogels were also used to load antigens and 
prepare a CHP-HER2 vaccine, which was used in a phase I clinical trial to assess the 
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safety of the vaccine and HER2-specific T-cell immune responses. Following the 
treatments, the only adverse event showed by the patients was a mild skin irritation at 
the site of vaccine injection. The vaccine was deemed to be safe and HER2-specific 
immune responses of T-cells, as well as antibody production, were detected. 47, 48 
Nukolova et al. presented another interesting work that highlighted the use of nanogels 
as promising DDS towards ovarian carcinoma. 49 The nanogels were conjugated to folic 
acid (FA), a targeting moiety capable of specific interaction with folate receptor, which 
is overexpressed in ovary cancer cells. This system showed very good anti-cancer drug 
uploading and cellular uptake. The DDS proved to inhibit the tumour growth and 
exhibited lower toxicity (i.e. body weight loss) compared to the free drug. Moreover, 
the bio-conjugation with the FA allowed the release of the drug only in the cancer cells, 
reducing eventual side effects connected to the drug accumulation in healthy tissues.  
In the context of this project there was the desire to contribute to study the potential of 
the molecular imprinting approach for the development of polymers to be used as 
sensing unit for a specific drug as well as drug delivery system. In particular it was 
decided to use the same target drug, Tamoxifen, for both applications given its 
importance and wide use in the clinics. The choice of drug was a very important one, as 
it determined the type of monomers that could be used.  
1.3. Tamoxifen as model drug 
Tamoxifen (figure 1.2) is a British discovery. It was first synthesised in 1966 by 
researchers at Imperial Chemical Industries, but was only licensed for the treatment of 
breast cancer in the early 1980s, becoming one of the very successful drugs in the 
history of medical oncology.  
  




Figure 1.2. Molecular structure of tamoxifen.  
Drugs such as tamoxifen belong to a class of compounds known as SERMs (selective 
oestrogen receptor modulators), acting as oestrogen agonist or antagonist depending on 
the target tissues. Tamoxifen has an oestrogen antagonist effect on breast tissues, but it 
also exhibits an oestrogen-like action on bones and uterus tissue. 50 Tamoxifen is a 
widely used anticancer drug, both in prevention and in the treatment of all stages of 
breast cancer. 80% of the breast cancer is oestrogen receptors positive, in other words 
the growth of the tumour is promoted by signals received from oestrogens. The 
antagonistic effect of TAM on oestrogen receptors in breast tissues involves preventing 
oestrogen from exerting its normal effect, thus inhibiting the proliferation of breast cells 
and hence the propagation of the tumour. 51 Tamoxifen has also an effect on bones and 
endometrium, as agonist for oestrogen receptors located in these tissues. On one side 
TAM helps to preserve the density in the bones, 52 on the other tamoxifen-treated 
patients have a small risk (2 per 1000 women per year) of low-grade endometrial cancer 
insurgence. However, the benefits of tamoxifen in breast cancer treatment outweigh the 
risk associated with endometrial tumour. 53 
Interestingly, as a result of its anti-oestrogenic activity in breast tissues, tamoxifen is 
also largely abused by bodybuilders and athletes to mask the side effects of doping with 
anabolic androgenic steroids (AAS). AAS aromatise during the metabolism, forming 
oestrogens, which cause the development of breast tissues in man (gynecomastia). 
O
N
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Tamoxifen is, therefore, used in conjunction with AAS as it binds the oestrogen 
receptors, stopping gynecomastia. For this inappropriate use, the World Anti-doping 
Authority (WADA) and the International Olympic Committee (IOC) banned tamoxifen 
in sports and competitions. 54, 55  
Tamoxifen is extensively metabolised after oral administration. The metabolism of this 
drug is mediated by the hepatic cytochrome P450 (P450), which is a family of enzymes 
responsible for the biotransformation of many potentially toxic compound. 56 Two main 
routes of metabolism have been identified: 4-hydroxylation and N-demethylation, 
which give hydroxylated and demethylated metabolites, respectively. 4-
hydroxytamoxifen (4-OHT) and N-desmethyltamoxifen are the main metabolites of 
these two pathways. The latter metabolite is further transformed into into 4-hydroxy-N-
desmethyltamoxifen, also known as endoxifen (figure 1.3). 
 
Figure1.3. Structure of tamoxifen and its primary metabolites. The relevant cytochromes responsible for 
each bio-transformation are also indicated, together with the organic fluid in which each metabolite is 
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Each metabolite shows a specific binding affinity for the oestrogen receptors. In 
particular it was found that 4-OHT and endoxifen are the major active metabolites in 
tamoxifen treatment. Both metabolites exhibit a higher anti-oestrogenic activity than 
TAM or other studied metabolites, however the concentration in plasma of endoxifen is 
higher than 4-OHT. 57 The concentration of metabolites in the serum is different in each 
individual and it influences the efficacy of the drug. The polymorphic of the enzymes 
responsible for tamoxifen metabolism, together with potential additional contributors, 
not yet fully understood, are responsible for such difference in concentration. 58 
There are two major issues related to the use of tamoxifen. On one hand, although 
tamoxifen is pharmacologically important, it suffers from low solubility and 
bioavailability, together with poor selectivity towards the affected area. This involves 
significant side effects for the patients’ health, such as a higher risk to have uterine 
cancer and venous thromboembolism. 59 The development of a delivery vehicle could 
contribute to increase the bioavailability of the drug and target only the malignant 
tissues, thus reducing the side effects. More details will be given in section 1.3.2. 
 On the other hand, the detection and quantification of tamoxifen and its metabolites 
remains a challenging problem that has attracted a variety of approaches. The 
development of a fast, easy and reliable sensor, which does not involve complex 
instruments, for the evaluation of tamoxifen and/or its metabolites in urine or serum 
would have a large impact on many aspects. It would help fighting the illicit use of 
tamoxifen, and, in case of breast cancer, it would provide an instrument for monitoring 
the response of the tumour to tamoxifen and the treatment status. In the next section the 
key findings and the state of the art for the detection of tamoxifen will be given. 
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1.3.1. Detection and quantification of tamoxifen and metabolites 
Since the late 1970s, when tamoxifen became one of the most successful drugs in the 
treatment of breast cancer, multiple resources and funds have been committed to the 
identification, detection and quantification of the drug or its metabolites in plasma, 
serum and bile. One of the first examples in literature is from 1979. Daniel et al. 
reported the detection of tamoxifen and one of its hydroxylated metabolites in plasma 
samples obtained from patients treated with tamoxifen. 60 The samples were extracted 
with organic solvent and purified by ion-exchange chromatography. The samples were 
then analysed by gas chromatography coupled with mass spectrometry (GC-MS) and 
quantified by means of a standard curve.  
In the early 1980s Kemp et al. reported another interesting work on the identification 
and quantification of tamoxifen and metabolites using GC-MS. 61 The group reported a 
method based on thin-layer densitometry as a technique to separate N-
desmethyltamoxifen, N-desdimethyltamoxifen and tamoxifen’s primary alcohol, which 
structures are shown in figure 1.4. 
 
Figure 1.4. Chemical structures of tamoxifen metabolites investigated in Kemp’s work 61 
Serum samples were obtained from patients who had received 100 mg b.d (twice a day) 
of Nolvadex® (tamoxifen citrate). The three metabolites were extracted from serum at 
different pH using an organic solvent and separated on thin-layer chromatography. The 
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fluorescent metabolites containing the triphenylethylene group into highly fluorescent 
phenanthrene derivatives (figure 1.5). The quantification was then carried out 
employing densitometry.  
 
Figure 1.5. Photoreaction of tamoxifen and metabolites. By UV irradiation the molecules containing 
triphenylethylene moiety are converted into phenantrene derivatives, which are high fluorescent 
The authors identified the metabolites using three independent methods: 1) by 
assessment of their extractability under different pH conditions; 2) by comparison of the 
retention factor (Rf) of the extracted compounds with the Rf of the synthesised ones; 3) 
by using gas chromatography coupled with mass spectrometer (GC-MS) and analysis of 
the fragmentation pattern.  
Although GC-MS is characterised by high-resolution power and sensitivity, it requires 
complicated samples preparation prior the analysis. The biologic samples need to be 
treated to separate the analytes from the matrix or background material, as described in 
the previous example. 61 A far more convenient method is based on high performance 
liquid chromatography (HPLC).  
Golander et al. 62 and Stevenson et al. 63 presented interesting methods of identification 
and quantification of tamoxifen and its metabolites that involved HPLC coupled with 
fluorimeter. After photochemical reaction induced by UV-light source, as showed in 
figure 1.5, the reaction mixture was separated onto HPLC columns. The analytes were 
quantified as photoreaction products, by measuring the peak area and comparing it with 
a standard curve. In these examples the technique employed was “off-line”, as the 
photoreaction was carried out before the chromatographic separation. However, the 
RR
UV
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phenantrene derivatives produced during the irradiation of the sample was subject to 
photodegradation over time, which led to complex chromatograms and poorer 
resolution. In order to overcome the disadvantages caused by the off-line approach, the 
photoreaction was introduced after chromatographic separation. This new procedure 
took the name of “on-line” approach, in which the UV-absorbing materials were 
separated from the compounds of interest before irradiation. This way the risk of 
fluorescence quenching or photochemical side products was minimised. The on-line 
procedure was, therefore, more reproducible and sensitive than the off-line 
photoconversion. In the “on-line” approach the photoreaction was coupled into a HPLC 
system. After the separation, the elute was illuminated by a UV-light source before 
passing through the fluorescent detector. An example of this approach was given by 
Nieder et al. who focused on the optimisation of a method for detection of tamoxifen 
and N-desmethyltamoxifen in plasma. 64 A few years later Kikuta et al. used the same 
approach for the detection of tamoxifen, N-desmethyltamoxifen and 4-
hydroxytamoxifen. 65 However, the authors introduced innovation to the preparation of 
the sample and in the photoconversion. Plasma samples were treated with HCl and 
centrifuged to remove solid material. The pre-column was conditioned with methanol-
water-HCl, the supernatant was then loaded onto the pre-column, which was washed 
with water before switching into HPLC stream (figure 1.6). The authors introduced a 
newly designed photoreactor with a 3D configuration, which allowed a faster and more 
efficient conversion of the analytes in the fluorescent products. The resulted system was 
characterised by high selectivity and specificity of separation and detection. Moreover, 
results showed sensitivity for tamoxifen and metabolites in plasma samples down to 
subnanogram levels.  




Figure 1.6. Schematic representation of Kikuta detection system.  
Lien et al. picked up on the same path of Kikuta and developed a fully automated assay 
able to detect the tamoxifen and four metabolites in human serum. 66 The sample 
preparation consisted in only one step, deproteinisation of the serum and its 
centrifugation to remove the precipitated protein. The supernatant was then injected into 
a small pre-column and equilibrated in order to concentrate the analytes. An automated 
column-switching valve allows the direction of the flow from the pre-column to the 
reversed-phase analytical column after which the cyclisation occurred via UV 
irradiation, converting the analytes in phenantrene derivatives to be detected. The in-
column concentration of the sample increased the sensitivity and reproducibility of the 
whole system. This fully automated assay was characterized by simple sample 
processing, high recovery of analytes, precision, and simultaneous quantification of the 
parent drug and four serum metabolites. One year later the group applied the same 
method to human bile samples. 67 Results showed the presence of a new peak, not 
present in serum samples, which was identified as 4-hydroxy-N-desmethyltamoxifen, 
also known as endoxifen (figure 1.7).  
 
Figure 1.7. 4-hydroxy-N-desmethyltamoxifen, metabolite found in bile samples. 
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An alternative to on-line in-column pre-concentration of the analytes with no sample 
treatment was possible in the 90’s with the development of solid-phase extraction 
systems (SPE). The extraction of the analytes from complex biological matrices such as 
plasma68 and urine69 became fast, noise-free and easy with the SPE. Although the 
extraction efficiency obtained with the on-line extraction were higher that that observed 
with SPE, this technique overcome the time-consuming organic extraction of samples 
and the use of complicated pre-column and column-switching valves. McCullum et al. 
demonstrated that the levels of tamoxifen and N-desmethyltamoxifen detected in 
plasma using SPE for extraction and HPLC assay for separation and detection of the 
analytes were similar to those obtained with previous methods with same detection 
limits.68 With the development of the SPE, which make the extraction fast and easy, also 
GC-MS became a viable alternative to the HPLC. 69, 70  
As described in section 1.2, molecularly imprinted polymers provide high selectivity 
and affinity for the target analyte. MIPs, therefore, represent the perfect sorbent 
materials for SPE, which allows to selectively isolating biological analytes from 
complex matrices. MIP-SPE have successfully been used for the specific extraction of 
tamoxifen followed by quantification via HPLC. 71-73  
In the last few years MIPs have also found application in the development of sensor for 
the detection and quantification of tamoxifen and its metabolites. In 2005 Nie et al. 
developed a new material in which MIPs, packed into a column, provided the 
recognition material to a system based on chemiluminescence. 74 The group found that 
the reaction of tamoxifen with Mn (IV) produced a detectable chemiluminescence 
signal. However, other substances in the samples could react in the same way with Mn 
(IV), producing the same signal. In order to introduce selectivity towards tamoxifen, the 
sample solution was pumped through the MIP column specific for the drug. A solution 
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of Mn (IV) was then pumped in the column in which it reacted with tamoxifen, 
incorporated within the MIP matrix, producing the signal. Such system was successfully 
used to determine the drug in urine collected from breast cancer patients treated with 
tamoxifen, obtaining good analytical parameters and low detection limit. Another recent 
example of MIP employed in the detection of tamoxifen was reported by Yarman et al.75 
The group developed an electrochemical MIP sensor in the format of film in which the 
detection of the drug was achieved by an indirect method. The binding event of 
tamoxifen on the MIP film caused the suppression of the signal produced by the 
reduction of the ferricyanide redox probe. The sensor proved a fast rebinding of the 
analyte and a linear range from 1 to 100 nM, reaching saturation above it.  
Although different methods for the detection and quantification of tamoxifen and its 
metabolites have been suggested, the reviewed methodologies depend on complex 
instrumentation, which involve trained staff and high cost. Nevertheless, the use of MIP 
opens new opportunities for the development of a new range of sensors, which could 
provide fast and reliable analysis. In relation to tamoxifen, in addition to the detection 
of the drug, its delivery by means of nanomaterials has also attracted interesting studies, 
which are summarised and discussed in the next section.  
1.3.2. Drug delivery systems for tamoxifen  
Drug delivery systems (DDS) are specialised devices used for the delivery of 
therapeutics, allowing improvement of the selectivity, effectiveness and safety of drug 
administration. The ideal drug delivery system should be able to transport the active 
substance in the affected area and release the drug in a controlled and sustained manner. 
By using DDS it is possible to increase the stability and bioavailability of drugs 
otherwise having poor solubility in water and thus limited administration. The increased 
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bioavailability also allows a reduction of the overall dosage and frequency of 
administration of the therapeutics in question. This way the adverse effects caused by 
higher dosage and accumulation of the drug in areas of the body other than the affected 
one are reduced. 76 The routes of drug administration are mainly divided in enteral, 
parenteral and topical, among others. Each one of the administration routes, with its 
advantages and disadvantages, affects the drug metabolism and clearance therefore 
influencing its dosage. In other words, the total amount of drug that arrives at the target 
area of action is largely dependent on how the medication is administrated in the body.77  
All the routes of administration need to face the problem of the lack of bioavailability of 
the drugs. The bioavailability is influenced by several factors such as the first-pass 
metabolism, the solubility of the drug and its chemical instability to acidic pH of the 
stomach. One possible way to overcome these issues it to apply nanotechnology to drug 
delivery. Nanomaterials, characterised by their size in the order of nanometres and their 
large surface-to-volume ratio, can be modulated in order to protect the drugs from 
metabolising enzymes. Nanoformulation can also improve the hydrophilicity of the 
drugs via conjugation or encapsulation within nano-vehicles, providing an increased 
deliverability of such drugs. Moreover, nanomaterials can influence the chemical 
stability of the medication, protecting it from harsh conditions. Nanomaterials can also 
be designed in such a way to be attracted to diseased cells and activated to release 
therapeutic in response to a trigger, thus allowing direct treatment of those cells sparing 
the healthy ones and reducing the potential accumulation off-target. 78 Nanomaterials, 
therefore, contribute to increase the bioavailability of the drugs, resulting in an extended 
blood circulation time, and deliver the therapeutics specifically in the affected area.  
When a medication is administered in the body, regardless of the route of administration, 
several barriers need to be crossed before the therapeutic substances reach the site of 
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action, and only a small portion of the drug reaches the targeted organs. 79 The use of 
nanomaterials as drug carriers was shown to assist the drugs in traveling across these 
barriers. However, only particles with size < 200nm are considered suitable for drug 
delivery applications. The recent progress in the field of nanotechnology positively 
influenced the development of drug delivery systems, moving from macro- to nano-
sized drug vehicles. 80, 81 Nanomaterials can penetrate even small capillaries, with 5–6 
μm in diameter, and are characterised by higher intracellular uptake, compared to 
microparticles, which allows efficient drug accumulation at the target sites in the 
body.82,83 As shown by Desai et al. in their study carried out on adult rats, 100 nm 
particles were able to penetrate the submucosal layer while larger microparticle were 
concentrated in the epithelium. 84 As aforementioned, nanomaterials have a high 
surface-to-volume ratio, which implies that a significant amount of material can be 
loaded in the network maintaining the stability of the material. Moreover, the large 
surface can be functionalised and modified in order to generate conjugation with 
biomolecules, making the nanomaterials more reactive compared to larger molecules or 
bulk counterparts. The high surface area can also improve the water solubility and the 
bioavailability of such nanomaterials. 85 However, being able to cross the barriers and 
deliver the therapeutics in the targeted region in a controlled release rate, are not the 
only challenges that are faced during the development of a DDS. The ideal DDS should 
have the capability to transport the therapeutics without any loss before reaching the 
targeted location. The release of the drug is required at the most appropriate time and 
dose only upon reaching the affected area. Any release of the medication in areas other 
than the targets could have toxic effects and serious side effects for the patients. Four 
different mechanisms of drug release have been identified: diffusion-controlled, 
swelling-controlled, erosion-controlled and stimuli-controlled release (figure 1.8). 86 
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Figure 1. 8. Representation of the different possible mechanisms of drug release  
In the last two decades drug delivery nanosystems with stimuli-responsive features have 
been largely studied and reviewed. 87-89 Such systems respond to environmental stimuli, 
which trigger a physicochemical change of the nanocarriers, thus promoting the release 
of the medication. Such triggers could be external (e.g. electric field, ultrasound, 
magnetic field) or internal (e.g. difference in pH, temperature, and ionic environment).  
Literature data suggest that polymeric nanoparticles have lately attracted much interest 
as drug delivery vehicle90 due to their high physical stability, biocompatibility, ease of 
surface modification, biodegradability, just to cite some of their characteristics. 39 
Different formats have been studied and developed such as polymeric micelles, 91 
dendrimers92 and coated nanoparticles93, 94 among others. In particular, the number of 
nanomaterials developed as vehicles for the delivery of tamoxifen, considerably 
increased during the last decade. As mentioned in section 1.3, tamoxifen suffers from 
poor hydrophilicity and low bioavailability together with scarce specificity and 
insurgence of side effects, such as increased risk of endometrium tumour and 
thromboembolic events. Such issues could be overcome with the aid of nano-DDS. 
Very recently, C60-fullerenes have been used for delivery of N-desmethyltamoxifen, one 
of tamoxifen metabolites, to cancer sites in a controlled and sustained manner. 95 
Promising results showed that this system was internalised by cancer cells in which it 
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exhibited enhanced cytotoxicity. The nanostructure also improved the bioavailability of 
the drug and modified its pharmacokinetic profile decreasing its clearance time, 
therefore requiring smaller doses.  
Other recent examples of nanocarriers of tamoxifen include the development of 
biocompatible micelles based on natural compounds as polyunsaturated fatty acid (i.e. 
peanut oil, corn oil, sesame oil, soya bean oil, sunflower oil) with self-nanoemulsifying 
properties. 96 The nanosystem demonstrated to have good cellular uptake compared to 
the control system or to a tamoxifen suspension, in fact the steady concentration of 
tamoxifen in plasma increase of 5.6 fold when the nanoemulsion was used. Also, the 
permeability of the drug increased due to the effect of the nanosystem. Furthermore, the 
nanoemulsion improved the anti-cancer activity of the drug, reducing the size of the 
induced breast tumour in female rats after repetitive oral dose of the nanosystem for 
thirty days.  
Thakur et al.97 incorporated tamoxifen into polymeric micelles based on the 
biodegradable poly (lactic-co-glycolic) acid (PGA) and on the non-toxic polysaccharide 
chitosan. Such chitosan-PGA micelles exhibited good drug release at the cancer cell pH 
and also high drug loading and good uptake by cancer cells with resulting enhancement 
of cytotoxicity. 
Magnetic nanoparticles, functionalised with PEG (polyethylene glycol) have also been 
applied for tamoxifen, obtaining good levels of drug loading within the system, 
increased cytotoxicity of cancer cells and bioavailability of tamoxifen. 98  
The monitoring of the drug delivery systems, both in vivo and in vitro, is a key 
requirement to obtain information regarding the safety and efficacy of the nanosystem, 
prior to start human clinical trials. Although a variety of approaches (i.e. magnetic 
resonance imaging, computed tomography, positron emission tomography, optical 
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imaging or ultrasound) are conventionally utilised for imaging, fluorescence 
spectroscopy has recently attracted much attention. 99 In fact, the above-mentioned 
nanocarriers, developed for the delivery of tamoxifen, were all conjugated with 
fluorescent tags in order to allow an easy tracking of the nanomaterials.  
In the next section the basics of fluorescence spectroscopy, together with its advantages 
in imaging and the different available fluorophores will be described. 
1.4. Fluorescence 
Fluorescence occurs when a particular fluorescent molecule, also called a fluorophore, 
emits light after previous absorption. 100 The fluorescence process is therefore divided in 
two steps: the absorption (excitation) and the emission of light (figure 1.9). During the 
excitation step, an electron of a fluorescent molecule exposed to UV light absorbs a 
photon of energy, which results in the formation of an unstable excited electronic state 
(S1). The lifetime of the excited state is in the order of a few nanoseconds, during this 
time the molecule relaxes towards the lowest vibrational energy level (S10) within the 
electronic excited state via non-radiative transition, dissipating the energy as heat to the 
solvent. The fluorescence originates when a photon is emitted during the relaxation of 
the electron back towards the ground state (S0).  
  




Figure 1.9. Representation of Jablonski diagram in which the electronic states and the transition of the 
electrons are illustrated. The electron is excited to S1 level after absorption of a photon; the electron then 
quickly relaxes to the lower level of the excited state by non-radiative transition. The further relaxation 
back to S0 occurs with emission of a photon generating the fluorescence 
As the energy acquired during the excitation is partly dissipated by non-radiative 
transition, the emitted photon carries less energy and it is therefore characterised by 
longer wavelength compared to the absorption wavelength. The difference between the 
two wavelengths (excitation and emission) is called the Stokes shift. This is 
characteristic of each fluorophores and defines the sensitivity of the fluorescence 
technique. Large Stokes shifts are desirable to enhance the signal-to-noise ratio and for 
high quality optical imaging. The excitation/emission of a fluorophore is cyclical; the 
fluorescent molecule can be excited again after emission. However, the fluorescence 
emission of the fluorophores fades over time, giving rise to the phenomenon called 
photobleaching.101 This is an irreversible loss of fluorescence signal due to 
photochemical changes of the fluorescent molecule, including reactions with 
neighbouring dye molecules. The choice of photo-stable fluorophores and the use of 
high sensitivity detector can prevent the photobleaching.  
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Fluorophores, are widely used in imaging, tracking and detection. Fluorescence 
spectroscopy, compared to other methods of detection and imaging (based on X-Rays, 
IR, microwaves, electromagnetism etc.) has many advantages. It is characterized by 
high efficiency, versatility, sensitivity and sensibility and in fact fluorescence is 
frequently used for the detection of small quantities. Moreover the fluorescence of the 
fluorophores can be modulated by interaction with other molecules therefore providing 
a detectable signal, useful in sensing application. The number of available fluorophores, 
with different characteristics and performance, provides flexibility for research 
application. The fluorophores are generally divided into three general groups, namely 
biological fluorophores, quantum dots and organic dyes; each of this subgroup is 
defined by their specific characteristics in terms of stability, availability and sensitivity.  
The biological fluorophores are fluorescent proteins such as the green fluorescent 
protein (GFP), which was first cloned in the early 1990s by jellyfish Aequorea 
victoria.102 Since its discovery, GFP has largely been used as gene expression 
reporter,103, 104 or successfully incorporated into herpes virus in order to analyse the 
kinetics and the effect of the virus infections. 105 Moreover, GFP was found to have no 
effect on the cell growth, resulting to be not toxic. 106  
Quantum dots (QD) are nanosized fluorophores characterised by broad excitation and 
narrow emission, high quantum yields, photostability and resistance to photobleaching 
(the irreversible destruction of fluorophores). The emission bands of the quantum dots 
can be tuned by changing their size. Bigger dots with radius of 5-6 nm emit longer 
wavelengths compared to smaller QDs, 2-3 nm in radius. However the specific 
emissions also depend on the shape and composition of the QDs. 107, 108 The 
characteristics of QDs make them appropriate for biological applications such as 
labelling of living cells109,110 tracking cancer cells, 111 or dynamic trackers for biological 
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events. For example it was possible to track the glycine receptors and to observe their 
entry into synapses by diffusion. 112  
The organic dyes are synthetic fluorophore molecules. Amongst this class, fluorescein 
and its derivatives are the most commonly used as tags and imaging agents for a variety 
of applications. 113 In particular, since its synthesis in the 80’s, fluorescein has been 
largely used in health care as diagnostic tool in gastrointestinal endoscopy114,115 and 
ophthalmic angiograms. 116 In order to be suitable fluorophores the synthetic dyes need 
to have the following characteristics: high visible extinction coefficient, which allow 
them to absorb the visible light even at low concentrations; high fluorescence quantum 
yield, which is an indication of the minimum concentration required for fluorescence 
detection; high ability of tissues penetration in order to observe sufficient fluorescence 
in vivo. 113 These features are easily addressable by chemical modifications. The 
addition of specific functional groups can change the emission wavelength, the 
hydrophilicity, the photostability, and can introduce specific binding sites to conjugate 
the fluorophore to biomolecules or nanosystem. 117 In fact, a range of synthetic 
fluorophores has been used over the past few years for nanocarrier labelling. Two recent 
examples are reported by Dong et al.118 and by Saxena and Jayajannan. 119 The two 
groups proposed nanovehicles conjugated with fluorophores to simultaneously track the 
cellular uptake of the systems and monitor the tumour therapy efficacy.  
As this class of fluorophores is quite versatile and the chemical structure can be 
modified to satisfy the requirements for the specific applications, it was decided to 
adopt organic synthetic fluorophores for the preparation of fluorescent MIP with 
potential application as detector and drug carrier. This will be explained in details in the 
following section.  
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1.5. Aim and objectives 
 The overall aim of this project is to develop novel polymers based on molecular 
imprinting and labelled with a fluorescent tag, which could be applied in sensing and 
delivery using tamoxifen as the drug target. Four main objectives were identified: i) 
synthesis and characterisation of polymerisable coumarin derivatives with dual 
functionality, fluorescence and pH-responsive; ii) development of coumarin-based 
MIPs in bulk format to be potentially used for tamoxifen sensing; iii) synthesis and 
characterisation of coumarin-based MIPs in nanogel format for application as drug 
delivery system; iv) toxicity study and evaluation of the drug loading of nanogels in 
transgenic zebrafish.  
In order to simplify the discussion of the results, the data for each of the above 
objectives are presented in a dedicated chapter, as summarised here below.  
Chapter 2 presents the design and synthesis of the fluorescent functional monomers. 
To this purpose, three main features were identified as essential: 1) good fluorescence 
yield and production of a detectable signal upon binding the analytes; 2) polymerisable 
unit to covalently link the molecule to the polymer; 3) functional groups to anchor the 
template. A novel synthetic pathway was developed and two different coumarin 
derivatives monomers were synthesised and characterised by NMR and fluorescence 
emission. However, only one monomer (VCC, 6-vynilcoumarin-4-carboxylic acid) was 
taken to the next stage.  
Chapter 3 describes the use of the MIP bulk polymer (obtained at Polyintell by Dr. 
Ray) based on the VCC fluorescent monomer and its potential as detector for tamoxifen 
and its metabolite, 4-hydroxytamoxifen. Initially, the interactions between the 
functional monomer and the analytes clomiphene (the drug analogue employed as 
template), tamoxifen, and 4-hydroxytamoxifen were studied, demonstrating a 
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fluorescence quenching of the VCC upon binding of the analytes. Finally, the MIP was 
tested against the same analytes, ensuring the formation of interactions that quenched 
the fluorescence of the polymeric matrix. The generation of the signal in the presence of 
the analytes was also assessed by naked eye, thus confirming the potential of the system 
to be used as detector.  
Chapter 4 covers the work done on the synthesis and optimisation of NIPAM-based, 
water-soluble nanogels imprinted with tamoxifen with potential application in drug 
delivery. The fluorescent functional monomer VCC was employed to provide a specific 
binding site for the drug, stimuli-responsiveness to the final matrix as well as the 
opportunity to track the nanosystem via fluorescence. Different sets of MIP and NIP 
were obtained and optimisation was done based on solubility, fluorescence emission 
and particle size. The polymerisation of the fluorescent monomer was confirmed 
followed by sample treatment with MeOH and dialysis. Finally, the quantification of the 
drug in the MIP was carried out by indirect method. The tamoxifen, loaded in the matrix, 
was converted into a phenantrene derivative by UV irradiation of the MIP solution, 
which gives a new absorbance peak. Tamoxifen was, thus quantified as its 
photochemical product using a reference line.  
Chapter 5 presents the in vivo studies of the nanogels presented in chapter 4. The 
zebrafish tamoxifen reporter line ubi:loxP-EGFP-loxP-mCherry (ubi:switch) was 
utilised for toxicology studies and for evaluation of the drug loaded in the MIP nanogel. 
Ubi:switch larvae were first treated with two different concentrations of tamoxifen in 
order to confirm the activation of the genetic system, which generated a red 
fluorescence when the drug was present in the organism. Afterwards, the ubi:switch 
embryos were fed with fish water solution of NIP and MIP. The nanogels were non-
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toxic to the zebrafish at the tested concentrations and the presence of tamoxifen loaded 
in the imprinted nanogel was confirmed by exhibition of red fluorescence.    
Chapter 6 describes the experimental conditions and methodologies together with the 
materials and instruments employed in this work.   
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2. Synthesis and characterisation of polymerisable coumarin 
derivatives with dual functionality  
2.1. Introduction 
This project targeted the development of novel nanomaterials for two types of 
applications: as drug delivery system (DDS) of tamoxifen and as sensor unit for the 
direct detection of the same drug and its metabolites. The common feature of the two 
systems was the preparation of polymeric matrices with high molecular recognition 
capability. The polymers were prepared using the molecular imprinting approach based 
on a template-casting procedure. As described in Chapter 1, prior to polymerisation the 
functional monomers (FM) assemble around the template (T), forming a pre-
polymerisation, monomer-template complex. The polymeric matrix is then formed 
following the addition of the cross-linker together with the initiator, and 3-D cavities 
that are complementary in shape and functionalities to the imprinting molecule, are 
obtained after removal of the template. The interactions between FM and T play a key 
role in the rebinding properties of imprinted polymers. Usually, the stronger and more 
stable the complex is, the higher the specificity of the polymer will be. Therefore, 
considerable effort needs to be invested in the choice of FM and the study of the 
polymerisation conditions that lead to the formation of the most stable complex. This is 
true whatever the applications of the polymers, whether it is for sensing purposes, for 
catalysis or as a drug delivery vehicle. In particular, in the case of detector devices, the 
functional monomer anchors and interacts with the target and an additional unit 
provides a detectable signal upon binding of the analyte. A variety of nanosized 
materials often used for detection of biomolecules are reported in the literature. Such 
systems are all based on the generation of different signals, such as colorimetric1 
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electrochemical, 2 magnetic, 3 electric4 signal. Nonetheless, as described in chapter 1 
(section 1.4), applications of fluorescence in sensing presents many advantages, 
compared to other techniques of detection, namely high efficiency, sensitivity and 
sensibility. It was therefore, decided to focus the attention on this technique and to 
design a fluorescent tag that would be covalently linked to the polymeric network, as 
opposed to being simply incorporated.  
In the group where this project was developed, a considerable amount of work was 
previously carried out on the screening and identification of suitable fluorescent 
monomers.5 Dansylaminoethylacrylamide, fluorescein O-methacrylate and 7- 
acrylamidecoumarin-4-trifluoromethyl (TCA), which structures are shown in figure 2.1, 
were all investigated as potential fluorescent monomers. Several imprinted nanogels 
were prepared and tested for solubility, particle size and fluorescence intensity, 
identifying TCA as the fluorescent monomer that ensured the desired characteristics in 
the final polymer.  
 
Figure 2.1. Structure of fluorescent monomers previously evaluated.  
However, one of the main objectives of this work was to design a monomer that could 
provide fluorescence features to the matrix, as well as enable the interactions with the 
target. Considering the fundamental role played by the pre-polymerisation complex in 
the molecular recognition properties of the final imprinted matrix, a careful design of 
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groups to strongly bind the template, thus ensuring the formation of the most stable 
complex. After studying the optical characteristics of the TCA (identified in the 
previous study) and evaluating its structure, it was decided to use the same core and to 
chemically modify it in order to add functional groups to interact with the template. In 
the following section an account of the coumarins properties and their different possible 
synthetic approaches will be given. 
2.1.1. Overview of coumarin properties and synthetic pathways 
Coumarin is a natural compound, part of the benzopyrone family, found in many 
different plants. Its main core can be functionalised, giving rise to several different 
structures with a variety of biological activities. In fact, coumarins are well known for 
their analgesic, anti-oxidant, anti-inflammation, anticoagulant, antiviral and anti-
bacterial activities.6 These compounds have also unique photochemical and 
photophysical properties as well as high photostability and quantum yield.7 They have 
large Stokes shift, which is defined as the difference in wavelength between the 
maximum absorption and emission peaks. Large Stokes shift is desirable for fluorescent 
molecules as it allows a strong signal while eliminating the overlap between absorption 
and emission spectra. For this feature, coumarins have been widely used as fluorescent 
probes for the selective detection of a number of compounds.8-12 The long excitation and 
emission maxima that characterise the coumarins make them also largely used in in vivo 
applications, as the background autofluorescence of the cellular components and 
biological fluids is minimised.  
The first appearance of coumarin in literature goes back to 1820 when Vogel isolated 
this compound from tonka beans, but wrongly classified it as benzoic acid.13 It was only 
in 1835 that Guillemette identified the compound isolated by Vogel as coumarin instead 
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of benzoic acid.14 Coumarin was employed as precursor in the synthesis of 
anticoagulant drugs. The most common one is commercialised with the name 
Coumadin®, which reduces the risk of forming blood clots by inhibiting the vitamin K-
dependent synthesis of clotting factors, proteins in the blood that control bleeding.15 
Perkin was the first scientist to synthesise the simple coumarin in 1868 using the aldol 
condensation of o-hydroxybenzaldehyde and acid anhydrides (scheme 2.1).  
 
Scheme 2.1. Schematic representation of Perkin reaction for synthesis of coumarin. 
After that, many other named reactions have been optimised for the synthesis of 
coumarin and derivatives (scheme 2.2). The most famous ones are the Pechmann 
reaction, used for the synthesis of 3-, 4- and 7-substituted coumarins; the Kostanecki-
Robinson reaction, used for the synthesis of 3- and 4-substituted coumarins; the 
Reformatsky reaction, involving condensation of aldehydes or ketones with organo-zinc 
derivatives of α-halo esters; together with the Witting reaction and the Knoevenagel 
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Scheme 2.2. Schematic representation of several name reactions for synthesis of coumarins. 
2.2. Design of functional monomer – coumarin derivatives 
As mentioned in section 2.1, TCA (7-acrylamidecoumarin-4-trifluoromethyl), was 
previously used in the preparation of nanogels with potential DDS applications, together 
with acrylic acid as functional monomer (figure 2.2). Acrylic acid had the role of 
capturing and interacting with the target molecule via ionic bond, while the coumarin 
monomer was used as a fluorescent probe to enable nanogel tracking during in vivo and 
in vitro experiments.5  
  
Figure 2.2. Molecular structure of the two monomers selected as fluorescent monomer and functional 
















































Fosca Mirata  Chapter 2 
 
 57 
Using two separate molecular entities, one for fluorescence properties and one for 
specific binding interactions with the target, could cause additional issues in the 
preparation of imprinted polymers. In fact, different reactivity of the involved 
compounds could result in a different kinetics of their incorporation in the final matrix. 
This could, therefore, have an impact on the morphology and the physical chemical 
properties of the polymer. To minimise such potential issues it was decided to design a 
functional monomer with dual functionality. The fluorescent tag and the anchor unit 
were combined in one molecular structure. Moreover, such monomer could also cover 
the role of sensing unit, providing a signal upon binding of the target, when employed 
in the development of a detector system. Therefore, for the purpose of preparing 
coumarin-based smart monomers, three main features of the molecules were identified 
as essential: i) good fluorescence emission and ability to produce a signal when in 
contact with the analytes; ii) polymerisable unit to covalently link it to the polymer; iii) 
presence of functional groups to anchor the template.  
After careful evaluation of the template structure and also considering the successful 
results obtained within the research group, it was decided to incorporate a carboxyl 
group on the coumarin monomer. This would allow ionic interactions between the 
amine group of the tamoxifen, or its analogues, and the coumarin smart monomer, as 
showed in figure 2.3.  
 
Figure 2.3. Proposed interactions between the smart monomer coumarin derivative, in which R 
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After identifying the carboxylic acid as the best choice of anchoring group, different 
options for the choice of polymerisable unit were evaluated. The polymerisable group 
plays an important role in the incorporation of the monomers in the final matrix, as the 
rate of incorporation depends on the kinetic of the different radicals.17 To ensure that the 
incorporation ratio of the different component in the polymeric network matches the 
ratio employed in the pre-polymerisation mixture, polymerisable units with similar 
chemical structures should be used. Analogous structures should, in fact, lead to similar 
reaction rates, thus maximising the addition of the monomers in a ratio that is as 
comparable as possible to the initial mixture.  
Following these considerations two smart monomers, represented in figure 2.4, 6-
acrylamidecoumarin-4-carboxylic acid (monomer 1a) and 6-vinylcoumarin-4-
carboxylic acid (monomer 1b), were chosen.  
 
Figure 2.4. The chosen smart monomers with dual functionality. 
Envisaging the incorporation of the monomers into a polymer system with N,N'-
methylenebis(acrylamide) used as a cross-linker, the polymerisable acrylamide unit on 
monomer 1a was favourite, as the polymerisable groups were the same. However, it 
was also interesting to study how the vinyl group on monomer 1b would have affected 
the overall system. The difference in the chemical structure of the vinyl group compared 
to the acrylamide group of the cross-linker, involved a different kinetic, which could 
lead to different incorporation rate. Nevertheless, the reactivity of the monomer 1b was 
expected to be higher as he radical formed was stabilised by the resonance in the 
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compared with 1a could involve the formation of simpler systems with no extra inter- or 
intra-molecular interactions. 
Careful analysis of the chemical structures of the functional group and the target 
molecule suggested two possible modes for binding interactions. On one hand a π-π 
stacking between the aromatic rings of the target and the monomer, on the other ionic 
bond between the carboxyl group on the monomer and the amine group on the target. 
However, it is important to underline that the strength of the interactions will depend to 
a certain extent on the type of solvent used. Detailed studies of the interactions are 
described later in chapter 3. 
2.2.1. Retrosynthetic analysis  
The synthesis of the target monomers could be achieved via a number of different 
approaches. Retrosynthetic analysis (scheme 2.3) showed that both selected monomers 
1a and 1b could be derived from intermediates 2a and 2b, characterised by identical 
core. The identified precursors were characterised by a carboxylate group in position C4, 
which could be easily hydroxylated to give the desired carboxylic acid group.  
 
Scheme 2.3. Retrosynthetic analysis of the monomers 1a and 1b. The compound 2 (a, b) was identified 
as convenient precursors for the synthesis of the monomers.  
It was decided to initially focus the efforts on the synthesis and optimisation of the 
carboxylate precursors 2a leading to monomer 1a and 2b leading to monomer 1b. 
Although the retrosynthetic approach was quite similar, for clarity of explanation the 
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2.3. Synthesis of coumarin monomers 
2.3.1. Towards the synthesis of 6-acrylamidecoumarin-4-carboxylate (2a)  
Different pathways and starting materials were evaluated to obtain the coumarin 
derivative with an acrylamide group in position C6. The strategy represented in scheme 
2.4 was eventually identified as the most convenient in which commercially available 
N-boc-aminophenol was used as starting material.     
 
Scheme 2.4. Synthetic pathway for the synthesis of precursor 2a  
The first step was based on the formation of a di-substituted coumarin derivative at C4 
and C6, followed by Boc cleavage to achieve the 6-aminocoumarin-4-carboxylate (4). 
Compound 4 was further reacted with acryloyl chloride to add polymerisable moiety in 
position C6 and obtain the desired precursor 2a.  
In the following subsections all the steps of the synthesis are discussed.  
2.3.1.1. 1st step – synthesis of 6-N-boc-aminocoumarin-4-carboxylate (3a)  
The first attempt focused on the modification of a synthetic strategy already published 
in 1998.18 The synthesis proceeded via a vinyl triphenylphosphonium salt formed by the 
initial attack of triphenylphosphine (PPh3) to the dimethyl acetylenedicarboxylate 
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the hydroxyl group of the starting material, which was the para-substitued aminophenol. 
Further intramolecular lactonization closed the ring, forming the coumarin derivative.  
  
Scheme 2.5. Synthetic step for carboxylate derivate 3a  
According to the procedure found in the literature, which was followed carefully in the 
first instance, the synthesis required reflux for 120 hours (scheme 2.5). However, TLC 
(thin layer chromatography) of the crude showed four spots, three of them compatible 
with N-boc-aminophenol, DMAD and PPh3, suggesting that all the starting materials 
were not completely consumed during the 5 days reaction. Although the extra spot 
showed the formation of some product, it was decided to leave the reaction for longer, 
monitoring it with TLC. No changes were observed in the TLC after 7 days, hence the 
reaction was quenched and the product purified via flash chromatographic column. Four 
fractions were isolated, two of them were the starting materials, the third was a mixture 
of N-boc-aminophenol and the product, and the fourth fraction was the pure product. 
The third fraction was further purified to give more pure compound. The product 3a 
was successfully obtained with 20% yield and fully characterised. Part of the product 
was probably lost during the purification step, as an impure fraction of product was 
isolated after the chromatographic column. Moreover, half of the initial amount of N-
boc-aminophenol and DMAD was recovered after purification. This suggested scarce 
reactivity of the chemicals under the conditions applied, which further explained the 
low yield obtained.  
At this stage, the main purpose was to obtain product 3a with sufficient yield to allow 
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2a. Given the low yield obtained following the published procedure 18 and the concerns 
raised by the purification process, an alternative approach was considered. Considering 
that the product was obtained after refluxing the mixture for over 7 days, it was agreed 
that the intramolecular lactonization was very energetically demanding. Extensive 
survey of literature data identified an interesting study by Hekmatshoar et al.19 during 
which microwave irradiation was used in the synthesis of coumarin derivatives.  
Microwaves (MW) are part of the electromagnetic field characterised by wavelengths 
ranging from 1 millimetre to 1 metre, corresponding to frequencies of 300 GHz to 300 
MHz. Microwaves have an effect on the electric charges; polar molecules irradiated by 
microwaves rotate and align themself with the applied field. The dielectric constant of 
the material is directly proportional to its ability to convert electromagnetic energy into 
thermal energy. The bigger the dielectric constant, the more rapidly the material is 
heated up.20 MW irradiation applied to organic synthesis has become very popular in the 
last few years, completely transforming protocols for numerous organic reactions.21 The 
use of microwaves, with increased homogenous and rapid heat, accelerates the reactions, 
allowing the formation of the products in very short time when compared with classical 
thermal methods. Microwave assisted synthesis has several advantages over 
conventional reflux, such as uniform and highly efficient heating throughout the 
material, low operating cost, an increase in process speed and a reduction in unwanted 
side reactions, obtaining more pure products.20 Following these considerations, it was 
decided to adapt the method reported by Hekmatshoar19 for the synthesis of product 3a. 
Although same chemicals were used both in the microwave approach and in the 
traditional reflux synthesis, significant amount of time was spent in optimising the 
synthesis and accelerating the process (scheme 2.6).  




Scheme 2.6. Microwave assisted synthesis of monomers 3a  
Generally the optimisation of synthetic procedures tends to focus on two main 
paramenters: the solvent and temperature. However, in this case the temperature of the 
reaction was directly dependent on the solvent. The reaction was carried out in a sealed 
microwave vessels with no possibility for the potential pressure, formed inside the tube, 
to be released. Hekmatshoar, in his work, used the solvent acetronitrile (ACN). ACN is 
characterised by a good dielectric constant (ε: 37.5) and high boiling point (82°C), 
which allows it to reach a high temperature with no concerns about pressure formed 
inside the microwave tube. ACN was therefore, the first choice in the solvent selection 
process. However, the reaction mixture was not soluble in this solvent, making it 
inappropriate for performing the reaction. A suitable alternative choice would have been 
DCM, which was successfully used in the previous attempt (scheme 2.5) and it was 
shown to well solubilise the starting materials. However, DCM was discarded upfront 
due to its low boiling point (bp: 40°C) and low dielectric constant (ε: 8.93). 
Consequently, dichloroethane was considered as a possible option due to its similarity 
to DCM in terms of polarity. Although DCE has a dielectric constant smaller than ACN 
(ε: 10.36), it has a higher boiling point than DCM (bp: 83°C). This allowed to reaching 
high temperature that seemed to be the key of this step. The reaction was monitored via 
TLC every 30 minutes. After 2 hours no significant changes in the TLCs were noticed; 
the starting materials were not completely consumed although formation of the product 
was observed. The reaction was, therefore, quenched and the mixture purified by flash 
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target molecule 3a was confirmed by 1H-NMR (figure 2.5). The characteristic peaks of 
the fused rings of the coumarin were assigned using a COSY spectrum, reported in the 
same figure. The spectrum shows the typical singlet of the boc- protecting group at 1.54 
ppm, together with the distinctive peaks of the coumarin moiety in the chemical shift 
range 8.3 – 7 ppm and the carboxylate singlet at 4 ppm.   
 
Figure 2.5. 400MHz 1H-NMR and COSY spectrum in CDCl3 of 3a  
Although the yield (26.5%) remained low, more than 5% of product was recovered by 
using MW assisted synthesis compared to the reflux synthesis previously applied. 
Moreover, this approach was shown to be incredibly timesaving as the reaction only 
took 2 hours compared to 7 days of the reflux strategy. It was, therefore, decided to 
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2.3.1.2: 2nd step – synthesis of 6-aminocoumarin-4-carboxylate (4) 
Having obtained compound 3a, the following step focused on the deprotection of the 
amine from the Boc group before proceeding to the addition of the acrylic moiety in C6 
position.  
 
Scheme 2.7. Boc cleavage of the compound 3a to obtain product 4.   
The general approach for Boc cleavage involving TFA in DCM was used to achieve 
product 4. The reaction was monitored via TLC and quenched only when the starting 
material was fully consumed. The reaction mixture was then washed with phosphate 
buffer to remove the TFA salt formed with the amine group, and extracted with DCM. 
However, after five extractions the TLC of the aqueous phase still showed the presence 
of the product, suggesting that DCM was not sufficiently polar to allow complete 
recovery of the product. Ethyl acetate was then used and showed to allow optimal 
extraction of the product from the aqueous phase, which was obtained with a yield of 
86% and fully characterised by 1H-NMR in CDCl3. The 1H-NMR spectrum in figure 2.6 
shows a shift towards lower ppm of the characteristics peaks of the coumarin moiety. 
The removed Boc- group exposed the electron-donating amino group, which generated 
a shielding effect on the aromatic protons, moving the signals. The missing singlet of 
the Boc group at 1.5 ppm and the new peak at 3.21 ppm, given from the amine, were 


















Figure 2.6. 400MHz 1H-NMR spectrum in CDCl3 of 4  
2.3.1.3: 3rd step – synthesis of 6-acrylamidecoumarin-4-carboxylate (2a) 
Once product 4 was obtained and characterised, it was possible to add the polymerisable 
acrylic group.  
 
Scheme 2.8. Synthesis of precursor 2a  
Product 2a was successfully obtained in 61% yield by following a method reported in 
literature by Chanthamath et al.22 The product was insoluble in CHCl3, MeOH and ACN, 
however it was opportunely solubilised in DMSO and its purity confirmed via 1H-NMR. 
COSY spectrum and coupling constant values were used to help assign the correct 
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the molecule. The singlet at chemical shift 10.45 ppm was originated from the proton of 
the acrylamide group, which showed the deshielding effect produced by the acrylic 
group, which caused a shift of the peak to the downfield. The peaks of the acryloyl 
group in the chemical shift range of 6.47 - 6.27 ppm provided further evidence of the 
formation of the acrylamide group. Moreover, the typical peaks of the four protons on 
the fused rings of the coumarin are clearly visible in the chemical shift between 8.47 
and 6.91 ppm.   
  
Figure 2.7. 400MHz 1H-NMR spectrum in DMSO of 2a  
2.3.2: Towards the synthesis of 6-vinylcoumarin-4-carboxylate (2b) 
The strategy represented in scheme 2.9 was identified to achieve the coumarin 






















Scheme 2.9. Synthetic pathway for the synthesis of precursor 2b  
The two-step synthesis of monomer 2b was already reported in 2009 by Nguyen et al.23 
The first step involved formation of the coumarin skeleton substituted in C6 and 
characterised by the methyl ester group in C4. The following step involved the addition 
of the vinyl group in position C6.  
2.3.2.1. 1st step – synthesis of 6-bromocoumarin-4-carboxylate (3b)  
A first attempt to synthesise the product 3b was carried out by following the procedure 
published by Nguyen.23 4-bromophenol, DMAD and PPh3 were refluxed in DCM for 
120 hours, as reported in scheme 2.10. Similar procedure carried out in the synthesis of 
3a, as described in section 2.3.1.1, was applied for the synthesis of 3b.  
 
Scheme 2.10. Synthetic scheme for 3b   
The literature data reported a purification step based on recrystallization of the crude 
and further purification of the solid via flash chromatography to obtain the product in 
52% yield. The same protocol was applied; recrystallization of the crude mixture 
provided the pure product in 10 % yield. However, TLC showed the presence of 
residual product in the filtrate. Therefore, the mixture was then evaporated and another 
recrystallization was carried out, collecting further 6% of pure product. A new TLC 
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recrystallization in isolating the product. A flash chromatography column was then 
performed on the filtrate solution, following the same conditions reported in literature. 
Unfortunately, no separation of the pure product was achieved in such conditions; the 
1H-NMR spectra showed the presence of both 4-bromophenol and the product in each 
one of the fractions collected from the column, suggesting a problem in the polarity of 
the eluent used. The reaction was repeated several times (> 3) and other solvent 
mixtures commonly used for chromatographic columns, were investigated to obtain a 
better separation. Although, the maximum yield obtained in one of the attempts was 
24% the 1H-NMR spectrum of the product showed small impurities from the residual 
starting material 4-bromophenol. Given the similarity in the synthesis of product 3a and 
the issues that rose during the product purification and the time-consuming reaction, it 
was decided to adapt the same approach involving microwave irradiation used and 
described in section 2.3.1.1. The synthesis was, once again, based on the data published 
by Hekmatshoar.19  
 
Scheme 2.11. Synthesis of 3b by microwave irradiation.   
The synthesis of compound 3b was carried out in ACN, the same solvent reported in 
literature 19. The reaction was monitored via TLC and quenched after 3 hours, as no 
significant differences were observed. The purification step was improved compared to 
the previous attempt. A gradient elution mode was employed; this allowed to gradually 
increasing the polarity of the mobile phase to obtain better separation of the compounds. 
The product 3b was obtained in 31% yield and the NMR spectrum, reported in figure 
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were identified in the chemical shift ranging 8.49ppm - 7.01 ppm, whereas the -CH3 of 
the carboxylate group gave the typical singlet at 4.02 ppm.  
 
Figure 2.8. 400MHz 1H-NMR spectrum in CDCl3 of 3b  
2.3.2.2: 2nd step – synthesis of 6-vinylcoumarin-4-carboxylate (2b) 
The second and final step of the synthesis of the coumarin derivative 2b was based on 
the Stille reaction, a C-C coupling between organostannanes and halides catalysed by 
palladium.24 The reaction was carried out as reported in literature, by refluxing for 120 
hours in THF (tetrahydrofuran).  
 
Scheme 2.12. Synthesis of compound 2b 
The first attempt to carry out the reaction via this approach was a success and product 























Fosca Mirata  Chapter 2 
 
 71 
scale and the final amount obtained (< 10 mg) was insufficient to proceed with the rest 
of the project. However issues of reproducibility occurred when the reaction was scaled 
up, in particular in the purification step, which appeared to promote decomposition of 
the product. Due to time restriction, this approach was not optimised, instead the 
microwave protocol, which proved to give better results in the synthetic paths already 
explored, was immediately employed (figure 2.13). The microwave irradiation synthesis 
was carried out in THF, which was used in the previous attempt involving reflux. 




Scheme 2.13. Microwave-assisted synthesis of compound 2b 
The spectrum 1H-NMR, figure 2.9, confirmed the purity of the product showing the 
doublet of doublet at chemical shift 6.75 ppm derived from the =CH- and the two 
doublets at 5.78 and 5.33 ppm from the =CH2-, typical of the vinyl group. The usual 
four peaks of the coumarin and the singlet of the carboxylate are showed in the range 
8.27-6.95 ppm and at 4.01 ppm, respectively. 



















Figure 2.9. 400MHz 1H-NMR spectrum in CDCl3 of 2b  
2.4. Fluorescence characterisation of the monomers   
The synthesis described in the previous section led to the two precursors, 2a and 2b, 
which purity was assessed by 1H-NMR. The following step was to evaluate the 
fluorescence properties of the two precursors. As aforementioned, the high fluorescence 
yield of the functional monomers is a required feature to provide the final polymer with 
sufficient fluorescence for future applications. Study the fluorescence properties at this 
stage of the synthesis was necessary because of the concerns related to the stability of 
the polymerisable acrylamide group during the hydrolysis step.  
2.4.1: Fluorescence studies of 6-acrylamidecoumarin-4-carboxylate (2a) 
As previously shown during the synthetic procedure, monomer 2a could only be 
solubilised in DMSO (see section 2.3.1.3), thus all the fluorescence studies were carried 

















Figure 2.10. The molecular structure of precursor 2a 
The UV-Vis spectrum in figure 2.11 shows two peaks at λabs= 300nm and λabs = 366 nm. 
Literature data shows that, although the compound absorbed more at short wavelengths, 
the emission intensity was higher when the compound was irradiated at longer 
wavelength.23 The fluorescence of monomer 2a was, therefore, evaluated after 
excitation at λabs = 366 nm. 
 
Figure 2.11. UV-Vis spectrum of precursor 2a in DMSO at concentration 0.092mM (0.025mg/mL). Two 
absorption peaks are shown at λabs = 300 and 366nm 
The fluorescence of different solutions of 2a in DMSO, with varying concentrations, 






















Figure 2.12. Fluorescence emission at λem = 557nm following excitation at λabs = 366nm of 2a in DMSO 
at different concentration ranging between 0.92 - 7.32mM. 
Figure 2.12 shows some evidence of fluorescence emission of 2a, however the changes 
in concentrations also provide evidence of quenching. The overall maximum emission 
was observed at 0.92mM, with no significant change when the concentration was 
doubled to 1.83mM, suggesting that the emission reached a plateau. Furthermore when 
the concentration was further increased to 3.66 and 7.32mM respectively, a strong self-
quenching effect was observed.  This is a regular effect that usually occurs in high 
concentration and it is caused by the collision of the fluorophore with a neighbouring 
one. Taking into consideration the requirements in terms of fluorescence intensity for 
the final polymers, these data clearly indicate that probe 2a was not a suitable 
fluorophore for this application. 
2.4.2. Fluorescence studies of 6-vinylcoumarin-4-carboxylate (2b) 
Considering the unexpected results obtained from the fluorescence evaluation of 
precursor 2a in DMSO, it was decided to study the fluorescent of monomer 2b (figure 


























Figure 2.13. The molecular structure of precursor 2b 
The UV-Vis spectrum of 2b was recorded in ACN and showed three main peaks at λabs 
= 255, 280 and 345nm (figure 2.14). 
 
Figure 2.14. UV-Vis spectrum of precursor 2b in ACN at concentration 0.11mM (0.025mg/mL). Three 
peaks are identified at λabs = 255, 280 and 345nm.  
As mentioned in the previous section, in the case of coumarins the long wavelength was 
selected to have a higher fluorescent emission. Solutions of precursor 2b were prepared 

























Figure 2.15. Fluorescence emission at λem = 510nm, following excitation at λex = 345nm, of 2b in ACN in 
concentrations ranging between 0.92 to 7.32mM. 
At a concentration as low as 0.92mM, the precursor 2b displayed high fluorescence 
emission, which significantly decreased when the concentration was doubled to 
1.83mM, reaching a minimum with 3.62 and 7.32mM. Also in this case a self-
quenching effect was observed, as the fluorescence decreases with increasing 
concentration. However, the overall emission of the precursor 2b was ten fold higher 
than what observed for precursor 2a. This difference could be due to an effect of the 
solvent. In order to confirm such hypothesis a solution of precursor 2b at concentration 
0.92mM, which reported the highest fluorescence emission in figure 2.15, was prepared 
in DMSO. The UV-Vis spectrum of 2b in DMSO (figure 2.16 A) did not show 
significant differences compared to the spectrum recorded in ACN. Therefore, the 2b 




























Figure 2.16.  A) UV-Vis spectrum of precursor 2b in DMSO at 0.11mM (0.025mg/mL). Three peaks are 
identified at λabs = 270, 280 and 345 nm. B) Fluorescent emission at λem = 480 and 510nm, following 
excitation at λex = 345nm, of precursor 2b at the same concentration 0.92mM, but in different solvent. 
Figure 2.16 (B) shows the emission of the precursor 2b in DMSO compared to that in 
ACN. For equal concentration, the fluorescence in DMSO was significantly lower 
(<4000cps) than that in ACN (50000cps), clearly proving that the solvent plays a major 
effect in the fluorescence emission. Although the two molecule 2a and 2b had the same 
core of coumarin, the polymerisable unit demonstrated to have a huge impact on the 
suitability of using these monomers as fluorescent tags. The change in solubility 
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solution due to intermolecular forces. In fact, the additional groups of the polymerisable 
acrylamide moiety of the precursor 2a could generate hydrogen bonding with the 
carbonyl on the coumarin, contributing in the reduction of fluorescence emission. Only 
the precursor 2b showed the required features for further applications. The last step of 
hydrolysis was carried out on precursor 2b to obtain the monomer 1b.  
2.5. Synthesis of 6-vinylcoumarin-4-carboxylic acid (1b): 
hydrolysis of 6-vinylcoumarin-4-carboxylate (2b)  
The final step of the strategic synthesis required the hydrolysis of the ester group in 
position C4. The reaction was carried out in basic conditions at 40°C in the dark.  
 
Scheme 2.14. Basic hydrolysis to achieve monomer 1b 
The reaction was monitored via TLC and quenched when the starting materials was 
completely consumed. The successful of the hydrolysis was assessed by 1H-NMR. The 
spectrum, reported in figure 2.17, showed the lack of the singlet of the -COOCH3 at δ: 
4ppm, confirming the presence of the desired product. The characteristic peaks of the 
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Figure 2.17. 400MHz 1H-NMR spectrum in DMSO of 1b  
2.6. Conclusions 
The precursors 2a and 2b were successfully synthesised and purified with good 
chemical yields.  A new synthetic strategy for the synthesis of coumarin derivatives was 
identified and optimised. In both cases, data suggested that microwave irradiation 
significantly improved the synthetic pathway, compared with the more traditional 
approach based on reflux. By using the novel procedure the reaction time was reduced 
from 7 days to about 3 hours, with significant reduction of side products, leading to an 
easier purification protocol, and increased chemical yields.  
Fluorescence studies carried out on both monomers identified 2b as the only suitable 
compound to be taken forward to the next stage of the work.  The fact that 2a could 
only be solubilised in DMSO had a clear impact on its fluorescence emission. 
The desired monomer 1b was obtained by hydrolysis of the methyl ester of precursor 2b. 
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monomer in the preparation of molecular imprinted polymers for sensing and drug 
delivery applications.  
This will be described in details in the following chapter 3 and 4.  
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3. Development of a detector for tamoxifen and its metabolites 
based on bulk molecularly imprinted polymers  
3.1. Introduction  
As already reported in chapter 1, tamoxifen (figure 3.1) is one of the most widely used 
drugs for anticancer therapy. The drug acts as an antagonist on oestrogen receptors in 
breast tissues, inhibiting the proliferation of cells and hence the propagation of the 
tumour.1 Due to its anti-oestrogen effect, the World Anti-doping Authority (WADA) 
has listed tamoxifen as one of the prohibited substances. Although the drug is not 
responsible for enhancing the performance of athletes, it is frequently used in 
conjunction with doping agents to minimise gynecomastia (enlargement of breasts), one 
of the frequent side effects of doping with steroids.2 The presence of tamoxifen 
metabolites in athletes’ biological samples is always considered to be a red flag for 
doping. Unfortunately the evaluation of large numbers of samples is limited by the lack 
of a fast, cheap and reliable test that would act as a strong deterrent. This was the drive 
for the development of the work that is described in this chapter and that was published 
as an article in Analytical Bioanalytical Chemistry.3 
 
Figure 3.1. Molecular structure of tamoxifen 
The state of the art regarding the detection of tamoxifen and its metabolites was already 
discussed in the introduction (session 1.3.2). Although some important advances in 
terms of accuracy and efficiency were made in the last decade, all reported 
O
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methodologies relied heavily on complex instrumentation and trained personnel, which 
results in associated high cost, limiting the number of samples that can be screened. 
Given the high level of interest, one of the objectives of this project was to develop a 
novel material to be used for the detection of tamoxifen metabolites in athletes’ 
biological samples. The polymer matrix was prepared by molecular imprinting and was 
characterized based on its optical properties. The results presented in this chapter were 
organised in two parts, the first one describing the interactions between the functional 
monomer and the analytes, the second one focusing on the synthesis and 
characterization of the obtained polymer matrix.  
3.2. Design of the polymer matrix  
The molecular imprinting technique, described in chapter 1 (section 1.2) allows the 
formation of cavities, which are complimentary in shape and functionalities to the 
template used. The polymers prepared using this method have the potential to 
selectively recognise the template molecule. The degree of recognition is highly 
dependent on the polymer formulation, the monomers structure and ratio, the cross-
linking agent, and the experimental conditions. All of the above play an important role 
and need to be carefully optimised for each application. 
3.2.1.  Functional monomer and template 
3.2.1.1. Functional monomer 
The functional monomer carries the main functional groups that are relevant for the 
formation of the interactions with the template via covalent, non-covalent or semi-
covalent approach (section 1.2). Such interactions play a key role in the formation of 
imprinted polymers. The stronger and more defined the interactions are, the higher the 
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selectivity and the imprinting efficiency of the resulting polymer. Molecular imprinting 
is a promising method for preparing artificial receptors bearing pre-determined binding 
cavities capable of recognizing target molecules. Molecularly imprinted receptors can 
also be functionalised in order to produce a specific signal triggered by the binding 
event. One possible way to obtain this is by functionalising the matrix and incorporating 
a fluorescent probe close to the binding site. When the analyte is recognised and bound, 
a change of fluorescence is therefore produced.  
Fluorescence spectroscopy is a good technique for sensing analysis, due to its non-
invasiveness and high sensitivity (chapter1, section 1.4). Literature data suggested that a 
common approach for the development of optical sensors involved the use of 
nanomaterials with intrinsic fluorescent properties, namely quantum dots, carbon dots, 
carbonanotubes or encapsulation via non-covalent interactions of the fluorescent probe 
in the nanomaterials.4 However, the latter approach implied a potential decrease in the 
sensitivity of the nanosensor, due to the possible leakage of the tag. MIPs have largely 
been employed in the development of optical sensors both for non-fluorescent5 and 
fluorescent analytes.6, 7 An interesting example was reported by Levi et al. about the 
development of optical sensor for the detection of chloramphenicol. The system was 
based on the competitive displacement of the drug conjugated with the dye methyl red 
from the cavities of an imprinted polymer.8 The group prepared different analogous of 
chloramphenicol in order to determine the ability of the polymer to recognize the target 
molecule and to better understand the nature of the interactions involved (figure 3.2). 
This system presented two main drawbacks, HPLC equipment was still required for the 
analysis and the polymer was not able to sufficiently differentiate the analyte and 
tiamphenicol, the structural analogue, hence suggesting a lack of specificity. 




Figure 3.2. The target molecule is represented in the top left corner; the chloramphenicol diacetate and 
the tiamphenicol are the synthesised analogues, while the chloramphenicol-Methyl red is the drug 
conjugated with the dye 
Although the use of expensive and complicated instruments was still largely required 
when detectors were developed, there was a continuous drive towards innovative 
applications of MIP in sensing. Two recent interesting examples involved the selective 
detection of antibiotics, enrofloxacin9 and vancomycin.10 Carrasco et al. described the 
preparation of a microarray of optical fibre bundles with MIP microspheres.9 The 
advantages of such optical fibres were their reproducibility, resistance to organic 
solvents and the possibility to be applied in real serum samples with good LOD. While, 
Korposh and co-workers developed a novel sensor based on a long period grating (LPG) 
fibre optic. The combination of the LPG with nanomaterials, such as MIPs, produced 
sensors with high sensitivity and specificity, as demonstrated in their work.10  
For the purpose of this objective, the efforts focused on the selection of a fluorescent 
monomer able to give a signal upon binding with the analyte. Chapter 2 described the 
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figure 3.3. The fluorescence of VCC, resulting from the conjugation of the benzene and 
the pyran rings, was evaluated and found to be dependent on the solvent used. 
 
Figure 3.3. Structure of 6-vinylcoumarin-4-carboxylic acid, VCC. The monomer designed for this project.  
Based on previous knowledge, the monomer and the template were expected to interact 
via π-π stacking and ionic bond, with the strengths of these interactions depending on 
the solvent system.11 The aromatic portions of the two molecules, which were the 
benzene ring fused to a heterocyclic pyran ring and the triphenylethylene moiety, were 
expected to give rise to π-π stacking, while the amine group of the template could 
interact with the carboxylic acid of the monomer via ionic bonding (figure 3.4).  
 
Figure 3.4. Schematic representation of the ionic bond between the tertiary amine of tamoxifen and the 
carboxylic acid of the monomer  
3.2.1.2. The template 
As already mentioned the preparation of MIPs is based on the formation of strong 
interactions between the imprinting species and the functional monomer. One of the 
issues that might occur during development of a MIP is that, despite numerous and 
repetitive washings of the final material, trace amounts of the template (generally <1%) 
may remain entrapped within the cavities. This could leak during analysis and interfere 
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catalysis or separation of mixtures. However, when MIPs are used in sensing and 
analysis of traces levels, the template bleeding cad cause false positive results. In order 
to address this issue of potential template contamination of the samples, three main 
approaches are reported in literature. These are the use of strong solvent in combination 
with acids, use of specific triggers like temperature, and use of template analogous. 
Rashid et al. were able to quantitatively elute the tamoxifen employed in the preparation 
of a MISPE (molecularly imprinted solid phase extraction) by using stronger washing 
conditions.13 Although a mixture of methanol-acetic acid, in different ratios, was used 
for washing out the tamoxifen, the drug was not fully recovered and the group 
experienced some leakage during the application, causing significant interference. A 
mixture of acetonitrile and acetic acid 4 to 1 was eventually required to completely 
wash the tamoxifen out. Zander et al. demonstrated that by using a combination of heat-
treatment and numerous washings of the polymer with strong solvents, 95% of template 
removal was achieved, compared with removal of 60-90% when weaker solvents were 
used.14 Although successful, such protocols were highly dependent on the type of 
polymer matrix and functional monomers.  
A more common approach, identified to avoid false positive during the analysis, is 
based on the use of a structural analogue of the target molecule as template15. This 
could result in loss of specificity, if the structural similarities are limited, and therefore 
great care has to be exercised when choosing such analogue. For the synthesis of MIP in 
this work, clomiphene, a chlorinated analogue of tamoxifen, was chosen as template. Its 
chemical structure is represented in figure 3.5.16  
Clomiphene was first synthesised in 1956 at William S. Merrell Company. Although the 
successive experimentation in rats showed antifertility properties of clomiphene, the 
evaluation of its biological activity in human females resulted in an unexpected reversed 
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behaviour.17 In fact, just like tamoxifen, clomiphene is part of the SEM (selective 
oestrogen modulators) family, acting both as the agonist or the antagonist in different 
species, organs, tissues and cell type. Clomiphene was found to induce the ovulation in 
female patients affected by amenorrhea and anovulation, thus becoming widely and 
successfully used in the treatments of female infertility. The drug inhibits oestrogen 
receptors in the hypothalamus, stimulating the release of the two main gonadotropins, 
the FSH (follicle-stimulating hormone) and LH (luteinizing hormone), leading to 
follicular growth, ovulation and pregnancy.18  
The structure of clomiphene is very similar to tamoxifen, with one chlorine atom to 
replace the ethyl group and a di-ethylamine instead of the di-methylamine (figure 3.5). 
The use of the analogue was not expected to have a significant impact on the molecular 
recognition ability of the matrix. The binding sites in the tamoxifen molecule were 
identified as the amino group, for potential ionic interactions and the three aromatic 
rings, for π-π stacking. Such moieties were still present in the molecule of clomiphene.  
 
Figure 3.5. Molecular structure of tamoxifen and clomiphene. The binding sites, as the tertiary amine and 
aromatic groups are present in both structures   
3.2.2. Interaction studies of functional monomers and analytes. 
Previous results reported by Nguyen et al. demonstrated that VCC could be applied as a 
fluorescent monomer in the preparation of a molecular imprinted sensor for chiral 
amines.19 By using (-)-ephedrine as the template, the group prepared MIPs in which the 
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amines and template. The interactions between the monomer and ephedrine were 
proved to occur via hydrogen bonds between the carboxylic acid on the fluorophore and 
the amine on the template. Given the similarity of the system described by Nguyen and 
the system proposed here, a comparable behaviour and a quench of fluorescence upon 
binding of the analytes were expected. Nevertheless, studies on the interactions between 
VCC and the analytes were carried out to ensure the formation of a detectable signal 
triggered by the binding of the target molecules. Three analytes were investigated: 
clomiphene (CLO), the structural analogue of the drug, tamoxifen (TAM) and 4-
hydroxytamoxifen (4-OHT), one of its main metabolites (figure 3.6). 
 
Figure 3.6. Structure of the three analytes from left to right: CLO - clomiphene, 4-OHT - 4-
hydroxytamoxifen, TAM - tamoxifen 
The first step in this work focused on the identification of the optical characteristics of 
VCC. In order to favour the formation of non-covalent interactions between VCC and 
TAM a polar, non-protic solvent was necessary. Literature research showed that 
Ansell’s group employed NMR titration and data analysis to study the association of 
ephedrine and the carboxylic acid of the methacrylic acid. The group successfully 
demonstrated that strong interactions were obtained using the solvent acetonitrile 
(ACN).20 It was, therefore decided to perform the interaction studies in the same solvent. 
The UV-Vis spectrum of the monomer, recorded in ACN, showed the presence of three 














Figure 3.7. UV-Vis spectrum of VCC in ACN at 0.11mM. Three main peaks are identified at λabs = 260, 
280 and 345nm  
Although the UV-Vis spectrum showed λmax = 260nm, the fluorescence spectrum was 
recorded after excitation at λex = 345nm. In fact, literature data showed that the 
fluorescence emission of the monomer VCC was more intense after irradiation at λex = 
345nm, rather than λex = 260 or 280nm.19 Figure 3.8 shows the strong emission of VCC 
at λem = 521nm, following excitation at λex = 345nm. 
 
Figure 3.8. Emission spectrum of the functional monomer, VCC, at λem = 521nm, after excitation at λex = 
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In order to study the effect of the analytes concentration on the fluorescence intensity of 
VCC, six different solutions containing monomer-analyte ratios ranging between 0 and 
5 were prepared (table 3.1).  
Table 3.1. The appropriate volume of CLO, TAM and 4-OHT from stock was added to 1 mL of VCC 
stock solution (5.93x10−4 M) followed by addition of ACN to give a total volume of 2 mL (the minimum 
volume required by fluorimeter limitation).  
Ratio  






in ACN  
1:0 2.97x10−4 M - 2 mL 
1:0.25 2.97x10−4 M 7.4x10−5 M 2 mL 
1:0.5 2.97x10−4 M 1.49x10−4 M 2 mL 
1:0.75 2.97x10−4 M 2.23x10−4 M 2 mL 
1:1 2.97x10−4 M 2.97x10−4 M 2 mL 
1:5 2.97x10−4 M 1.48x10−3 M 2 mL 
Each solution was kept at room temperature for 5 minutes before being analysed. The 
fluorescence was recorded after irradiation at λex = 345nm, monitoring the emission 
between λem = 345-680nm. The data obtained are reported in figure 3.9   
  





Figure 3.9. Fluorescence quenching of the monomer 6-vinylcoumarin-4-carboxylic acid following 
addition of increasing concentrations of the analytes: tamoxifen (a), clomiphene (b) and 4-
hydroxytamoxifen (c). Fluorescence spectra recorded after excitation at λex: 345 nm. [VCC] = 2.97 × 10−4 
M, Vtot = 2 mL.  
Figure 3.9-a shows the effect of increasing amount of tamoxifen on the fluorescence 
emission of VCC, while figure 3.9-b and -c show the effect of clomiphene 4-
hydroxytamoxifen, respectively. As expected, based on available literature data, there 
was a direct relationship between the quenching of VCC fluorescence and the 
concentration of analytes, together with a mild hypsochromic shift (shift of the emission 
bands towards shorter wavelength). 4-OHT was expensive to acquire and not easily 
available, therefore it was decided to evaluate the large monomer-analyte ratio (1:5) 
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Results showed a further quench of fluorescence by TAM and CLO in such conditions. 
Considering the comparable trend of quenching obtained by the three analytes, it was 
possible to assume that a further quenching of VCC would be recorded in higher ratios 
of 4-hydroxytamoxifen.  
A potential explanation for the observed fluorescence quench and the hypsochromic 
shift could be found on the fact that coumarin molecules were not characterized by a big 
separation in energy between the states π, π* and n, π* and were, therefore, easily 
perturbed. Moreover, in VCC a π, π* state may lie below the n, π *, this could explain 
the intense fluorescence of VCC and the blue shift. The π ← π * transitions were more 
intense than n← π * transitions.  
Figures 3.9-a, -b and -c show a variation in the fluorescence intensity of the samples 1:0, 
containing only the monomer, regardless the quencher. Such variation was probably due 
to human error while preparing the samples or to errors related to the instruments 
(balance/fluorometer), however it is possible to assume that the same errors were 
maintained within each set of sample, prepared and tested at the same time. Therefore, 
to be able to compare the effects obtained by each analyte, the data were expressed as 
percentage of VCC residual fluorescence, following addition of the quencher solution 
(figure 3.10). In order to consistently evaluate the intensity value of fluorescence, it was 
decided not to take into account the small blue shift effect (hypsochromic shift) and to 
measure the emission intensity at fixed wavelength λem = 521nm. After averaging the 
triplicates, the results were then compared with the VCC fluorescence value, which was 
normalised to 100.  




Figure 3.10. Percentage of residual 6-vinylcoumarin-4-carboxylic acid monomer (VCC) fluorescence, 
following addition of the tamoxifen (TAM), 4-hydroxytamoxifen (4-OHT) and clomiphene (CLO) in 
increasing concentrations in ACN. VCC fluorescence is normalised to 100. Fluorescence spectra recorded 
after excitation at λex: 345nm and read at λem: 521nm. [VCC] = 2.97 × 10−4 M, Vtot = 2 mL 
By normalising the values recorded for samples 1:0, containing only VCC, it was 
possible to minimise the variation in fluorescence previously observed. By using this 
approach to plot the experimental data, a more significant comparison of the effect of 
the three different quenchers on VCC fluorescence could be carried out. The three 
analytes showed progressive and rapid quenching of fluorescence as a function of 
increasing concentration. The experimental conditions, concentrations, solvent and set-p 
were all kept constant during the tests. Therefore any variation in the residual 
fluorescence could be attributed to the variations in chemical structure of the molecule, 
which, ultimately, influence the interactions with the monomer. CLO and 4-OHT were 
able to quench 54% and 52%, respectively, of the monomer fluorescence, compared to 
40% quenching obtained with TAM. Interestingly, 4-OHT was a stronger quencher than 
TAM, in any of the ratios. Although the variation in structure was minimal, the presence 
of the hydroxyl group in the metabolite played a key role in the binding interaction, 
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compared to 4-OHT was not a cause of concern. In fact, tamoxifen is normally 
metabolised shortly after it is consumed, therefore, in potential applications in real 
samples, the metabolite 4-OHT would be the main analyte.  
Having obtained evidence of interactions between VCC and CLO, TAM, 4-OHT by 
quenching of the monomer fluorescence, the next step focused on the characterisation of 
the polymeric matrix.  
3.3. Preparation of the molecularly imprinted polymer 
3.3.1. Choice of format polymer 
The different polymer formats have been described in chapter 1. Nowadays the 
imprinted polymers in the bulk format are still very widely used for sensing applications. 
Bulk polymerisation is considered one of the simplest synthetic processes for MIP. The 
grinding and sieving procedures of the final monoliths are easy to optimise. The bulk 
format was therefore chosen for the development of the optical detector. Dr. Judith Ray, 
a previous member of the Resmni’s research group, synthesised the polymers employed 
in this work during her secondment at Polyintell. This is a French company specialised 
in bulk MIPs for applications as solid phase extraction (SPE) absorbent material for 
sample clean-up in food safety or environmental analysis, life science and 
pharmaceutical R&D.21,22 The polymers were then shipped to Queen Mary University 
of London, where they were tested and analysed for their potential applications as 
detector of tamoxifen and its metabolites.  
3.3.2. Polymers synthesis (carried out by Dr. Ray)  
Although the synthesis of the polymers for sensing application was carried out by Dr. 
Ray, it is briefly reported in this section for completeness. The synthesis of molecular 
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imprinted polymers involved a careful evaluation of the possible combination of 
backbone monomers (BM) and cross-linking agents (XL), which led to the selection of 
methacrylic acid as BM and EDGMA as cross linker. The chosen porogenic solvent was 
ACN, as this solvent was shown to favour the formation of strong interactions between 
FM and T.20 After different attempts the synthesis of MIP and the corresponding NIP 
was optimised using the ratio 1:1:3:20, T/FM/BM/XL (clomiphene, 6-vinylcoumarin-4-
carboxylic acid, methacrylic acid and EDGMA respectively), with 80% crosslinker and 
a 1:1 ratio between clomiphene and VCC. 95% template removal was obtained after 
braking, grounding and sieving the bulk polymers and after several washings with 
2.5 % acetic acid in methanol. The template seemed to be hard to remove completely 
from the MIP; nevertheless the left over template, being it an analogue of the analyte, 
was not expected have an impact in the analysis. Before being sent to Queen Mary 
University of London, the size of the particles was confirmed between 45 and 25 µm. 
Moreover, the different binding capacities of the polymers, both MIP and NIP, towards 
the analytes were evaluated. The imprinted polymer showed a superior molecular 
recognition capacity towards clomiphene and tamoxifen compared to the non-imprinted 
polymer, with an IF =21.7 and 18.7, respectively. Rebinding experiments were also 
carried out on both MIP and NIP confirming the imprinting effect of MIP. As expected, 
the imprinted polymer showed higher affinity towards the template than towards 
tamoxifen, while the non-imprinted polymer showed very little rebinding affinity with 
similar values for both clomiphene and tamoxifen.  
3.3.3. Interaction studies of MIP-analytes 
The interactions between the polymers and the analytes were investigated as a function 
of the matrix fluorescence quenching. The amount of VCC incorporated in the polymer 
(VCCMIP) was calculated at Polyintell by fluorescence, using a reference line. It was 
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found to be 2.36x10−4 moles of VCC per milligram of imprinted polymer; such value 
was then used to prepare solutions of known ratios VCCMIP-analytes.  
3.3.3.1. Optimization of the method  
Preliminary studies were carried out by testing the change of MIP fluorescence in 
relation to tamoxifen, exploring a range of ratio VCCMIP-TAM between 0 and 5. Due to 
lack of polymer the fluorescence measurements were carried out on a plate reader, 
which allowed using small amounts of material and volumes. The solutions VCCMIP-
TAM were prepared in ACN into the wells of a standard 96-well plate, in order to 
minimize as much as possible any loss of material. Control solutions were also prepared 
with the polymer at the same initial concentrations, to monitor the effect of the dilution 
on the fluorescence. The results, reported in figure 3.11, showed that the fluorescence of 
the MIP was gradually quenched as the concentration of tamoxifen increased. The data 
demonstrated the ability of the polymer to rebind tamoxifen into the cavities and to 
provide a detectable signal. Moreover, it was proved that VCC maintained its capability 
to establish interactions with the target molecule, although being incorporated within 
the polymeric matrix. On the other hand, the control solutions showed a constant value 
of fluorescence emission, independently from the dilution. This confirmed that the 
quenching observed in the presence of the drug was a direct result of the interactions 
between the matrix and tamoxifen, as opposed of an effect due to the dilution of the 
sample.  
  




 Figure 3.11. Fluorescence intensity of MIP (5 mg/mL in ACN, 1.18x10−3 M in VCC), following the 
addition of increasing amount of tamoxifen, compared to successive dilution of MIP solution. 
Fluorescence recorded with FLUOstar OPTIMA plate reader; the excitation filter used was 340-10 and 
the emission filter was 510-20 
Once established that the methodology used provided encouraging results, it was then 
applied to evaluate the interactions between the polymer and the other analytes. 
3.3.3.2. Fluorescence studies of MIP-analytes. 
The same procedure described in the previous section was employed to investigate the 
interactions of MIP with TAM, 4-OHT and CLO. Five solutions containing VCCMIP-
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Table 3.2. Solutions of MIP/NIP containing an increasing amount of analytes compared to the functional 
monomer incorporated for fluorescence quenching studies.   
Ratio  
VCCMIP-Analyte 
n° of moles of VCC 
in MIP 
n° of moles of 
Analyte 
1:0 2.36x10−7 mol - 
1:0.25 2.36x10−7 mol 5.9x10−8 mol 
1:0.5 2.36x10−7 mol 1.18x10−7 mol 
1:0.75 2.36x10−7 mol 1.77x10−7 mol 
1:1 2.36x10−7 mol 2.36x10−7 mol 
The data presented here were expressed as a percentage of MIP residual fluorescence 
following addition of the quencher to the solution. After averaging the duplicates, the 
results were then compared with the value obtained by the MIP fluorescence, which was 
normalised to 100.   
 
Figure 3.12. Residual fluorescence of MIP (5 mg/mL in ACN, 1.18x10−3 M in VCC), following the 
addition of varying equivalents of analytes (tamoxifen, 4-hydroxytamoxifen and clomiphene). 
Fluorescence recorded with FLUOstar OPTIMA plate reader; the excitation filter used was 340-10 and 
the emission filter was 510-20. Data are presented as percentage of residual fluorescence compared to the 
MIP fluorescence 
The results, showed in figure 3.12, confirmed the formation of interactions between 
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Interestingly, the progressive quenching of the MIP followed the same trend already 
showed in figure 3.10 in which the fluorescence of the non-polymerised VCC, 
quenched by the analytes, was reported. This suggested that the incorporation of the 
functional monomer within the polymeric network did not affect its binding sites, 
maintaining the ability of VCC to interact with the target molecules. Clomiphene 
showed to be the strongest quencher, followed by 4-hydroxytamoxifen and tamoxifen. 
This result confirmed the higher affinity of the polymeric matrix towards the template, 
already measured with the re-binding experiments carried out at Polyintell. Table 3.3 
shows a summary of the percentage of MIP/VCC fluorescence quenching following 
addition of the analytes. Higher quenching by each of the analytes was obtained in case 
of MIP, providing clear evidence of the formation of selective 3D cavities that involve 
tighter interactions with the target molecules. This was noticed in particular when using 
a ratio VCCMIP/VCC-CLO 1:0.5 in which the quenching of MIP was 1.5 times bigger 
than what observed in case of VCC functional monomer. However, the difference in 
quenching, between the MIP and VCC, decreased as the ratio increased, probably as the 
saturation point of the MIP was being approached. 
Table 3.3. Summary of percentage of MIP/VCC fluorescence quenching following addition of analytes. 
Ratio VCC:TAM MIP:TAM VCC:4OHT MIP:4OHT VCC:CLO MIP:CLO 
0.5 16% 35% 34% 40% 35% 53% 
0.75  27% 45% 45% 47% 50% 64% 
1 40% 43% 52% 64% 54% 68% 
 
3.3.4. Visual detection of clomiphene 
One of the main objectives of this work was to develop a polymeric matrix with 
potential application as detector for fast and easy screening, without using complex 
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equipment. Having confirmed the generation of a signal, detectable with a 
fluorimeter/plate reader, the feasibility of using the MIP as material for the development 
of a visual detector was evaluated. A new set of preliminary experiments was, therefore, 
designed and optimised in order to assess with the naked eye the quenching of MIP 
fluorescence in relation with the strong quencher clomiphene. Four glass vials were 
prepared containing MIP and NIP in ACN. To each vial, an increasing amount of 
clomiphene was added to obtain a ratio VCCMIP:CLO ranging between 1:0 to 1:1. The 
samples were placed in a dark room under a standard 365nm UV light and observed 
with the naked eye. Figure 3.13 (A and B) shows the images taken in such conditions. 
When the four vials containing NIP and CLO were irradiated with the UV lamp, no 
significant changes in the fluorescence brightness were visible, regardless the 
concentration of CLO (figure 3.13-A). While, when the vials containing MIP and CLO 
were placed in the same conditions, a clear difference in emission between the vials was 
detected (figure 3.13-B). In particular, the fluorescence brightness of the solutions 
decreased as the amount of CLO increased from 0 to 1 equivalent.  
  






Figure 3.13. Visual detection of clomiphene with NIP and MIP by using a standard 365 nm UV light. A) 
NIP solutions from left to right, ratio of fluorophore - clomiphene 1:0, 1:0.5, 1:0.75, 1:1. No significant 
variation in fluorescence by increasing the amount of clomiphene can be detected. B) MIP solutions from 
left to right, ratio of fluorophore - clomiphene 1:0, 1:0.5, 1:0.75, 1:1. A clear quenching of fluorescence 
by increasing the amount of clomiphene from 0 to 1 equivalents is shown  
These preliminary results were very encouraging, as it represented a first step towards 
the use of this material in the development of a visual sensor for easy detection of the 
drug. Moreover, the difference between the two matrices reinforced the HPLC data 
previously obtained, which showed the higher binding affinity of the imprinted polymer 
towards the template, when compared to the non-imprinted counterpart. The very little 
change of fluorescence in the NIP, in comparison to the significant fluorescence 
quenching observed in the MIP, suggested a lack of cavities in the non-imprinted 
network that would allow tighter interactions with CLO, and thus higher quenching.  
A) 
B) 
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3.4. Conclusion and future work 
VCC was identified as a suitable fluorescent functional monomer for the preparation of 
MIP with potential application as detector of tamoxifen and its metabolites. Data 
demonstrated that interactions between the functional monomer and clomiphene, 
tamoxifen and 4-hydroxytamoxifen provided a measurable effect on the fluorescence of 
the monomer. In fact, the residual fluorescence of VCC progressively reduced as the 
amount of CLO, 4-OHT and TAM increased from 0 to 1 equivalents.  
Having confirmed the interactions between the monomer and the targets, an imprinted 
polymer was obtained in bulk format using clomiphene as template. The use of 
structural analogues of analyte is a very common technique in the synthesis of MIP 
intended for detection and trace analysis. This way any potential bleeding of analyte 
during the analysis, which could lead to false positive results, is minimised. The 
imprinted polymer was characterized by good molecular recognition properties in ACN 
towards clomiphene and tamoxifen, with imprinting efficiencies of 21.7 and 18.7, 
respectively. The larger affinity of the MIP towards clomiphene was also confirmed by 
fluorescence study. Although significant fluorescence quenching was obtained when the 
MIP was in contact with each of the analytes, CLO provided a bigger quenching. This 
was proved to be consistent with the data obtained with the non-polymerised VCC and 
the analytes. Finally, the MIP was tested for visual detection in comparison with the 
NIP. The results showed that the quenching of the MIP can be seen with the naked eye, 
while the NIP fluorescence remains almost unaltered. The results reported in this 
chapter put the bases for the production of a detector of drug metabolites based on a 
switchable polymer, which can be used by a layperson.  
The polymer obtained in this work is expected to perform in combination with SPE 
(solid phase extraction) cartridge. Tamoxifen and its metabolites are insoluble in water 
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and are excreted in urine as conjugates of glucuronic acid. Therefore, a pre-treatment 
involving hydrolysis, in order to obtain the free drug/metabolite, followed by a SPE step, 
to concentrate the sample, is essential before the analysis. At this point, the polymer 
here developed can be used to carry out the detection of the analytes in organic solvent, 
as ACN, where the interactions between the FM and the target are favoured.  
Future work should involve the determination of the lower detection limit of the bulk 
polymer and the evaluation of the characteristics of this detector system in real samples. 
Moreover, the sensitivity of the system could be increased by reducing the size of the 
polymer and preparing it in the format of nanoparticles. By increasing the surface-to-
volume ratio, more active sites could be available to rebind the drug, thus providing a 
lower detection limit  
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4. pH-responsive molecularly imprinted nanogels for delivery 
of tamoxifen  
4.1. Introduction 
The results described in the thesis have so far centred on the synthesis of the fluorescent 
functional monomer 6-vinylcoumarin-4-carboxylic acid (VCC), reported in chapter 2, 
and its use for the preparation of bulk imprinted polymers for sensing applications, 
described in chapter 3.  
 
Figure 4.1. 6-vinylcoumarin-4-carboxylic acid, VCC.  
The fluorescence studies reported in chapter 3 highlighted the strength of the 
interactions occurring between VCC and tamoxifen, suggesting the possibility of using 
the same monomer for the preparation of a new MIP with potential application as drug 
delivery vehicle. The sections in this chapter will describe the work done and discuss 
the results obtained.  
4.1.1. Molecularly imprinted nanogels as drug delivery vehicles 
As mentioned in chapter 1 (section 1.3.2), one of the main requirements of new drug 
delivery systems (DDS) is the capacity to provide sustained and tailored drug release. 
The use of the molecular imprinting approach for loading drugs has shown interesting 
results. Researchers have largely explored the potential of MIPs as DDS and many 
reviews have been published during the past few years.1-3 The use of functional 
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control of the release profile, by altering the strengths of the interactions.1 For examples, 
MIPs have been studied as transdermal carriers for enantioselective-controlled 
delivery.4 The particularly high specificity and selectivity of MIPs make these materials 
ideal vehicles in cases of chiral drugs delivery in which one of the enantiomers is more 
active than the other. By delivering only the active enantiomer, instead of a mixture, the 
efficiency of the drug increase and the potential toxicity and side effects, caused by the 
inactive enantiomer, decrease considerably. The use of MIPs represents a good 
alternative to the methodologies employed for the production of pure single enantiomers, 
which are expensive and time-consuming. Moreover, the risk associated with the 
racemization of a single enantiomer of the chiral drug, both in raw material and 
pharmaceutical products, requires constant control of the substance. 
In the group where this project was developed, there is a strong expertise in polymeric 
nanoparticles, developed for a variety of applications, as well as considerable 
knowledge in the area of molecular imprinting. In particular the group was the first to 
report the development of imprinted nanogels as enzyme mimics, to catalyse carbonate 
hydrolysis.5 The design of nanogels (already discussed in chapter 1) has evolved during 
the years, together with different synthetic approaches that can be used to prepare 
them.6 The literature abounds with reviews that explain in detail the different methods 
employed, such as suspension polymerisation, photolithographic technique, (inverse) 
mini- or micro- or emulsion, precipitation, high dilute free radical or living radical 
polymerisation (figure 4.2).7  




Figure 4.2. Schematic representation of the synthetic steps in some of the existent polymerisation 
procedures. Image reproduced with permission from Moral and Mayes8  
Each polymerisation method produces final materials characterised by different 
rebinding ability, morphology and particle size, as reported in 2004 by Moral and 
Mayes.8 The choice of the most appropriate synthetic approach is therefore important in 
order to tailor the size and the morphology of the particles, to suit the different 
applications. The emulsion polymerizations, micro- or mini-, are heterogeneous 
processes and depend on the nature of the monomers. If the monomers are hydrophilic 
the polymerisation is carried out in aqueous droplets in organic solvents, vice versa if 
the monomers are hydrophobic. Such approaches resort to the use of surfactants in order 
to disperse the monomers in the continuous phase, stabilise the system and inhibit the 
aggregation of particles.9 Whereas, high dilution radical polymerisation is based on the 
use of low concentration of the monomers to increase the distance between the growing 
polymer chains, therefore favouring the intramolecular rather than intermolecular 
crosslinking and preventing macrogelation. Conversely from the emulsion 
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polymerisation, the high dilution is a homogeneous process in which the components 
are completely soluble in the polymerisation solvent.9  
In the Resmini’s group high dilution radical polymerisation has been optimised as the 
prevalent synthetic approach for the preparation of nanogels.5, 10, 11 The high dilution 
does not require the presence of the surfactants for stabilising the particles; this is one of 
the main reasons for selecting this particular approach. Surfactants are useful in 
stabilising the systems, but they can also be toxic and difficult to remove during 
purification. Furthermore, surfactants can alter the recognitions properties of the matrix 
and compete with the formation of hydrogen bonds thus weakening the binding affinity 
of the network towards the substrate. 
4.2. Imprinted nanogels formulation 
The first part of the work towards the development of imprinted nanogels to be used 
potentially for the delivery of tamoxifen, involved some fundamental studies to identify 
the key parameters, essential to obtain the best polymer formulation. This involved the 
selection of the most suitable monomers, the crosslinker, and the initiator. Other 
important factors to consider during the design of imprinted polymers were the 
porogenic solvent and the concentration of monomers (CM) as these have been shown to 
influence the particle size. In the following sections the choice of each component of the 
polymer mixture is discussed.  
4.2.1. Choice of the functional and backbone monomers 
• THE FUNCTIONAL MONOMER  
As already discussed in chapter 1, the formation of a stable template-functional 
monomer complex is a key requirement to the formation of polymers with high 
recognition characteristics. The VCC monomer (6-vinylcoumarin-4-carboxylic acid), 
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whose synthesis is described in chapter 2, was selected as functional monomer as a 
result of the strong interactions that occur with the target drug tamoxifen, in addition to 
its fluorescent properties. The latter in particular is very important, because it allows 
monitoring carefully the fate of the nanoparticles both in vivo and in vitro, in addition to 
allowing the investigation of the internalisation mechanism.  
Careful evaluation of the structures of VCC and tamoxifen suggested the formation of 
two possible main interactions, strongly dependant on the chosen solvent system. 
Hydrophobic interactions can take place as a result of π-π stacking of the aromatic units, 
as well as ionic bond between the carboxylic group on VCC and the amino group on 
TAM (figure 4.3). However, given that the primary target for this work was to develop 
a system in which the drug release could be controlled by pH, it was required to ensure 
good ionic interactions. For this purpose a polar, aprotic organic solvent, with dielectric 
constant sufficiently high to allow solubilisation of all the components, will be 
necessary for the polymerisation. Section 4.2.4 will cover more in details the choice of 
the polymerisation solvent. 
 
Figure 4.3. Representation of the ionic interaction that take place between the amine group of the 
tamoxifen and the carboxylic acid in VCC.   
The pH-sensitive drug vehicles, as the one proposed, are based on the lower pH values 
existing in inflamed, infected and malignant tissues. These tissues are slightly more 
acidic than the physiological pH of 7.4, due to high glycolytic activity that produces 
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internalised in cancer cells in which the intracellular pH was shown to vary between 4 
and 6.14 However, pH 5.5 is conventionally reported in the literature when studying the 
release of novel materials as proof of concepts.15, 16 The carboxylic acid of the VCC has 
a pKa of 2.50 in water (SciFinder prediction tool) thus existing predominantly in its 
deprotonated form. Whereas the amine group of tamoxifen, with a pKa 8.9 in water, is 
mainly protonated, favouring the formation of an ionic bond. This project was 
developed on the hypothesis that the low pKa of VCC would significantly hinder the 
release of tamoxifen in healthy cells at physiological pH, while a slow release of the 
drug could be favoured inside cancer cells. In fact, the more acidic intracellular 
environment would disrupt the interactions between the monomer and the drug allowing 
the free tamoxifen to link on the oestrogen receptors and exert its biological actions.  
• COLLOIDAL STABILITY AND THE BACKBONE MONOMER 
Nanogels have polymeric networks able to absorb water and form a stable, dispersed 
colloidal solution, which is directly linked to the chemical structure and the solvent 
system used. In this chapter the term solubility, when referred to nanogels, will be used 
to identify the degree of stability of the colloidal dispersion. In this context the 
applications of nanogels also need to be considered, and for this project applications in 
water are targeted.  
Considering the hydrophobicity of the functional monomer, VCC, it was necessary to 
choose a backbone monomer that could maximise the solubility of the nanogels in water. 
During previous studies carried out in the research group of Prof. Resmini, the 
hidrophilic acrylamide was often used as backbone monomer in the preparation of 
nanogels for a variety of applications (figure 4.4).17,5,10 Although the monomer 
acrylamide is well known to be neurotoxic, genotoxic and carcinogenic, once the 
monomers react to form long polymer chains the toxicity is no longer present. 
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Furthermore, the FDA approved the use of polyacrylamide as a film former in the 
imprinting of soft-shell gelatin capsules when the polymer does not contain more than 
0.2% acrylamide monomer.18 
 
Figure 4.4. Representation of the structure of acrylamide monomer 
However, there was a concern that acrylamide-based nanogels would display low 
solubility in aqueous systems and would therefore not be suitable for drug delivery 
studies.17 In order to overcome this issue, work was carried out to develop nanogels 
using N-isopropylacrylamide (NIPAM, figure 4.5) as backbone monomer, as this 
monomer was previously used and showed to have much more suitable characteristics 
in terms of solubility.19, 11 This is an interesting monomer, characterised by the isopropyl 
group as a substituent on the N atom of the amide, and when polymerised gives rise to 
matrices that can show thermoresponsive properties.   
 
Figure 4.5. Representation of the structure of N-isopropylacrylamide (NIPAM) 
Thermoresponsive N-isopropylacrylamide (NIPAM) based polymers, formed by long 
linear chains of the units, display a phase transition above or below a particular 
temperature defined as lower critical solution temperature (LCST).20 The polymer can 
loose about 90% of its own volume when heated above the LCST in water, passing 
from a swollen hydrate state to a shrunken dehydrated state. Below the critical 
temperature water molecules form a hydrated shell around the hydrophobic moieties of 
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LCST a de-solvation of the hydrophobic moieties of the polymer chains occurs (figure 
4.6). The entropy of the water molecules increases, resulting in the collapse of the 
polymer as the hydrophobic interactions polymer-polymer increase.21, 22  
  
Figure 4.6. Graphic illustration of the thermo-responsiveness characteristics of p-NIPAM. On the left, 
when the temperature is below the LCST, the polymer (purple line) is hydrated and swollen. On the right, 
when temperature rises above the LCST, the polymer is dehydrated and shrunk  
Linear poly-N-isopropylacrylamide (p-NIPAM) show a LCST at 32°C. However, in 
cross-linked gels, changes in the chemical compositions can lead to values closer to the 
human body temperatures (36.5 – 37.5°C). The degree of flexibility of the polymer 
matrix has been shown to have an impact on the temperature at which the phase 
transition occurs (Salinas et al. unpublished data). This particular characteristic 
contributed to make p-NIPAM promising stimuli-responsive drug delivery carriers, in 
which the release of the drug is triggered by a difference in temperature.23 Therefore, by 
using NIPAM as backbone monomer in the nanogels here presented, a new, extra 
feature could be added to the final system. If the right combination of monomers and 
crosslinkers were used, it would be possible to obtain a carrier able to respond to double 
stimuli for drug release: a change in pH and also change in temperature. As mentioned, 
there is plenty of research showing that cancer cells have more acidic pH compared to 
the healthy cells. In the same way tumours are subject to mild hyperthermia, generally 1 
or 2°C warmer than healthy cells, due to the higher replication rate of cancer cells, 
which release energy. Thermo-responsive drug delivery system, with phase transition 
temperature at 38-39°C, have been developed in order to deliver the drug only in the 
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vicinity of cancer cells. In the hyperthermia conditions of the tumour environment the 
polymers collapse and become hydrophobic, favouring the release of the drugs. 
Whereas in normal tissue the polymers are in their hydrophilic, thermodynamic stable 
state, and the drugs remain encapsulated within the matrix.24 
4.2.2. Choice of initiator 
The initiator is the component responsible for the activation of the free radical 
polymerisation. Two main general types of free radical initiators are commercially 
available, the organic peroxides and the azocompounds, both of which decompose 
thermally to produce two radicals. In the peroxides groups (R-O-O-R’), the cleavage of 
the oxygen-oxygen bond produces two free radicals, while in the azocompounds (R-
N=N-R’) the decomposition causes the scission of the two carbon-nitrogen bonds 
producing nitrogen and two alkyl radicals. Some peroxides show a considerable solvent 
and concentration effect, i.e. the decomposition rate increases/decreases depending on 
the solvent and concentration used. On the other hand the decomposition rate of 
azocompounds is not affected by concentration, solvent or environment, making them 
more stable and generally safer than the peroxide initiators.25 Among azocompounds, 
azobisisobutyronitrile (AIBN) is a very common initiator, widely used in radical 
polymerisations. AIBN was selected as initiator for the preparation of the imprinted and 
non-imprinted nanogels. This initiator undergoes a thermal decomposition at 60°C, 
following the mechanism illustrated in figure 4.7.  
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In case of high dilution radical polymerisation, AIBN is generally used in 1% mol of 
double bonds in the mixture. However, this amount requires each time optimisation, 
especially when chemical compounds that can act as radical quenchers are present in the 
polymerisation mixture.   
4.2.3. Choice of the cross-linker 
The cross-linking agent is one of the essential components involved in the preparation 
of imprinted nanogels. The cross-linker (XL) allows the formation of a three-
dimensional network by linking different polymer chains; it stabilizes the imprinted 
binding sites and influences the morphology and physico-chemical characteristics of the 
system. 26 The chemical structure of the XL impacts mainly on the physico-chemical 
properties; whereas the content of XL impacts on the rigidity of the matrix and binding 
sites. Moreover the XL has to be chosen accordingly to the environment in which the 
polymer will be applied, weather it is aqueous or organic. Depending on the 
applications that has been targeted, which is either catalysis, sensor or drug delivery, the 
content of cross-linker in a polymer system can vary ranging from 80-90%, for very 
cross-linked and rigid system, to as low as 10-5%. 27-29  
The chemical structure of the polymerisable unit of the different components has an 
effect on the rate of the polymerization, which potentially lead to a different degree of 
incorporation. 30 The pre-polymerisation mixture is prepared using a well-defined ratio 
of functional monomer  (FM) to backbone monomer (BM) to crosslinker (XL) to 
template (T). The main target is to maintain this ratio also in the final polymer. 
However, such aim can be seriously affected if the polymerisable groups on the 
different components have dissimilar chemical structures. The difference in chemical 
structures can lead to a different kinetics of reaction, resulting in a variation of the ratio 
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FM:BM:XL:T in the final product. Given the random nature of the radical 
polymerization it is quite difficult to establish subsequently the percentage of 
incorporation. This becomes significantly important if the chemical yield is below 80-
85%. In such cases the incorporation of the monomers in the final polymer could not 
reflect the ratio used in the pre-polymerisation mixture. Given the choice of the 
functional and backbone monomer, which contains a vinyl and an acrylamide group, 
respectively, it is necessary to find a cross-linker with similar functional group. Taking 
into account these considerations, cross-linker agents widely used that have all the 
requirements listed above are the N,N' - methylenebis(acrylamide) (MBA) or N,N' - 
ethylenebis(acrylamide) (EBA) represented in figure 4.8.  
  
Figure 4.8. From left to right, structure of cross-linking agents N,N' - methylenebis(acrylamide) (MBA) 
and N,N' - ethylenebis(acrylamide) (EBA) 
Both MBA and EBA cross-linkers are water soluble, they carry the same polymerisable 
unit as the backbone monomer, and they do not have any other major functional groups 
that could give rise to any additional interactions, with the exception of the carbonyl and 
the -NH- group. However, the presence of an extra methylene group in the EBA, 
compared to MBA, could contribute to make the matrix too flexible, in addition to 
increasing the hydrophobicity. In fact, although a certain degree of flexibility is 
desirable, it is important to achieve tight cavities to prevent the risk of non-specific 
binding. Both the structure and the amount of cross-linker influence the rigidity of the 
final network, which is important for retaining the structure of the cavities. High cross-
linker content, usually between 70% and 80%, involves a lack of flexibility and high 
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appropriate solvent. In the case of DDS it is important to have cavities that enclose the 
drug, but in order to allow the release of the template, the network should not be partly 
flexible. Papadimitriou et al. demonstrated that polymers prepared with 20% XL 
showed good uploading and good release profile of the therapeutic cargo. 19 Therefore, 
the content of MBA was fixed at 20% for the preparation of nanogels, which would 
exhibit its function in aqueous environment and would be able to release the drug from 
the cavities. 
4.2.4. Choice of the polymerisation solvent 
The nature of the solvent plays an important role in the polymerisation process. It is 
necessary for the polymerisation solvent to completely solubilise the components 
involved in the process so that a homogeneous solution can be obtained. As reported by 
Beltran et al. the imprinted polymers would work better if the solvent used during the 
polymerisation was the same as the final solvent required by the applications. 31 The 
nanogels will potentially be used in aqueous environment, however, using water as 
polymerisation solvent could be problematic. Tamoxifen, as a large percentage of 
commercially available small molecule drugs, is hydrophobic and therefore a 
homogeneous solution could not be achieved in water, preventing interactions between 
the drug and the functional monomer. Water was, therefore, discarded as polymerisation 
solvent, as well as other protic solvents. In fact, protic solvents would interfere with the 
formation of potential hydrogen bonds between tamoxifen and the monomers, thus 
limiting the specificity of the cavities. However, considering the choice of using VCC, 
NIPAM and MBA as functional monomer, backbone monomer and cross-linker, 
respectively, a polar solvent is required in order to solubilise the components. Inspired 
by previous published works, it was decide to use the polar aprotic dimethylsulfoxide 
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(DMSO) as polymerisation solvent. 5, 11,17,19  
4.2.5. Concentration of monomers (CM) 
To generate nanosized intramolecular crosslinked particles, the prevention of 
intermolecular particle-particle interactions in the polymerisation mixture is a key 
requirement. As demonstrated by Graham et al., this is achievable by considering 
combination of good polymerisation solvent and overall monomer concentration (CM).32 
In fact, nanogels can be formed only when the CM is below a well defined value referred 
to as critical gelation concentration, which depends on the polymerisation solvent and 
its solubility parameter (figure 4.9).33,34 In such conditions the swollen particles are 
dilute enough not to create intermolecular connections, acting as steric stabilisers 
against aggregations.  
 
Figure 4.9. Plot of monomer concentration at gel point versus solubility parameter of the used 
polymerisation solvent. The two regions in which the formation of macrogels or micro/nanogels occurs 
are clearly labelled. Figure reproduced with permission from Graham et al.33  
The considerable amount of work carried out by the Resmini’s group and others has 
shown a direct correlation between the values of CM, the particle size and the 
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observe the aspect of the mixture after polymerisation. A low viscosity, clear solution 
suggests the formation of small particles, while high viscous mixture or gelatinous 
lumps suggests macrogelation. 
It was previously shown that value of CM equal to 0.5% produced nanogels with small 
particle size and low polydispersity index, while maintaining good chemical yields.35-37 
It was therefore decided to use this as initial value for the preparation of nanogels and to 
optimise it if necessary. 
4.3. Synthesis and characterisation of nanogels 
The polymerisation was based on an established procedure, involving two days 
polymerisation at 70°C, after degassing the mixture.10,17 The final nanogel solution was 
dialysed against water for two days, by changing dialysis water 3 times a day. Dialysis 
is an important step for the purification. Previous work indicated that the use of 
membranes with pore size of 3.5 KDa were suitable for ensuring isolation of polymers 
with the desired size.38 Therefore, only the remaining un-reacted components, as well as 
smaller polymer chains, were removed from the mixture through the pores. The 
resulting aqueous solution, containing the nanogels, was freeze-dried and fluffy solids 
were recovered. All polymers were prepared in DMSO with 20% MBA and NIPAM as 
backbone monomer. A recent work published by Zielinska et al.11 has shown that the 
content of cross-linker influences the volume phase transition temperature (VPTT), 
feature provided by the presence of the thermo-responsive backbone polymer. The work 
demonstrated that polymers containing 20% MBA showed a phase transition at around 
39°C and were considered suitable for drug delivery applications. However at this stage 
of the development the thermoresponsive properties were not considered essential and 
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therefore the polymer preparations were instead evaluated based on yields, solubility, 
particle size and fluorescence properties.  
4.3.1. Characteristics of the nanogels  
Here below a brief explanation of the different parameters, used to judge the polymers 
and guide the optimisation process, is given.  
4.3.1.2. Chemical yield 
The chemical yield is the first parameter taken in consideration during evaluation of the 
nanogels. Preparations with chemical yields lower than 30% were discarded, as the loss 
of material during purification was too high and the exact composition of the resulting 
polymer could not be confirmed. The yield was determined after the polymerisation 
process and the dialysis purification step. The solid polymer, obtained after the freeze-
dryer, was weighted out and compared with the amount of material that was initially 
inserted in the pre-polymerisation mixture (equation 4.1). 
%  𝐶ℎ𝑒𝑚𝑖𝑐𝑎𝑙  𝑌𝑖𝑒𝑙𝑑 = !"#$%&  !"#$%  
!!!"#!$%&'(  !"#$%  
  ×  100         Equation 4.1 
4.3.1.3. Solubility in water 
As already mentioned, the solubility of the nanogels is an important characteristic for 
drug delivery applications. The solubility was evaluated as the amount of polymer that 
would give rise to a stable and clear colloidal dispersion in water, which would not 
show any particles visible to the naked eye. The evaluation started with a concentration 
of 2mg/mL. The polymer was weighted out and the correct volume of water was added 
to give the desired concentration. The sample was then sonicated for 10 minutes and its 
aspect was observed. The sample was then diluted down with the addition of further 
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portions of water in case insoluble material was present. At that point the sonication 
step and the visual evaluation were repeated. 
4.3.1.4 Particle size (Zetasizer) 
The size of the nanogels was measured by Dynamic Light Scattering (DLS) technique. 
This technique consists of a laser beam that illuminates the particles contained in the 
sample solution and a detector placed at 90°C to the source of laser, which measures the 
light scattered by such particles. The zetasizer system interprets the size of the particles 
present in the sample by correlating the Brownian motion of such particles and the 
scattered light.39, 40 The Brownian motion is defined as “the erratic random movement of 
particles in a liquid due to the bombardment by the molecules that surround them”. The 
smaller the particles are, the quicker they move around, vice versa the larger ones move 
slower. This continuous diffusion of the particles suspended in the liquid samples, 
involve a fluctuation of the intensity of the scattered light, accordingly to the size of the 
particles. In particular, if the particles are large and move slowly then the intensity 
fluctuates slowly as well, while a quick fluctuation is expected in case of small particles. 
By using a correlation function, the zetasizer system measures the rate of the intensity 
fluctuation and the degree of similarity between two signals over time. This information 
is then used to calculate the size distribution. The standard size distribution obtained 
from the zetasizer is by light intensity, which can be converted into volume and number 
distribution using the Mie theory (figure 4.10). As the names suggest, the number 
distribution reflects the number of particles with different sizes. In other words, if there 
were equal number of particles with different size, the graph would show two peaks 
with the same intensity. The volume distribution gives a measurement of the volume 
size of the particles. Bigger particles have a larger volume and give bigger contribution, 
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therefore, considering the same example as above, the graph would show two peaks, 
one of which 103 fold larger than the other, accordingly to the volume of a sphere (4/3 
πr3). Whereas the intensity distribution is a measurement of the amount of light 
scattered by the particles. Big particles scatter more light and generate higher 
contribution than small ones. The graph would show two peaks, one of which 106 fold 
bigger than the other, accordingly to Rayleigh’s approximation.     
 
Figure 4.10. Number, Volume and intensity distributions of a sample containing two populations of 
particles, one with 5 nm and one with 50 nm diameters39 
It is important to note that the actual properties of the material are taken into account 
only when the size is expressed by volume or number distributions. The intensity has a 
multimodal particle size distribution and it is proportional to the square of the molecular 
weight, therefore this distribution could be misleading in real samples. The intensity 
distribution can be dominated by other particles in case large impurities like dust or 
small number of aggregates are present in solution. Figure 4.11 represents a schematic 
illustration of the intensity distribution graph in the case in which a large number of 
particles with size 10 nm are present in a sample together with only one particle of 100 
nm. The graph shows two peaks with same intensity for the two different particles size.   




Figure 4.11. Schematic representation of the contribution to size distribution by intensity of particles of 
different size  
Therefore, in the cases of small particles, number and volume distribution give the most 
accurate representation of the actual size.  
Only the size distribution by number of the nanogels prepared will be shown in this 
section, however it is possible to find the intensity and volume distribution graphs in the 
appendix at the end of this thesis.  
After polymerisation, every preparation has been dialysed against water before being 
freeze-dried and stored as a solid at room temperature in the dark. The particle size of 
all the nanogels were measured at 0.5 mg/mL in water at pH = 5.5. In order to break 
down any possible aggregates formed in the solution, the samples were prepared by 
filtering the mixture on a 0.45µm GHP filter after sonication for 10 minutes.  
4.3.1.5. Fluorescence properties  
When developing a novel drug delivery system it is of high importance to be able to 
monitor in vitro the pathway taken by the vehicle. By studying the cellular uptake and 
the distribution of the DDS, it is possible to predict the accumulation, the safety, and 
efficiency of such materials within the body. As described in chapter 1 (section 1.4), 
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fluorescence is widely used as imaging technique due to its high sensitivity, low 
radiation, and non-invasiveness.  
Considering that the final application of nanogels will be in aqueous environment, the 
fluorescence spectra were recorded in water. The UV-Vis of the fluorescent monomer 
was initially recorded in the same solvent, as shown in figure 4.12.  
 
Figure 4.12. UV-Vis spectrum of VCC functional monomer in water. [VCC]= 0.28mM. Two main peaks 
are visible, λabs = 350 and 285nm 
VCC in water showed two main peaks, one with λabs = 350nm and another one, with 
higher absorbance, at λabs = 285nm. However, the fluorescence emission of the 
polymers was carried out after excitation at λexc = 360nm. This value was chosen to 
ensure that none of the other functional groups in the polymeric matrix were excited. 
The lower the wavelength of excitation is, the higher the risk to irradiate other 
components that can influence the emission. The fluorescence of the nanogels was 
therefore measured by emission at wavelength λem = 470nm following excitation at 
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4.3.2. Nanogels preparation  
The first polymer preparation that was attempted was FM-P1. The content of functional 
monomer is a fundamental parameter to take in consideration in the synthesis of 
nanogels. It directly influences the amount of drug incorporated within the matrix and 
deeply affects the morphology of the final polymers. When hydrophobic monomers, 
such as VCC, are introduced in the nanogels the risk of obtaining insoluble polymers is 
very high. Previous work in the group identified the content of such functional 
monomers between 10% and 20% as the ideal percentage. Given the hydrophobicity of 
the VCC, it was decided to prepare the first nanogel, FM-P1, with 10% of functional 
monomer.  
Table 4.1. Preparation of the first NIP. Polymerisation was carried out at 70 °C for 2 days in DMSO. 
Dialysis was performed against water for two days followed by freeze-drier. 
 
MIP/NIP MBA VCC AIBN CM Yield 
Solubility 
in Water 
FM-P1 NIP 20% 10 % 2 % 0.5 % 5% 2 mg/mL 
 
This polymer was prepared using 10% of VCC and 2% of AIBN. Considering the anti-
oxidant effect of coumarin derivatives, described in chapter 2, and the high likelihood 
that the formed free radicals would be quenched by the functional monomer, it was 
decided to use a higher content of initiator to overcome such effect of the VCC (section 
4.2.2). Although the solubility in water and the particle size were satisfying, (figure 
4.13), this formulation was discarded. The chemical yield was 5%, which was 
considered too low to be accepted for any purposes. Such little yield was probably due 
to the radical quenching effect of the VCC and to the insufficient content of initiator. 
The media, in which nanogels are formed when high dilution radical polymerisation is 
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employed, is so diluted that the few radicals formed do not hit each other very 
frequently. Therefore the obtained polymer chains are too small to be retained within 
the dialysis membrane during the purification process, hence obtaining a low yield.   
 
Figure 4.13. Particle size of FM-P1 at 1 mg/ml in water, distribution by number. The measurements were 
recorded as triplicates. The particle size by number of FM-P1 was 96 ± 32 nm with PDI = 0.110. Each 
line represents the average particle size over 15-17 scans of the nanogel.  
In the subsequent preparation the content of VCC was lowered to 5% while maintaining 
all the other parameters constants.  
Table 4.2. Preparation of the NIP. Polymerisation was carried out at 70 °C for 2 days in DMSO. Dialysis 
was performed against water for two days followed by freeze-drier. 
 MIP/NIP MBA VCC AIBN CM Yield 
Solubility 
in Water 
FM-P2 NIP 20% 5 % 2 % 0.5 % 8.5% 2 mg/mL 
 
The chemical yield of FM-P2 slightly increased compared to FM-P1, although very 
marginally, therefore suggesting that probably the content of VCC was still having an 
important effect in the polymerisation process.  




Figure 4.14. Particle size of FM-P2 at 1 mg/ml in water, distribution by number. The measurements were 
recorded as triplicates. Each line represents the average particle size over 15-17 scans of the nanogel. The 
particle size by number of FM-P2 was 61 ± 19 nm with PDI = 0.130  
The new preparation showed good solubility and small particle size, however the 
chemical yield was not sufficiently high to consider this formulation any further. The 
low yield implies poor incorporation of the monomers within the polymeric matrix. 
Also, due to the random aspect of the free radical polymerisation process, the cross-
linker may polymerise first. The cross-linker agent has faster kinetic because of the 
presence of two units of polymerisable moiety in the same molecule, thus involving 
slower incorporation of the monomers. Interestingly, the VCC content in both 
preparations was higher than AIBN, so it was decided to investigate what would happen 
if the proportion was inverted. 
Two new polymers were synthesised: a non-imprinted nanogel, NIP FM-P3 and the 
corresponding imprinted nanogel (MIP FM-P4), using 5% of AIBN and 2.5% of VCC, 
while CM was reduced to 0.2% as an attempt to keep small particles size.  
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Table 4.3. Preparation of the NIP/MIP. Polymerisation was carried out at 70 °C for 2 days in DMSO. 
Dialysis was performed against water for two days followed by freeze-drier. 
 MIP/NIP MBA VCC AIBN CM Yield 
Solubility 
in Water 
FM-P3 NIP 20% 2.5 % 5 % 0.2 % 18.3% 2 mg/mL 
FM-P4 MIP 20% 2.5 % 5 % 0.2 % 22% 1 mg/mL 
 
By using AIBN in double concentration of VCC an improvement in the yield was 
observed. From < 10% obtained with FM-P2 the chemical yield raised to around 20% 
for FM-P3 and P4. This result confirmed the essential part played by the ratio AIBN-
VCC. The particle size by number distribution was in the right range for the potential 
application of the nanogels, as shown in figure 4.15, with the size for both NIP and MIP 
found to be around < 30nm. However, the chemical yield was still particularly low, 
which meant there was a risk that the final polymer would be characterised by a very 
different ratio of the components used in the pre-polymerisation mixture.  
  





Figure 4.15. a) Particle size of NIP FM-P3 was 27 ± 8 nm with PDI = 0.418. b) Particle size of MIP 
FM-P4 (bottom graph) was 27 ± 8 nm with PDI = 0.303. The measurements were recorded as triplicates. 
Each line represents the average particle size over 15-17 scans of the nanogel  
The fluorescence emission of the two nanogels was recorded after excitation at λexc = 








Figure 4.16. Fluorescence emission at λ em = 460nm of FM-P3 (NIP) and FM-P4 (MIP) at 1 mg/mL in 
water after excitation at λ exc = 360nm  
The data show a very clear difference between the emission of FM-P3 and MIP FM-P4. 
There are two possible explanation for this observation: on one side this could be the 
result of the fluorescent monomer being incorporated in different percentages in the two 
matrices, while another explanation could be based on the assumption that the drop in 
fluorescence for the MIP is the result of the quenching due to the presence of tamoxifen. 
As demonstrated in chapter 3 the fluorescence of the polymers is quenched by 
interactions between the functional monomer and the drug. Although further studies, 
aiming to quantify the functional monomer and tamoxifen, would help clarify such 
behaviour, these two nanogels were discarded due to low chemical yield. As previously 
mentioned, such little yield was probably due to the formation of a large portion of low 
molecular weight polymeric chains, which are not retained within the dialysis bag 
during the isolation step. 
Following the first sets of preparation and careful analysis of the data the need for more 
work was very clear. At this stage there was a serious concern that the combination of 
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and initiator was having a negative impact on the polymerisation reaction and also on 
the yields. Therefore it was decided to try to further reduce VCC to 1% while increasing 
CM to 0.5%. This experiment was done only to evaluate the impact of these changes, as 
it was understood that polymers with 1% tag would not have sufficient cavities and 
fluorescence. The polymers NIP FM-P5 and MIP FM-P6 were prepared and 
characterised with the results shown in the table below. 
Table 4.4. Preparation of the NIP/MIP. Polymerisation was carried out at 70 °C for 2 days in DMSO. 
Dialysis was performed against water for two days followed by freeze-drier. 
 MIP/NIP MBA VCC AIBN CM Yield 
Solubility in 
Water 
FM-P5 NIP 20% 1 % 5 % 0.5 % 86.3 % 1 mg/mL 
FM-P6 MIP 20% 1 % 5 % 0.5 % 87.2 % 0.75 mg/mL 
 
It was very interesting to observe that the chemical yield increased dramatically to over 
85%.  The results suggested that the combination of decreasing VCC while increasing 
CM led to this result. It was evident at this stage that the challenge was to find a balance 
between two key factors, the presence of sufficient initiator to counter balance the 
quenching effect of VCC while maintain a concentration of monomers in solutions 
sufficiently high to allow for the formation of particles that would not be lost during the 
purification step. Figure 4.17 shows that the particle size have increased in size, 
although remaining in the range (<100nm) required for the desired applications. 
  





Figure 4.17. a) Particle size of NIP FM-P5 (top graph) was 93 ± 25 nm with PDI = 0.284. b) Particle 
size of MIP FM-P6 (bottom graph) was 48 ± 15 nm with PDI = 0.207. The measurements were recorded 
as triplicates. Each line represents the average particle size over 15-17 scans of the nanogel   
Although the issue of the radical quenching was overcome by using a low concentration 
of the VCC functional monomer, such low content also affected the fluorescence of the 








Figure 4.18. Fluorescence emission at λem = 460nm of FM-P5 (NIP) and FM-P6 (MIP) at 1 mg/mL in 
water after excitation at λ exc = 360nm 
The two preparations were obtained with very good chemical yields while maintaining 
the particle size in the desired range, however the fluorescent level displayed by the 
particles at the concentration of 1 mg/mL, required for further experiments, were not 
deemed sufficient.  
The next step focused on the synthesis of two new polymers, FM-P7 and FM-P8. 
Considering the low fluorescence intensity obtained with FM-P5 and P6, the content of 
VCC in the new preparations was increased to 2.5%. Moreover, after evaluating the 
previous results, it was clear that the amount of initiator had a big impact on the 
formation of the nanogels and on their chemical yields. It was, therefore, decided to 
double the content of AIBN to 10% in order to increase the amount of radicals in 
solution and to push the formation of polymer with higher molecular weight that could 
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Table 4.5. Preparation of the NIP/MIP. Polymerisation was carried out at 70 °C for 2 days in DMSO. 
Dialysis was performed against water for two days followed by freeze-drier. 
 MIP/NIP MBA VCC AIBN CM Yield 
Solubility in 
Water 
FM-P7 NIP 20% 2.5 % 10 % 0.5 % 53 % 1 mg/mL 
FM-P8 MIP 20% 2.5 % 10% 0.5 % 40 % 1 mg/mL 
 
Table 4.5 shows the content of each component for the new polymers FM-P7 and P8. 
Unfortunately the chemical yields obtained were not as high as the previous ones (FM-
P5/P6). However, recently, Mr. Pengfei Liu, a member of the Resmini’s group, carried 
out NMR studies on the preparation of nanogels based on 20%MBA and 80%NIPAM, a 
very similar formulation to what was used in the synthesis of FM-P7 and FM-P8. 
Results showed that increased amount of AIBN involved a faster polymerisation. After 
48hrs the totality of MBA was consumed when 5% of initiator to the double bonds in 
the mixture was used. However, some NIPAM was left unreacted, thus confirming the 
first hypothesis that cross-linking agent was more reactive than the other monomers. 
Therefore, considering the higher amount (10%) of AIBN used in the preparation of 
FM-P7/P8, it was possible to assume a successful polymerisation of each monomer. 
This being said, the low chemical yield was likely due to the formation of polymeric 
chains with low molecular weight, lost during the isolation process, rather than a scarce 
incorporation of the monomers. Mr. Liu kindly provided the NMR spectra, which are 
reported in the annex at the end of this thesis.    
The particle size of the imprinted polymer, 82nm, was bigger than the non-imprinted 
counterpart, 30nm (figure 4.19). One hypothesis is that the larger particle size was due 
to the presence of tamoxifen molecules trapped in the matrix. On the other side it is 
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Figure 4.19. a) Particle size of FM-P7 (top graph) was 30 ± 9 nm with PDI = 0.284. b) Particle size of 
FM-P8 (bottom graph) was 82 ± 24 nm with PDI = 0.207. The measurements were recorded as triplicates. 
Each line represents the average particle size over 15-17 scans of the nanogel    
In terms of fluorescence, NIP FM-P7 showed a suitable intensity, as a result of the 
higher chemical yield obtained, which reflects the incorporation of the fluorescent 
monomer. The fluorescence spectrum of the MIP FM-P8 was quite different compared 
to the NIP, showing significantly lower intensity (figure 4.20). Interestingly, the same 
trend previously observed in the other sets was maintained. Also in this case two 
possible scenarios were hypothesised. On one hand, the presence of the tamoxifen in the 
a) 
b) 
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imprinted nanogels, which quenches the VCC, on the other a different percentage of 
VCC incorporated in the two matrices.  
 
Figure 4.20. Fluorescence emission at λ em = 460nm of FM-P7 (NIP) and FM-P8 (MIP) at 1 mg/mL in 
water after excitation at λ exc = 360nm  
Although, increasing the CM to 1% or incrementing the ratio between VCC and AIBN, 
would have probably provided better characteristics to the polymer, lack of time 
prevented the optimisation to be carried any further. Nevertheless, the two nanogels 
were shown to have a combination of good solubility, small particle size and high 
fluorescence that allowed these polymers to be taken to the next stage.  
The thermo-responsiveness of the polymers FM-P7 and P8 was also investigated. 
NIPAM-based polymers are characterised by a phase transition or lower critical solution 
temperature. The cross-linked nanogels obtained by using this monomer show the same 
ability of swelling below the critical temperature and shrinking above it, as described in 
section 4.2.1. In the case of hydrogels/nanogels such temperature is known as volume 
phase transition temperature (VPTT), while the LCST is a term used for linear 
thermoresponsive polymers.41 The VPTT/LCST is often determined by turbidimetry, 
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wavelength due to the scattering effect of particles suspended in the sample. VPTT is 
the temperature at which the transmittance (T) reaches 50% or, in other words, the 
temperature at the inflection point of the transmittance curve.  
The VPTT of the nanogels was determined from the absorbance at λ = 500nm measured 
against temperature. The wavelength λ = 500nm was selected as this value was in the 
range of wavelength in which collapsed/shrunk nanogels where shown to absorb.11 
VPTT measurements were carried out on UV-Vis spectrophotometer coupled with a 
temperature controller in which the heating rate was set at 1°C every minute. The 
absorbance was transformed into transmittance in a second step.  The analyses were 
performed on a solution of polymer dispersed in water at pH = 5.5, in order to relate the 
thermo-responsiveness to the potential environment of action of the nanogels, which is 
cancer cells characterised by acidic pH. The samples were prepared at a concentration 
of 1 mg/mL and were filtered on a 0.45µm GHP filter after 10 minutes sonication.  
 
Figure 4.21. VPTT of NIP FM-P7 and MIP FM-P8.  Absorption at λ abs = 500 nm, heating rate 1°C per 
minute. Samples concentration: 1 mg/mL in water at pH = 5.5  
The NIP FM-P7 showed 50% of transmittance at T = 58°C, while the MIP FM-P8 at T 
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of temperature reached by cancer cells in hyperthermia conditions (Section 4.2.1: 
colloidal stability and the backbone monomer). Comparison of these results with 
literature data provides evidence that the addition of a functional monomer, such as 
VCC, leads to very significant changes in the characteristics and morphologies of the 
polymers, probably also due to changes in the hydrophobicity of the matrix. By varying 
the amount of the cross-linker, the VPTT could be lowered to values closer to the 
required ones for biological applications; however, this would have required to further 
reducing the content of cross-linker. This would have had a significant impact on the 
possibility of creating well-defined three-dimensional pockets.  
In order to demonstrate the formation of a covalent bond between the fluorescent 
functional monomer and the polymeric network, the two nanogels were further studied 
using fluorescence spectroscopy. Solutions of NIP and MIP FM-P7 and P8 were 
prepared in a mixture of 50:50 H2O/MeOH at 0.5mg/mL. After stirring for 2 hours, the 
two solutions were dialysed against 10% MeOH in H2O, changing the dialysis mixture 
three times in 24 hours, with the last change being 100% H2O. The nanogels solutions 
were freeze-dried and reconstituted in H2O at the same original concentration, sonicated 
and filtrated before recording their fluorescence spectra. 
This procedure aimed to cleave any possible non-covalent interactions between the 
VCC and the polymeric network, using a polar, protic organic solvent. MeOH was 
chosen, as it was previously demonstrated that this solvent was not sufficiently strong to 
disrupt the ionic interactions between tamoxifen and the acidic moiety of the functional 
monomer. To achieve it a mixture of MeOH and acidic acid was necessary to achieve 
drug release. 42, 43 Figure 4.22 shows the fluorescence spectrum of the two nanogels after 
treatment.  




Figure 4.22. Fluorescence emission at λ em = 460nm after excitation at λ exc = 360nm of NIP FM-P7 and 
MIP FM-P8 at 0.5 mg/mL in H2O after MeOH treatment and dialysis  
Due to lack of FM-P7 and P8, it was decided to work with concentration of 0.5 mg/mL 
and to compare the results obtained in figure 4.22 with the fluorescence spectrum 
recorded during the characterisation of the polymers reported in figure 4.23. 
 
Figure 4.23. Fluorescence emission at λ em = 460nm of FM-P7 (NIP) and FM-P8 (MIP) at 1 mg/mL in 
water after excitation at λ exc = 360nm  
Although different concentrations were compared, it was possible to confirm that the 
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two nanogels treated with MeOH, showed in figure 4.22, ensured that no loss of 
fluorescent monomer occurred during the treatment. This result also suggested that the 
difference in emission between the imprinted and non-imprinted polymers was mainly 
due to the presence of the drug, which quenched the fluorescence, rather than a different 
percentage in the incorporation of fluorophor.  
4.4. Quantification of the drug loaded in the polymeric matrix 
As described in chapter 1 a number of different methods are available for the detection 
of tamoxifen (TAM). One of the most common modern methods of detection involves 
the use of high performance liquid chromatography (HPLC). HPLC is an efficient and 
accurate technique, which provides more precise and reproducible results compared to 
other approaches already mentioned (section 1.3.1). Moreover, it is characterised by low 
detection limits, which are important, given the small amount of tamoxifen that is 
expected in the nanogels. It was, therefore, decided to employ the HPLC to attempt a 
quantitative evaluation of the amount of TAM loaded in MIP FM-P8.  
A new methodology was developed and optimised. It was found that good conditions 
for analysing tamoxifen in the column Hichrom C18 25mm were 85:15 methanol to 
water acidified with 0.5% acetic acid at a flow rate of 0.5 mL/min. This gave a peak at 
6.8 minutes. Initially a reference line of tamoxifen in ACN was established (figure 4.24).  




Figure 4.24. Reference line of the area under the curve obtained via HPLC against the concentration of 
tamoxifen injected. 20μL were injected in acetonitrile measuring the absorbance at 270nm. Flow rate was 
0.5 mL/min using 85% MeOH, 15% water acidified with 0.5% acetic acid 
Once the reference line was obtained and it was demonstrated to be reproducible by 
repeating the measurements, nanogel FM-P8 was analysed using the same methodology 
developed. After polymerisation the nanogel was purified via dialysis against water in 
order to remove the polymeric chains with small molecular weight as well as the 
unreacted components. After dialysis the nanogel was freeze-dried, weighted and stored 
in the dark at room temperature. The nanogel was reconstituted in acidic MEOH/ACN 
5:5 and stirred overnight in order to disrupt the interactions between the drug and 
functional monomer. The mixture was then filtered with a 20 nm filter to remove the 
polymer from the solution, leaving only the free tamoxifen in the filtrate. 20μL of the 
filtrate was then injected in HPLC. After such treatment of the sample, a clear HPLC 
profile with only one peak of the tamoxifen released from the nanogel was expected. 
Figure 4.25 shows the HPLC graph of the filtrate of FM-P8 in acidic MEOH/ACN. 
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Although a peak compatible with tamoxifen was visible at retention time 7.4 minutes, 
other peaks were also present.  
 
Figure 4.25. HPLC profile of the FM-P8 at 1 mg/mL in acidic MEOH/ACN 50:50 after filtration with 20 
nm filter. The peak at 7.4 min is compatible with tamoxifen  
The peaks at shorter retention time, 5.57 and 5.71 minutes, could be caused by 
equilibrium between different isomers of tamoxifen or other issues arisen because of the 
presence of the polymeric matrix. In fact, the peaks at retention time 14.97, 16.18 and 
20.47 minutes could probably be polymer peaks. Although the mixture was first filtered 
with a 20 nm filter, the nanogels are not all consistent in terms of size; therefore some 
small particles might have passed through the filter and be separated in HPLC giving 
the peaks. To ensure that the peak at retention time 7.404 min was tamoxifen, the same 
filtrate solution was spiked with a known concentration of tamoxifen free drug in the 
same solvent (figure 4.26). 
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Figure 4.26. Solution of MIP FM-P8 in acidic MEOH/ACN 50:50 filtrated with 20 nm filter and spiked 
with 70 μg/mL of tamoxifen in ACN 
As shown in the figure above, a big peak appeared at retention time in between the other 
peaks (6.84 minutes). This suggested that the peak obtained at 7.4 min, in figure 4.25, 
was given by tamoxifen present in the polymeric network. However, the peak of 
tamoxifen was broad and not separated from the other peaks at the baseline, making an 
exact reading of the area under the curve for quantification of the drug very difficult. A 
number of other treatments of the samples were carried out to eliminate the components 
that interfered with tamoxifen’s peak. However, a clearer and more defined HPLC 
profile was not achieved.  
A possible explanation of the difficulties encountered in the evaluation of the amount of 
loaded drug could lie in the instability of tamoxifen, which is well known and 
documented in literature. 44, 45 Tamoxifen absorbs light in the solar irradiations UVB and 
UVA region and undergo to photochemical reactions. Products of such reactions 
include geometrical isomerisation, oxidation product of the C=C double bod or ring 
cyclisation to form phenantrene derivatives. As described in chapter 1, the 
photocyclisation of tamoxifen and the formation of fluorescent phenantrene derivatives 
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were used in the past for detecting the drug using HPLC coupled with fluorimeter. 
Given the inconclusive results obtained by using the available HPLC system and the 
pressure on time to provide evidence that tamoxifen was loaded in the matrix, as 
opposed to its precise quantification, it was decided to develop a new approach. 
4.4.1. Photocyclisation of tamoxifen  
This new method for the evaluation of tamoxifen was based on the formation of the 
drug’s phenantrene derivative after UV irradiation and its visualisation using UV-Vis 
spectroscopy. The irradiation of a solution of tamoxifen in MeOH led to the presence of 
three new peaks in the UV spectrum of drug at λmax = 360, 344 and 300nm (figure 4.27). 
The intensity of the new peaks increased over time, reaching a maximum after 4 hours.  
 
Figure 4.27. UV-Vis spectrum of tamoxifen in MeOH at 0.202μM before irradiation and after 4 hours 
irradiation. Three new peaks at λmax = 360, 344 and 300nm are formed after irradiation  
Initially a reference line after 4 hours UV irradiation of tamoxifen in MeOH was 
recorded. After careful evaluation of the three peaks of the irradiated tamoxifen, it was 
chosen to monitor the peak at λabs = 360nm, as it was more stable over time compared to 


























Figure 4.28. Reference line of tamoxifen in MeOH after 4 hours irradiation using a standard UV lamp at 
365nm. The intensity of the peak at λmax = 360nm is reported against the concentration of tamoxifen  
Once the calibration curve was obtained, solutions of NIP FM-P7 and MIP FM-P8 in 
MeOH were irradiated under UV lamp and the formation of new species at λabs = 360nm 
was monitored via UV-Vis spectroscopy, as shown in figure 4.29. Figure 4.29 (a) shows 
the UV spectrum of NIP FM-P7. As expected, considering the lack of tamoxifen in the 
matrix, no peak was formed at λabs = 360nm and no difference were visible after 
irradiation. Figure 4.29(b), shows the UV spectrum of FM-P8 and, in figure 4.29(c), an 
enlargement between λabs = 350-370nm shows more in details the presence of a peak at 
λabs = 360nm.  
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Figure 4.29. UV-Vis spectra of 1mg/mL in MeOH of a) NIP FM-P7; b) MIP FM-P8; c) Enlargement 
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The formation of this new peak, which was not observed before irradiation, suggested 
the presence of tamoxifen within the MIP matrix. MeOH, used to dissolve the polymer, 
disrupted the ionic interactions between the drug and the functional monomer, allowing 
the tamoxifen to be released in solution. Once the tamoxifen was free from the matrix, it 
photoreacted forming a new derivative, which absorbed at λabs = 360nm. After 40 
minutes irradiation the intensity of the peak in the MIP solutions reached a maximum, 
suggesting that the total amount of tamoxifen was transformed. Using the spectrum 
recorded before the irradiation as baseline, the maximum absorbance at λabs = 360nm 
was determined. According to the reference line previously recorded, the evaluation of 
the loaded drug gave a value of 0.058mM of tamoxifen per mg of polymer. Once that 
the loaded tamoxifen was determined the percentage of drug incorporated in the matrix 
could be assessed. The percentage of tamoxifen incorporated was calculated as a ratio 
of the actual drug loaded in the matrix and the amount of drug used in the pre-
polymerisation mixture, taking into account the chemical yield of the polymer (equation 
4.2), which was found to be 31.2%.  
%  𝑜𝑓  𝑇𝐴𝑀 =    !"#$%&  !"#$  !"#$%&$%'()*
!!!"#!$%&'()  !"#$  !"#$%&$%'()*  
  ×100                      Equation 4.2 
The 31.2% of the total amount of tamoxifen added in the mixture during the preparation 
of nanogels was successfully incorporated within the polymeric matrix. The rest could 
have been lost together with the rest of smaller polymeric chains during the purification. 
These results provided interesting preliminary data and an estimate of the drug loading 
in the polymers. Although this method may seem as a convoluted way of quantification 
and it was based on a chemical transformation, which could lead to by-products, it 
presented evidence of the presence of tamoxifen in the nanogel FM-P8. Therefore, it 
was agreed to use the preparations FM-P7 and P8 to carry out in vivo experiments, 
described in chapter 5.  
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4.5. Conclusions and future work 
The molecular imprinting approach and high dilution polymerisation technique were 
employed in the preparation of water soluble nanogels with potential application as 
stimuli-responsive drug delivery carrier. The optimisation of the synthesis of nanogels 
containing 6-Vinylcoumarin-4-carboxylic acid (VCC) and N-isopropylacrylamide 
(NIPAM) led to the formulation of FM-P7 and FM-P8. Evidence showed that VCC 
was successfully polymerised and the polymers presented good water solubility of 1 
mg/mL, high fluorescence emission and small particles size in the range of 30-82nm. 
Initial issues, encountered during quantification of the loaded drug using HPLC, were 
overcome resorting to photochemical transformation of tamoxifen. UV-irradiation of 
MIP solutions gave a new absorbance peak, which was used to evaluate the amount of 
loaded drug. According to the reference line, previously obtained by irradiating solution 
of tamoxifen at different concentrations, the amount of drug incorporated in FM-P8 was 
0.058mM per mg of polymer.  
Future works should involve further optimisation of the HPLC-based method for 
quantification of the loaded drug. In fact, by using the HPLC quantification of the drug 
would become a lot faster and more sensible compared to the method applied in this 
project. Modification of the methodology, for example by changing the retention time 
of tamoxifen and the eluent solvent, could give better separation between the peak of 
TAM and contaminants. This would allow a clearer reading of the area under the curve, 
allowing more accurate quantification. Another way to optimise the quantification of 
the drug would be to adapt the HPLC approach to the detection of photocyclisation 
products. This could be possible by irradiate the sample with UV light, separate it in the 
chromatographic column and use a fluorescence detector to increase the sensitivity. 
Once an easier and more precise evaluation of the amount of TAM would be possible, 
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the next step for the FM-P8 nanogel would be to carry out drug release studies at pH: 
5.5, the conventionally chosen pH for anticancer drug delivery system test. The 
determination of the drug release profile would give information on the ability of the 
system to provide a sustained drug release.  
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5. In vivo system for toxicity and drug visualisation studies  
5.1. Introduction 
Given the recent growth in the design of nanomaterials for therapeutic uses, a thorough 
understanding of the associated systemic and local toxicity as well as the biodistribution 
of the nanomaterials is of high importance.1 These materials have different 
characteristics compared to their bulk counterpart, mainly due to their nano-size. The 
small particle size, the increased surface-to-volume ratio, the shape and the surface 
chemistry altogether influence the potential toxicity of the nanoparticles. 2 As already 
described in the previous chapter, small particles are expected to be easily internalised 
into the cells and to penetrate and translocate across epithelial and endothelial cells. For 
these reasons, nanoparticles tend to accumulate in tissues with high phagocytic activity 
like spleen, kidneys, liver and lungs, where they may interfere with the biological 
functions of the tissues. 3 As nanotechnology is a relatively recent field, the medium and 
long-term effects of such nanoparticles are still not completely known. Moreover, the 
use of nanoparticles with unknown toxicological properties represents hazards not only 
for human health but also for the environment and wildlife.  
International guidelines for assessing the effects of chemicals on human health and 
environment were first drawn up in 1980 and are constantly updated by the 
Organisation for Economic Cooperation and Development (OECD). Animals with 
similar genetics and physiology to humans are often used for testing potential human 
treatments. In vivo testing can provide important information regarding the absorption, 
distribution, metabolism and toxicity of nanomaterials. As expected, there are laws that 
regulate the use of animals in science, with particular attention to their care and 
welfare.4 The Animal (scientific procedures) Act, compiled in the UK in 1986, requires 
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scientists to obtain a personal licence, in order to perform procedures on animals, and 
also a licence for the project in which the animals are used; another licence is necessary 
for the institute where the animals are housed. Research proposals are fully assessed in 
terms of potential harm to the animals and the procedures or experiments are examined 
in details, before the licences are issued. Animal research is also governed by the 
principles of the 3Rs: Refinement, Replacement and Reduction, that were first defined 
by Russel and Burch. 5 “Refinement” means reducing the amount of stress and pain an 
animal is exposed to. In order to do so, it is important to employ the least invasive 
techniques and control the pain of the animal throughout the procedure. “Replacement” 
denotes the substitution of the living models with in vitro testing, computer modelling 
and statistical assessment, whenever it is possible. “Reduction” intends keeping the 
number of animals used in the experiments to a minimum. As a result of the above, all 
the experiments described in this chapter were done in compliance with these principles 
and carried out under the project licence, number P6D11FBCD, and the personal 
licence, number ICC74C01A1, issued by the Home Office.  
5.2. Review of in vivo models – Toxicity screening 
It is essential to screen the new therapeutics for pharmacological activity and potential 
toxicity, before starting human clinical trials. Pre-clinical toxicity screening on animal 
models shows toxic effects of the tested compound in relation to the organs, the dose 
and species. 6 The same amount of comprehensive information could not be obtained by 
using only animal-free alternatives, such as in vitro testing or computer modelling. 
Although these strategies are useful for initial indication of toxicity, the results obtained 
are significantly different from the information provided by in vivo experimentation.  
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A number of different animal species are used depending on the specific toxicity test 
carried out. For example, rabbits7 and guinea pigs8 are employed in acute toxicity 
testing for topical preparation, with particular attention on eyes and skin irritation; 
hamsters and gerbils are used for testing chronic toxicity and carcinogenesis bioassays; 9 
non-humans primates10 and dogs11 are often employed for toxicokinetic studies. 
However, mice represent the most widely used in vivo system. 12, 13 This is primarily due 
to the model’s physiological similarity to humans as well as the incredibly high amount 
of available mutant loci, either spontaneous or chemically induced, that gives rise to a 
number of potential models of different human diseases. Therefore, several treatment 
strategies are pre-clinically tested on mice, contributing to increasing the importance of 
mouse models. Examples of nanoparticle toxicity investigations carried out in mice are 
abundant in the literature. In 2007, for example, Cha and Myung tested the acute toxic 
effect of metal-based nanoparticles using a mouse model. 14 Non-specific toxicity 
manifested as a haemorrhage in the heart, lymphocytic infiltration in the liver, stomach 
and intestine, and medullary congestion in the spleen. The group was able to 
demonstrate that the acute toxicity was not dependent on the size of the nanoparticles 
but was instead due to the presence of the inorganic particles. Also magnetic iron oxide 
nanoparticles, with potential imaging and therapeutic functions, were widely tested in 
mice. 15 Quan et al. developed human serum albumin coated iron oxide nanoparticles, 
encapsulated with doxorubicin, to be subcutaneously injected into anesthetised mice. 16 
Such formulation was not toxic to the mice. In addition in vivo imaging as well as ex 
vivo biodistribution confirmed the tumour targeting characteristics of the nanoparticles 
and the tumour suppression effect of the encapsulated doxorubicin. Nanomaterials, 
other than metal nanoparticles, such as micelles, 17 nanotubes, 18 solid lipid 
nanoparticles19 and many others20, 21 have also been tested in mice over the years. As 
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already mentioned, animal testing is a necessary first step towards the development of 
new materials with therapeutic potential. Such compounds can move forward to human 
clinical trials only when their toxic levels and efficacy in the therapy have been 
evaluated in animals first.  
5.3. Zebrafish as novel in vivo system 
Although mammals are widely used as human pathology models and for toxicity 
screening, they present some disadvantages. Life cycles and developmental stages are 
time-consuming and involve high housing costs. Moreover, foetal experiments are 
difficult, due to internal fertilisation, which would require embryonic manipulations 
inside the mother.  
Recently, Denio rerio, more commonly known as zebrafish, has seen an exponential 
growth as a novel alternative to mammalian models for development, disease, and 
toxicological studies. Zebrafish is a species of tropical freshwater fish commonly found 
in slow-moving or stagnant water. 22 Females can spawn every 2-3 days producing 
between 100 and 200 eggs per clutch. 23 When fertilised, the eggs are only 0.7 mm in 
diameter and are optically transparent, thus allowing easy monitoring through all 
developmental stages. The development of the embryos is very rapid. In only 36 hours 
post fertilisation (hpf) it is possible to observe precursors of the major organs and at 3 
days post fertilisation (dpf) the embryos hatch, entering into their larval period. By 5 
dpf, the organs and tissues are fully developed; larvae grow their swim bladder, they 
start swimming actively, they show active avoidance behaviour (escape responses), 
respiratory movements and they start seeking for and swallowing food (figure 5.1). 24  




Figure 5.1.  A representative image of zebrafish developmental stages at 6, 24 and 120 hpf. By 120 hpf, 
the larvae are fully developed and start swimming and searching for food. Image reproduced with 
permission from McGrath et al.24 
Zebrafish are characterised by a series of features that make them complementary to the 
mammalian models. Their genome, brain patterning and structure/function of many 
neural, physiological and anatomical systems are similar to rodents and humans. 25 They 
also show an innate immune system, monocyte/macrophages, and adaptive immune 
systems. 26 Regarding the similarity with humans, the fully mapped genome of zebrafish 
shows that 70% of human genes have at least one obvious zebrafish orthologue, 
suggesting that there could be a match of the genes involved in human diseases to the 
zebrafish genome.27 Furthermore, targeted genetic modifications have been introduced 
in zebrafish embryos in order to generate mutant alleles that copy human disease loci, 
making this animal system a good human pathology model. 22  
The characteristics of zebrafish, including their small size, ease of handling, rapid 
development, transparency, high number of eggs per clutch and low housing costs, 
make them ideal for fast and reliable pre-clinical screenings of materials with 
therapeutic applications. 28, 29 The drug and toxicology screening procedure simply 
requires the dispersion of the chemical compounds under examination in water. Larvae 
at the same developmental stage are immersed in the solution and checked for physical 
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or behavioural changes caused by the molecules at different concentrations. In case of 
hydrophobic compounds or large molecules, it is safe to use DMSO up to 1% v/v as the 
carrier or to inject such compounds into the yolk sac, the sinus venosus or the 
circulatory system. Fish larvae can live for seven days in a single well of a standard 96-
well plate with no food, only supported by nutrients stored in the yolk sac. This is a 
significant advantage over mammalian models, which require higher maintenance 
efforts. Zebrafish larvae younger than 5 dpf can absorb any analyte, dispersed in the 
surrounding media, through their skin and gills; after 5 dpf they actively begin to 
swallow the materials. Another advantage of using zebrafish compared to other animals 
lies in the opportunity to use significantly larger numbers of zebrafish for each assay, 
with lower associated costs compared to mammals. Moreover, the larvae maintain their 
transparency for several days, therefore allowing an easier monitoring of the effect of 
the tested compounds. 24  
Literature review indicates that nanotoxicity screening using zebrafish has increased 
considerably in the last 10 years (figure 5.2). 
 
Figure 5.2. Increasing trend in the number of publications in zebrafish research (2006–2016). Keyword 
“zebrafish” searched performed on web of knowledge database and refined by “toxicology” and 
“nanoscience/nanotechnology”. Search conducted on 19th May 2017.  
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Recent examples found in the literature involve toxicity studies for graphen oxide, 30 a 
number of different nanoparticles31, 32 and carbon nanotubes functionalised with 
polyethylene glycol. 33 Zebrafish were examined in terms of survival rate and altered 
morphology, as well as hatching rate and spontaneous movement.  
5.3.1. LoxP - CreERt system for tamoxifen release studies 
Among the transgenic lines of zebrafish available at the moment, the Cre/loxP system is 
the most interesting for the purpose of this thesis. The Cre/lox is a site-specific 
recombination system, which was first employed in mice and gradually adapted for a 
variety of animal models, including zebrafish. 34 The Cre/loxP site-specific 
recombination is a technique commonly used to artificially control, either spatially or 
temporally, gene expression by recombination of DNA in vivo. This technique utilises 
the enzyme Cre recombinase, which recognises a specific 34 base pair DNA sequence, 
named loxP site (locus X-over in P1 bacteriophage). The Cre recombinase catalyses 
recombination of the particular genetic sequence contained between two loxP sites, 
called loxP-floxed genes. According to the orientation of the loxP sites, the Cre 
recombinase can catalyse deletion, translocation or inversion of the loxP-floxed genes 
(figure 5.3). 35  
  




Figure 5.3. Schematic representation of the Cre/loxP system. Gene A/B represents the loxP-floxed 
genetic sequence of interested, flanked by loxP sites represented by black triangles. a) The Cre 
recombinase catalyses the deletion of the flanked genes when the loxP sites are oriented in parallel (head-
to-tail). b) The translocation of genes A and B is promoted by the Cre recombinase when the loxP sites 
are on separate DNA strands. c) Cre recombinase catalyses the inversion of genes A when the loxP sites 
have an anti-parallel orientation (head-to-head) 
A very useful application of this approach lies in the generation of transgenic zebrafish 
lines designed to switch fluorescence from green to red (G2R) by knocking out or 
expressing two different fluorescent proteins: GFP (green fluorescent protein) and RFP 
(red fluorescent protein). 36 This is achieved by flanking the genetic sequence that 
expresses the GFP with two loxP sites. When the Cre recombinase becomes expressed 
in the tissue, it excises the loxP-floxed GFP, leading to its knockout. Only at this point, 
under the control of a ubiquitous promoter, the RFP, which is called cargo genes, 
becomes expressed and the fluorescence changes from green to red (figure 5.4). The 
ubiquitous promoter is a region of DNA, located next to the loxP sites, where the 
transcription takes place, which initiates the transcription of particular genes. The 
promoter helps to enhance the expression of the RFP ubiquitously.  




Figure 5.4. Schematic representation of the Cre/loxP site-specific recombination. A second gene of 
interest, the cargo gene, follows the loxP-floxed GFP. The cargo gene expresses the second fluorescent 
protein, the RFP. When the Cre recombinase is expressed in the system, the loxP-floxed GFP is knocked 
out and the cargo gene is brought closer to the promoter, hence switching expression of proteins  
It is possible to control the gene knockout and the RFP expression by inducing a 
temporal activity of Cre recombinase. A construct CreERt2 is obtained by fusing a mutant 
ligand-binding domain of the human oestrogen receptor (ER) together with the Cre 
recombinase. In this case, the activation of the recombination event depends only on the 
presence of anti-oestrogen. Mutant versions of the ER ligand-binding domain were 
employed in order to circumvent the potential binding and activation of the CreERt2 by 
endogenous oestrogens. The CreERt2 is, in fact, insensitive to the natural oestrogens and 
it is activated when the anti-oestrogen tamoxifen (TAM) or 4-hydroxytamoxifen (4-
OHT, tamoxifen metabolite) are introduced in to the system. 37 Tamoxifen binds the ER 
fused with the Cre recombinase, which penetrates into the nucleus producing the 
targeted mutation. This system was successfully employed by Hans et al. in 200938 and 
by Mosimann et al. in 2011. 39 The two groups explored the efficiency of the different 
available ubiquitous promoters, finding that they become progressively inactive during 
the course of development. Hans and co-workers discovered that the loxP-floxed genes 
knockout occurs within 2-4 hours of the administration of TAM or 4-OHT, however the 
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promoter they used (EF1α) only expresses in the early developing stages (from 5 to 24 
hpf).38 The reliability of loxP excision is required throughout all the stages of 
development, Mosimann’s group, therefore, employed a ubiquitin (ubi) locus in 
zebrafish to generate an ubiquitously expressed transgene driver, that would not be 
dependent on the developmental stage. 39 A new transgenic line, named ubi:switch, 
which contains GFP was therefore prepared by Mosimann.  
The loxP sites, as well as the Cre recombinase, are not native to the animal genome; it is 
necessary to artificially insert the sequences using transgenic technology. In order to 
obtain in vivo models containing the Cre/loxP site-specific recombination, two different 
transgenic lines were required: (a) one line containing the loxP-floxed GFP cassette, 
which express GFP and emits green fluorescence ubiquitously from 24 hpf; (b) one 
containing the CreERt2, which emits green fluorescence only in the heart from 48 hpf. 
Only the offspring of the crossbreed CreERt2 × LoxP that inherited both genes will give 
rise to the ubi:switch line. Figure 5.5 shows the possible allele combinations of the 
offspring in the progeny of heterozygous or homozygous adults. 
 
Figure 5.5. Schematic of zebrafish allele inheritance to form a ubi:switch transgenic zebrafish. A) 
crossbreeding of two heterozygous creERt2 and loxP lines, in this case only 25% of the offspring inherit the 
two alleles and form ubi:switch tg line. B) crossbreeding of two homozygous creERt2 and loxP species, in 
this case 100% of the offspring inherit the two alleles, forming ubi:switch tg line 
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Only 25% of the offspring generated from heterozygous fish and 100% of the offspring 
generated from homozygous fish inherit the two alleles and respond to the presence of 
tamoxifen by generating red fluorescence.  
This tamoxifen reporter line ubi:loxP-EGFP-loxP-mCherry (ubi:switch) was selected to 
test the presence of tamoxifen in the MIP FM-P8 matrix, discussed in chapter 4.    
5.3.1.1. Genotyping by breeding 
The two transgenic zebrafish lines were acquired from University College London’s 
fish facility, where they were maintained as heterozygous lines. The lines were 
subsequently maintained for a number of years according to the breeding program 
employed at Queen Mary University of London’s biological service unit. This resulted 
in both the lines being maintained in tanks containing a mendelian distribution of 
homozygous, heterozygous and wild type genotypes. As previously mentioned, using 
homozygous fish from both transgenic lines increases the percentage of the offspring 
that inherit both alleles and that are responsive to tamoxifen to 100%. It was therefore 
decided to identify the homozygous fish and only use them for future tests. A 
genotyping by breeding strategy was required in order to identify the homozygous 
fishes of the tg:loxP and tg:CreERt2.  
CreERt2 males and loxP females were individually housed in separated and labelled tanks, 
which were then crossbred with female and male wild type (WT), respectively. The 
eggs generated from the tg:CreERt2 exhibit a green fluorescence heart at 48 hpf, while the 
ones obtained from tg:loxP show a green fluorescence in the whole body at 24 hpf. In 
cases of heterozygous CreERt2 or loxP adults, 50% of the offspring would express GFP at 
48hpf or 24hpf, respectively, whereas in case of homozygous adults, the totality of the 
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offspring would display GFP. Figure 5.6 shows a schematic representation of this 
strategy.   
 
Figure 5.6. Schematic representation of the genotyping by breeding strategy, using the CreERt2 as 
example. The same process was applied for the genotyping of loxP adults. Only the heterozygous give the 
totality of the embryos that express GFP  
The fish identified as homozygous were kept in separate, labelled tanks and used for the 
crossbreeding CreERt2 × loxP in order to obtain ubi:switch.  
5.4. Tamoxifen - induced switch 
It was necessary to evaluate the reliability of the Cre/loxP system for the visual 
detection of tamoxifen prior to the evaluation of drug loading in the polymeric matrix 
MIP - FM-P8. The homozygous CreERt2 males were crossbred with homozygous loxP 
females. One CreERt2 fish and one loxP fish were paired together in a tank equipped with 
a removable insert with a perforated mesh at the bottom. The mesh allows the eggs to 
pass through and sink to the bottom of the outer box, preventing the adults from eating 
them. The following morning, the clutch from each couple was collected in different 
petri dishes using a strainer. Using a microscope, the embryos were sorted into petri 
dishes contained 50 healthy and fertilised eggs. The dishes were kept in an incubator at 
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during the first 24 hours and, if not removed from the dish, can cause the death of the 
entire group. The embryos were also sorted for ubiquitously expression of GFP at 24 
hpf. All of the embryos showed green emission under the fluorescence microscope, 
confirming that the adult fishes were homozygous and that the embryos contained the 
full loxP-CreERt2 system, which express red fluorescence (mcherry) on exposure to 
tamoxifen. Figure 5.7 shows an embryo of ubi:switch at 24 hpf in which the GFP 
expression is visible in the entire body.  
 
Figure 5.7. Confocal image of an embryo ubi:loxP-EGFP-loxP-mCherry at 24 hpf. GFP is expressed 
everywhere in the body  
Together with the evaluation of the efficacy of the system, the potential dose-dependent 
toxicity of tamoxifen at larval stages was assessed. Larvae at 4 dpf were chosen for this 
experiment, as at this stage the fish have already hatched and start seeking food. The 
drug dispersed in water can therefore be internalised by the larvae following two main 
routes, absorption through the skin and the gills or ingestion and absorption in the GI 
(gastro intestinal) tract.  
A literature review suggested that the concentration of tamoxifen and metabolites 
generally used to induce the recombination in zebrafish is in the range 5-10μM. 38-40 It 
was therefore decided to investigate the effect of tamoxifen at the limits of this range. 
Two concentrations of the free drug tamoxifen citrate, 5 and 10μM, were fed to two 
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different groups of zebrafish at 4dpf. The test was carried out in a 6-well plate, using 2 
wells for each concentration of TAM plus 2 wells for internal plate and negative 
controls. Figure 5.8 shows the set-up of the experiment; thirty larvae at 4dpf were 
immersed in each well. The plate was kept in an incubator at 28°C.  
 
Figure 5.8. Schematic representation of the experimental set-up 
This experiment lasted 5 days. Throughout the whole time zebrafish were monitored 
daily in terms of survival rate and any alterations in motility or morphological 
deformation. After only 4 hours the fish treated with both concentrations of TAM 
showed a lack of motility and response to touch, compared to the control groups. 
Although no deaths were recorded during the experiment, the fish displayed signs of 
stress and dorsal curvature of the body was observed in every fish treated with TAM. 
According to Mosimann et al. the mcherry expression was expected after 3 days of 
treatment.39 Given the ubiquitin promoter used in the Cre/loxP system, the intensity of 
red fluorescence was not expected to decrease over time. Two days later, five random 
fish per concentration were chosen as a representative sample and were prepared for 
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(PFA) to fix the tissues, before mounting them on microscope slides using a solution of 
1% w/v agarose in PBS for imaging.  
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Figure 5.9. Cre-mediated recombination fluorescence microscope images. A-I) Head and trunk lateral 
views of 9dpf larvae, anterior to the right.  A-C) Control fish immersed in fish water. This larva retains 
the green signal and does not show any mcherry expression, a part from the autofluorescent red signal in 
the yolk (bracket). D-F) Fish treated with tamoxifen 5μM. The mcherry is expressed everywhere in the 
fish tissues and in particular in the heart (arrow). G-I) Fish treated with tamoxifen 10μM. The mcherry is 
expressed everywhere in the fish tissues and in particular in the heart (arrow)  
Fluorescence microscope images of represented larvae are shown in figure 5.9. No 
mcherry expression was visible in the untreated fish (figure 5.9 C) apart from 
autofluorescence in the yolk. The fish treated with a solution of tamoxifen at different 
concentrations showed mcherry expression ubiquitously in the tissues, particularly in 
the heart. Every larva prepared for imaging displayed mcherry fluorescence in the 
tissues, however, for simplicity of representation, only one larva per concentration is 
shown in figure 5.9. 
The results obtained confirm the CreERt2/loxP system to be useful for the visual detection 
of tamoxifen with the presence of the drug inducing mcherry fluorescence.  
5.5. Toxicity and visualisation studies in vivo using ubi:switch 
zebrafish system  
Once it was demonstrated that the presence of tamoxifen could induce the switch of 
fluorescence in the CreERt2/loxP system available in the BSU at Queen Mary University 
of London, it was decided to use zebrafish to obtain preliminary data using the 
tamoxifen loaded nanogels FM-P8, obtained using the molecular imprinting approach 
for the drug incorporation. For comparison, the counterpart polymer non-imprinted FM-
P7 was also used in parallel. The experiments were designed to assess two important 
objectives: i) to assess the toxicity of the tamoxifen-loaded nanogels and to compare the 
data with the ones obtained for the nanogels alone; ii) to demonstrate the potential for 
nanogels to be used as drug delivery vehicles by showing the effective incorporation of 
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tamoxifen in the polymeric matrix. Given the limited time available to complete the 
work, it was decided to focus the work on only two concentrations of polymers and to 
follow the fish embryo acute toxicity test guidelines given by the OECD (Organisation 
for Economic Cooperation and Development).41 Embryonic stage ubi:switch zebrafish 
were exposed to two different concentrations of NIP FM-P7 and MIP FM-P8 at 24 hpf 
for a period of 96 hours. The embryos were monitored every 24 hours with particular 
attention to indicators of lethality, as stated in the test guidelines but using the later 
stage responses for embryos and larvae. The indicators were: immobility, absence of 
respiratory movement, lack of heartbeat, insufficient reaction to stimulus and 
abnormalities of body forms. Four standard 24-well plates were used, one plate for each 
concentration and nanogel. Twenty embryos per concentration, one embryo per well, 
were exposed to the nanogels. The remaining four wells in the plate were the control 
groups. Controls consisted of one embryo per well immersed in fresh fish water and 
used both as negative control and as internal plate control. The layout of the plates is 
reported in figure 5.10. 
 
Figure 5.10. Layout of the 24-well plates used in the evaluation of toxicity of two solutions of NIP FM-
P7 and MIP FM-P8. In the same time the presence of tamoxifen in the matrix of the MIP was 
investigated by monitoring the expression of mcherry fluorescence  
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Having demonstrated the successful activation of the Cre recombinase in the zebrafish 
following the incubation with tamoxifen at 5μM and 10μM, the subsequent step 
investigated the effect of polymeric matrix when a similar amount of drug is uploaded. 
Two solutions of MIP FM-P8 were prepared in fish water at a concentration of 
84.7μg/mL and 169.4μg/mL, with content of tamoxifen estimated to be approximately 
5μM and 10μM. Two solutions of the corresponding NIP FM-P7 counterpart at the 
same polymer concentrations of 84.7μg/mL and 169.4μg/mL were also prepared. The 
mixtures were sonicated for 10 minutes and filtered over a 0.45μm GHP filter 
immediately before transferring one embryo at 24 hpf to each well. The plates were then 
randomly positioned in the incubator at 28°C. 
At the end of the exposure period, no acute toxicity was observed for any of the 
solutions tested; no negative outcome in any of the indicators of lethality was recorded 
(figure 5.11).  
 
Figure 5.11. Effect of nanogels on 24hpf zebrafish embryos. Two concentrations of nanogels FM-P7  
(84.7μg/mL and 169.4μg/mL) and FM-P8, containing an estimation of 5μM and 10μM of tamoxifen, 
were fed to 24hpf zebrafish embryos for 8 days. Each solution was tested on 20 embryos and they all 
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The data obtained were very encouraging. As shown in figure 5.11, the tested 
concentration of nanogels, chosen accordingly to the concentration of free tamoxifen 
investigated in section 5.4, showed no toxicity in zebrafish. Comparison of toxicity data 
for these nanoparticles with previously obtained data42 demonstrates that these NIPAM-
based nanogels can be safely use at these concentrations as there is no evidence of 
significant toxicity. This result is very important and will play an important role for 
future applications.  
Evaluation of the presence of tamoxifen in the MIP was carried out by fluorescence 
microscopy. After 8 days of treatment, five random fish per concentration were chosen 
as a representative sample and prepared for imaging. However, for simplicity of 
representation only one larva per concentration is shown in figure 5.12. The fish were 
then anesthetised and immersed for 2 hours in paraformaldehyde (PFA) to fix the 
tissues, before mounting them on microscope slides using a solution of 1% w/v agarose 
in PBS for imaging.  
















































Figure 5.12. 1) A-I) Head and trunk lateral views of represented 8dpf larvae, anterior to the right. 
Ubi:switch 8dpf fish treated with NIP FM-P7 (A-C), MIP FM-P8 containing 5μM tamoxifen (D-F) and 
MIP FM-P8 containing 10μM tamoxifen (G-I). A-C) Control fish treated only with NIP show no 
mcherry expression; only the autofluorescent red signal is visible in the yolk (bracket). D-F) Fish treated 
with MIP containing 10μM tamoxifen. The mcherry is expressed everywhere in the fish tissues, 
particularly in the heart (arrow). G-I) Fish treated with MIP containing 5μM tamoxifen. The mcherry is 
expressed everywhere in the fish tissues. 
2) Enlargement of the region around the heart of C1) NIP treated fish, F1) MIP containing 10μM 
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The data represented in figure 5.12, which report the fluorescence microscope images 
taken of one set of fish treated with NIP 169.4μg/mL, MIP 84.7μg/mL and MIP 
169.4μg/mL respectively, show evidence for the presence of tamoxifen in the polymeric 
matrix. In fact the generation of mcherry fluorescence in the fish tissues and heart 
treated with MIP (figure 5.12 (1) D-F and G-I), compared to the lack of red signals on 
fish treated with NIP (figure 5.12 (1) A-C) confirmed that the drug was loaded in the 
polymeric network during the polymerisation process. The results also suggested a 
dose-dependent response of the Cre/loXP system to tamoxifen. The mcherry expression 
in the heart of the fish treated with the strongest concentration of MIP (figure 5.12 (2) 
panel F1) displayed a more intense fluorescence compared to the lowest concentration 
(figure 5.12 (2) panel I1).  
5.6. Conclusion and future work  
In conclusion the CreERt2/loxP proved to be a useful system for the visual detection of 
tamoxifen contained in the polymeric matrix. The presence of tamoxifen in the 
organism induces the activation of the recombination event producing red fluorescence 
in the fish tissues and in the heart.  
The nanogels were tested on zebrafish both for tamoxifen evaluation and for toxicity 
studies. Using the same array for both investigations saves time, money and reduces the 
number of animals needed. This preliminary study showed promising results as mcherry 
expression was only observed in the fish treated with two solutions of MIP at different 
concentrations, which means tamoxifen was loaded in MIP FM-P8. These results 
suggest that the imprinting process during the polymerisation step was successful. 
The zebrafish showed good tolerance to the coumarin-based imprinted polymers at the 
tested concentrations. However, a further toxicity screening, which could test a higher 
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number of concentrations, is needed to evaluate the LC50 of these polymers (lethal 
concentration at which half of the sample population is killed). 
Future work should involve the study of the drug release mechanism in the fish, which 
probably takes place in the acidic pH of the stomach after ingestion. Moreover, once the 
LC50 has been assessed in zebrafish, it would be essential to carry out in vivo testing on 
small mammals, such as mice. This is an important step to test the efficacy of the 
system as a drug delivery vehicle. Mice, unlike zebrafish, have breast tissue on which 
analogous human breast cancer could be grown. This could allow investigation of the 
potential advantage of using the nanogels over the free drug in reducing the tumour and 
preventing further growth.  
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6. Materials and methods 
6.1. Chemicals and Materials 
6.1.1. Chemicals and materials for the synthesis of functional 
monomers  
N-Boc-4aminophenol, dimethyl acetylenedicarboxylate, triethylamine, trifluoroacetic 
acid, palladium catalyst, tributyl(vinyl)tin and sodium fluoride were all purchased from 
Aldrich. Magnesium sulphate, sodium hydroxide and sodium chloride were purchased 
from Fisher. 4-bromophenol was purchased from Acros Organics, triphenylarsine from 
Alfa Aesar, triphenylphosphine from Fluka and potassium carbonate from BDH. Dry 
solvents dichloromethane (CH2Cl2) and tetrahydrofuran (THF) were supplied from 
MBRAUN MB SPS-800 solvent purification system. Dry dichloroethane was purchased 
from Acros Organics. Hexane, ethyl acetate, petroleum ether, acetone and acetonitrile 
were all purchased from VWR. Flash column chromatography was performed on 
reaction mixtures using VWR silica gel. Analytical thin layer chromatography (TLC) 
was carried out using pre-coated aluminium plates TLC Silica gel 60 F254, purchased 
from Merck. The plates were visualized under an ultraviolet lamp at λ = 254/365 nm. 
6.1.2. Fluorescence studies on bulk polymers for detection of 
clomiphene, tamoxifen and 4-hydroxytamoxifen 
Acetonitrile was purchased from VWR. Hamilton syringes were used for making the 
solutions for UV-Vis and fluorescent spectroscopy experiments. 96-well plates were 
purchased from FALCON and used on the plate reader. High precision quartz cell with 
light path of 10mm and total volume 1 mL, where purchased from Hellma Analytics 
and used for UV-Vis. High precision quartz cell with light path of 10mm and total 
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volume 2 mL, where purchased from Hellma Analytics and used for fluorescence 
experiments. 
6.1.3. Chemicals and materials for synthesis of nanogels for DDS 
N-isopropyacrylamide (NIPAM), N-N’-methylenebis(acrylamide) (MBA) and dry 
DMSO were purchased from Aldrich. Azobisisobutyronitrile (AIBN) was purchased 
from Acros Fisher Scientific UK and recrystallized from methanol before use. 
Tamoxifen citrate (98%) was purchased from Cambridge Bioscience. Dialysis 
membrane for nanogel isolation was purchased from MediCell International Ltd, 22 mm 
diameter and molecular cut off 3.5 KDa. Dialysis bag Float-A-Lyzer® G2 (5mL 
volume) with MWCO = 3.5-5.0 KDa were purchased from Spectrum Europe BV. GHP 
Acrodisc ® 13mm syringe filter with 0.45μm GHP membrane were purchased from 
PALL. Inorganic membrane filter Anotop ™ 10mm, 0.02μm, were purchased from 
Whatman. Solvent resistant disposable cuvettes in polystyrene 10x10x45 (DTS0012, 
Malvern) were used to record the size at the DLS. 
6.1.4. Chemicals and materials for the in vivo studies 
Phosphate buffered saline (PBS) was purchased from Sigma. Agarose low gelling point 
was purchased from BDH and used in a solution of 1% w/v in PBS at pH: 7.4.  
Paraformaldehyde (PFA) was purchased from Prolabo and used in a solution of 4% w/v 
in PBS pH: 7.4. Microscope slide and cover glass were purchased from BDH.    
Polystyrene 24- and 6-well cell culture plates were purchased from Corning 
Incorporated. 




6.2.1. NMR Spectroscopy 
1H-NMR, 2D-NMR and 13C-NMR spectra were recorded on a Bruker AV400 MHz  
(Avance and Avance III) or Bruker AV600 MHz (AV 600) spectrometers. Deuterated 
solvents, CDCl3 and DMSO-d6, were used depending on the solubility of the 
compounds. Chemical shifts in NMR spectra are reported as δ (in parts per million, 
ppm) relative to residual solvent signals: CDCl3 δH = 7.26 ppm; δC = 77.23 ppm or 
DMSO-d6 δH = 2.50; δC = 39.51. 
1H-NMR peak multiplicity were reported as follow: s = singlet, d = doublet, t = triplet, q 
= quartet, m = multiplet. Coupling constants (J) were measured in hertz. MestReNova 
software was used to analyse the NMR data. 
6.2.2. UV-VIS Spectroscopy 
UV-Vis spectra were recorded using Cary 100 UV-Vis Spectrophotometer (Agilent 
technologies), equipped with an internal thermostat.  
6.2.3. Fluorescent Spectroscopy 
All fluorescence data for the characterisation of the detector developed in chapter 3 was 
accomplished on a Flouromax-3 with emission slit set at 1.5. The other fluorescence 
studies were carried out on a Cary Eclipse Fluorescence Spectrophotometer (Agilent 
technologies). 
6.2.4. Plate Reader 
The interaction studies between MIP and the analytes were carried out on a BMG 
LABTECH FLUOstar OPTIMA Microplate Reader. Fluorescence was recorded using 
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the 340-10 excitation filter and the 510-20 emission filter.  
6.2.5. Zetasizer (Dynamic light scattering) 
DLS measurements were performed on a Malvern Zetersizer NaNo ZS. The instrument 
was equipped with a 4mV He-Ne laser operating at λ = 633nm, an avalanche 
photodiode detector with high quantum efficiency and an ALV/LSE-5003 multiple tau 
digital correlator electronics system.  
6.2.6. Freeze-dryer 
The polymers were freeze-dried using a Labcoco FreeZone 6 Freeze Dry System. 
6.2.7. High performance liquid chromatography (HPLC) 
All data was recorded on a manual injector Aglient Technologies 1220 Infinity LC 
fitted with a HiChrom 5 μm - C18 column 250 mm x 4.6mm id. The data were analysed 
using Agilent ChemStation software. 
6.2.8. Confocal Microscope 
Leica SP5 confocal laser scanning microscope. 
6.2.9. Fluorescent Microscope 
Leica DMRA2 fluorescence microscope, coupled with Hamamatsu ORCA-ER digital 
camera. 
6.2.10. UV lamp for irradiation  
UVP, UV GL 58 handheld UV lamp, 254/365nm. 




6.3.1. Synthesis of functional monomers 
6.3.1.1. Synthesis of 6-N-boc-aminocoumarin-4-carboxylate (3a) 
 
Reflux synthesis: 
Under a N2 atmosphere, N-Boc-4-aminophenol (0.5 g, 2.39 mmol) and PPh3 (0.6267 g, 
2.39 mmol) were dissolved in dry DCM (5 mL). The mixture was cooled to -10°C in 
dry ice and acetone bath and dimethyl acetylenedicarboxylate (0.2934 mL, 2.39 mmol) 
was added drop-wise. The reaction was stirred at -10°C for 1 hour and then refluxed for 
168 hours at 40°C. The solvent was reduced in vacuo and the crude was purified with 
flash chromatography. Two columns were necessary to isolate the product. In the first 
column a gradient elution mode was used starting from hex/EtOAc 80:20 and the 
second column started from DCM to arrive to DCM/EtOAc 90:10. The combination of 
the fractions containing pure compound gave the product 3a in a 20% yield.  
Microwave irradiation: 
PPh3 (1.31 g, 5 mmol), and N-Boc-4-aminophenol (1.046 g, 5 mmol) were added in a 
microwave tube. Once it was sealed, vacuum/nitrogen cycles were performed in order 
to remove any traces of oxygen. Dry DCE  (7.5 mmol) was then added. The mixture 
was cooled at -10°C (dry ice/acetone bath) and a solution of dimethyl 
acetylenedicarboxylate (614.5 μl, 5 mmol) in DCE (4 mL) was added dropwise over 10 
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microwave oven for 2 hours at 83°C. The solvent was reduced in vacuo and the crude 
was purified with flash chromatography. Two columns were necessary to isolate the 
product. In the first column a gradient elution mode was used starting from hex/EtOAc 
80:20 and the second column started from DCM to arrive to DCM/EtOAc 90:10. The 
combination of the fractions containing pure compound gave the product 3a in a 26.5% 
yield.  
1H-NMR (400 MHz, CDCl3) δ 8.26 (d, J = 2.5 Hz, 1H, H3), 7.68 (d, J = 8.0 Hz, 1H, 
H1), 7.27 (d, J = 8.0 Hz, 1H, H6), 6.94 (s, 1H, H8), 6.78 (s, 1H, H11), 3.98 (s, 3H, 
H12), 1.51 (s, 9H, H14). 
13C NMR (101 MHz, CDCl3) δ 164.14, 160.05, 152.73, 149.98, 141.77, 135.45, 123.47, 
120.03, 117.53, 115.87, 81.05, 60.40, 53.21, 28.30. 
6.3.1.2. Synthesis of 6-aminocoumarin-4-carboxylate (4) 
 
The compound 3a (0.1147 g, 0.359 mmol) was dissolved in DCM (2 mL) at 0°C (ice 
bath). Trifluoroacetic acid (2 mL) was added to the solution drop wise. After keeping 
the reaction mixture in ice bath for 10 minutes, it was left stirring at room temperature 
until completion. TLC monitoring (DCM/EtOAc: 9/1 plus few drops of triethylamine) 
showed the reaction to be complete after 3 hours. The solvent was reduced in vacuo and 
the solid re-dissolved in EtOAc (5mL) and washed with phosphate buffer pH: 8 (4 x 
15mL). The organic phase was dried over MgSO4, filtered and evaporated to give 
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1H-NMR (400 MHz, CDCl3) δ 7.53 (d, J = 2.7 Hz, 1H, H3), 7.17 (d, J = 8.8 Hz, 1H, 
H6), 6.92 (d, J = 2.7 Hz, 1H, H1), 6.91 (s, 1H, H8), 3.98 (s, 3H, H12), 3.21 (s, 2H, 
H11). 
13C-NMR (151 MHz, CDCl3) δ 164.47, 160.37, 147.72, 143.21, 141.81, 120.25, 119.75, 
117.85, 116.35, 110.70, 53.06. 
6.3.1.3. Synthesis of 6-acrylamidecoumarin-4-carboxylate (2a) 
 
K2CO3 (63.05mg, 0.456 mmol) was suspended in 5 mL of a mixture of H2O/Acetone 
(1:4 mL) and cooled down at 0°C (ice bath). The compound 4 (50 mg, 0.228 mmol) was 
solubilised in 1 mL of the same mixture and added to the cold K2CO3 solution drop wise. 
The reaction mixture was left to stir at 0°C. TLC monitoring (DCM/EtOAc: 9/1) 
showed the reaction to be complete after 2 hours. The mixture was filtered and the 
organic solvent evaporated at reduced pressure. The resulting water phase was extracted 
with DCM (3x15mL). The organic phase was dried over MgSO4, filtered and 
evaporated to give 38.1 mg of product 2a in a 61% yield.     
1H-NMR (400 MHz, DMSO) δ 10.41 (s, 1H, H11), 8.47 (d, J = 2.1 Hz, 1H, H3), 7.97 
(dd, J = 9.0, 2.2 Hz, 1H, H1), 7.45 (d, J = 9.0 Hz, 1H, H6), 6.91 (s, 1H, H8), 6.44 (dd, J 
= 17.0, 10.0 Hz, 1H, H15), 6.29 (dd, J = 16.9, 1.6 Hz, 1H, H17a), 5.79 (dd, J = 10.0, 1.6 
Hz, 1H, H17b), 3.31 (s, 3H, H12). 
13C-NMR (101 MHz, DMSO) δ 165.95, 165.52, 162.12, 153.43, 142.45, 134.32, 















Fosca Mirata  Chapter 6 
 
 194 
6.3.1.4. Synthesis of 6-bromocoumarin-4-carboxylate (3b) 
 
Reflux synthesis: 
Under a N2 atmosphere, 4-bromophenol (1 g, 5.78 mmol) and PPh3 (1.51 g, 5.78 mmol) 
were dissolved in dry DCM (15 mL). The mixture was cooled to -10°C in dry ice and 
acetone bath and dimethyl acetylenedicarboxylate (0.525 mL, 5.78 mmol) was added 
drop-wise. The reaction was stirred at -10°C for 1 hour and then refluxed for 120 hours 
at 40°C. The DCM was evaporated at reduced pressure and the product was purified by 
flash chromatography (DCM/Pet Ether: 75/25), which gave 389mg of product 3b with a 
yield of 24%.  
Microwave irradiation: 
PPh3 (700 mg, 4.046 mmol) and 4-bromophenol (1.06 g, 4.046 mmol) were added in a 
microwave tube. Once it was sealed, vacuum/nitrogen cycles were performed in order 
to remove any traces of oxygen. Dry ACN (6.069 mmol) was then added. The mixture 
was cooled at -10°C (dry ice/acetone bath) and a solution of DMAD (498 μl, 4.046 
mmol) in ACN (4 mL) was added dropwise over 10 min. After 10 min stirring at room 
temperature, the mixture was irradiated in a microwave oven for 2 hours at 83°C. The 
solvent was reduced in vacuo and the crude was purified with a gradient elution mode 
flash chromatography (hex/DCM 50:50) to give product 3a in a 31% yield.  
1H-NMR (400 MHz, CDCl3) δ 8.49 (d, J = 2.3 Hz, 1H, H3), 7.67 (dd, J = 8.8, 2.3 Hz, 
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13C-NMR (101 MHz, CDCl3) δ 165.52, 162.12, 152.78, 142.45, 137.05, 131.76, 121.56, 
121.12, 120.09, 119.16. 
6.3.1.5. Synthesis of 6-vinylcoumarin-4-carboxylate (2b) 
 
Reflux synthesis: 
Under a N2 atmosphere, 6-bromocoumarin-4-carboxylate 3b (30.54 mg, 0.106 mmol) 
and AsPh3 (6.59 mg, 0.02118 mmol) were dissolved in dry THF (5 mL) and the 
palladium catalyst (2.46 mg) was added to the mixture. The mixture was stirred for 10 
min, before adding tributyl(vinyl)tin (38.69 μl, 0.132 mmol) and refluxing for 192 h at 
70 °C. The reaction solution was left to cool to room temperature before adding 4 ml 
saturated sodium fluoride solution and 3 mL distilled water and stirring for 1 h. 
Following filtration, the solution was extracted with DCM (3x10 mL) and washed with 
saturated salt solution (2x10 mL). The extracts were dried over magnesium sulphate, 
filtered and evaporated in vacuo. The crude was purified by flash chromatography 
(DCM/Pet Ether 80/20) to give 7.4 mg of product 3b in a 30% yield.  
Microwave irradiation: 
6-bromocoumarin-4-carboxylate 3b (694.8 mg, 2.45 mmol), AsPh3 (150.3 mg, 0.49 
mmol) and the palladium catalyst (83.28 mg) were added in a microwave tube. Once it 
was sealed, vacuum/nitrogen cycles were performed in order to remove any traces of 
oxygen. Dry THF (2 ml) was then added followed by tributyl(vinyl)tin (896.68 μl, 
3.068 mmol). The mixture was irradiated in a microwave oven for 3 hours at 65°C. The 
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sodium fluoride solution and 1 mL distilled water and stirring for 1 h. Following 
filtration, the solution was extracted with DCM (3x5 mL) and washed with saturated 
salt solution (2x5 mL). The extracts were dried over magnesium sulphate, filtered and 
evaporated in vacuum. The crude was purified by recrystallization from hot EtOH to 
give 272 mg of product 3b in a 48% yield. 
1H-NMR (400 MHz, CDCl3) δ 8.26 (d, J = 2.0 Hz, 1H, H3), 7.65 (dd, J = 8.6, 2.0 Hz, 
1H, H1), 7.32 (d, J = 8.6 Hz, 1H, H6), 6.95 (s, 1H, H8), 6.75 (dd, J = 17.6, 10.9 Hz, 1H, 
H11), 5.78 (d, J = 17.6 Hz, 1H, H14a), 5.33 (d, J = 10.9 Hz, 1H, H14b), 4.01 (s, 3H, 
H12). 
13C-NMR (101 MHz, CDCl3) δ 164.19, 159.86, 153.75, 142.13, 135.29, 134.43, 129.79, 
128.65, 124.69, 119.73, 117.38, 115.16, 53.17. 
6.3.1.6. Synthesis of 6-vinylcoumarin-4-carboxylic acid (1b) 
 
6-vinylcoumarin-4-carboxylate 2b (184 mg, 0.796 mmol) was dissolved in a solution of 
4 mL THF and 10 mL ethanol. Sodium hydroxide (2 mL, 2 M) was added to the 
reaction and the solution was left to stir at 40°C under nitrogen and in the dark for 14 h. 
Solvents were removed under vacuum and 20 ml of water were added to the residue, 
which was washed with DCM (2 × 25 mL) and ethyl acetate (2 × 25 mL), before being 
acidified with concentrated hydrochloric acid. The aqueous phase was then extracted 
with ethyl acetate (3 × 25 mL) and the combined organic phase washed with a saturated 
NaCl solution (2 × 25 mL). The organic phase was dried over magnesium sulphate and 
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1H-NMR (400 MHz, DMSO) δ 8.17 (d, J = 2.1 Hz, 1H, H3), 7.84 (dd, J = 8.7, 2.1 Hz, 
1H, H1), 7.44 (dd, J = 8.7, 2.3 Hz, 1H, H6), 6.88 – 6.78 (m, 2H, H8 and H13), 5.84 (dd, 
J = 17.6, 0.7 Hz, 1H, H14a), 5.34 (dd, J = 11.0, 0.6 Hz, 1H, H14b). 
13C-NMR (101 MHz, DMSO) δ 165.22, 159.42, 153.34, 143.85, 135.33, 133.67, 
129.57, 124.47, 118.15, 117.22, 115.82, 115.22. 
6.3.2. Fluorescence studies chapter 3 
6.3.2.1. Interaction studies between VCC and analytes 
Solutions of VCC (5.9 × 10−3 M) were mixed with varying volumes of analytes stocks 
in acetonitrile, to give a final monomer to analytes ratio ranging from 1:0 to 1:5. All the 
samples were allowed to mix for 5 min at room temperature before being analysed. 
Triplicate experiments were carried out per each concentration. The fluorescence 
spectra were recorded at λexc = 521 nm following excitation at λem = 345 nm. 
6.3.2.2. Interaction studies between MIP and analytes 
Solutions of the imprinted polymer (5 mg/mL in ACN) were placed in 96-well plate and 
various amounts of analytes were added to give a VCC-analyte ratio ranging from 0 to 
0.25,0.5, 0.75 and 1. The solutions were left for 5 min after which the residual 
fluorescence was measured using a plate reader. Duplicate experiments were carried out 
per each concentration. The fluorescence spectra were recorded at λexc = 521 nm 
following excitation at λem = 345 nm 
6.3.2.3. Visual detection of clomiphene 
A suspension of 2 mg of either MIP or NIP in 400 μl of ACN (5 mg/mL of polymer, 
1.18 × 10−3 M in VCC) was prepared in glass vials. To each vial, a combination of ACN 
and clomiphene stock solution (1.42 × 10−2 M) was added to give a total volume of 500 
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μl and a ratio of VCC to clomiphene ranging from 1:0 to 1:1. The mixtures were 
allowed to stand for 5 min at room temperature and were then placed under the UV 
lamp.  
6.3.3. Synthesis and characterisation of nanogels for drug delivery 
6.3.3.1. Tamoxifen extraction from its citrate form 
Tamoxifen citrate was dispersed in a sodium carbonate solution (10 mM) and extracted 
with dichlorometane. The extracts were dried over MgSO4 and evaporated to dryness. 
6.3.3.2. General synthesis of nanogels 
Tamoxifen imprinted polymers (MIPs) and their non-imprinted counterpart (NIPs) were 
prepared by using the standard protocol of high dilution radical polymerization. Both 
nanogels were systhesised using the same conditions, with the only difference in the 
presence of tamoxifen when MIPs were prepared. The percentage of cross-linking agent 
MBA was fixed at 20%, while the other components were varied as described in chapter 
4, section 4.3.1. The chemicals involved were weighted out and added in a Wheaton 
glass bottle. After sealing the bottle, dry DMSO was added and cycles vacuum/nitrogen 
were performed. The solution was then polymerised for two days at 70°C in oven.    
6.3.3.3. General purification method and reconstitution of nanogels 
After polymerisation the nanogel solution was dialysed against non-distilled water for 
two days, with 2 water exchanges per day. The dialysis membrane used had pore size of 
3500 Daltons. On completion of dialysis the solutions were frozen in liquid nitrogen 
and freeze-dried. White, lightweight powders were obtained and stored in the dark at 
room temperature. 
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6.3.3.4. Particle size characterisation-zetasizer 
Solutions of nanogels were prepared in distilled water at 1 mg/mL and sonicated at 
room temperature for 10 minutes. The samples were then filtered with GHP 0.45μm 
filter (Acrodisc Pall) before being measured with the DLS.  
6.3.3.5. Fluorescence characterisation 
Solution at concentration 1mg/mL were prepared in a total volume of 2mL and 
sonicated at room temperature for 10 minutes. The samples were then filtered with GHP 
0.45μm filter (Acrodisc Pall) before being transferred into high precision quartz cell 
with light path of 10mm and total volume 2mL. Experiments were carried out on Cary 
Eclipse Fluorescence Spectrophotometer, slit:1.5.  λ exc = 360 nm, λ em = 460 nm. 
6.3.3.6. Lower Critical Solution Temperature characterisation 
Solutions of nanogels were prepared in distilled water at 1 mg/mL and sonicated at 
room temperature for 10 minutes. The samples were then filtered with GHP 0.45μm 
filter (Acrodisc Pall) before being transferred into high precision quartz cell with light 
path of 10mm and total volume 1 mL. Cary 100 UV-Vis Spectrophotometer (Agilent 
technologies), equipped with an internal thermostat was employed. The wavelength was 
fixed at 500nm, SBW (spectral bandwidth) was 1nm and the average time 1 seconds. 
The initial and final temperatures were set to 45°C and 70°C, respectively. Data interval 
was 1°C and the rate was 1°C/min.  
6.3.3.7. Establishing the polymerisation of functional monomer 
Solutions of NIP and MIP were prepared at 0.5 mg/mL in a mixture H2O/MeOH and 
stirred for two hours. The two solutions were dialysed against 10% MeOH in H2O, 
changing the dialysis mixture three times in 24 hours, with the last change being 100% 
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H2O. The nanogels solutions were freeze-dried and reconstitute in H2O at 0.5mg/mL, 
sonicated and filtrated with GHP 0.45μm filter (Acrodisc Pall) before being transferred 
before being transferred into high precision quartz cell with light path of 10mm and 
total volume 2 mL for fluorescence readings.      
6.3.3.8. Tamoxifen calibration curve via HPLC  
Two stock solutions of tamoxifen citrate at different concentrations were prepared 
independently by weight in acetonitrile. The solutions were cross-diluted to generate 16 
solutions with different concentrations ranging from 0.035 to 1.77 mM. 20 μl of each 
solution was injected into the HPLC using an eluent of 85:15 methanol to water 
acidified at 0.5% (v/v) with acetic acid at a flow rate of 0.5 mL/min. Tamoxifen eluted 
at approximately 7 minutes and the area under the curve was plotted against 
concentration to form a reference curve. Thus obtaining a value for b in the equation: 
𝑦 = 𝑏𝑥 + 𝑐      Equation 1 
Where y= area under the curve, x = concentration, b = slope of the curve and due to the 
curve passing through the origin c=0. 
6.3.3.9. Analysis of nanogels via HPLC 
The MIP was reconstituted in a mixture of acidic MEOH/ACN 5:5 (pH=3) at a 
concentration 1 mg/mL and stirred overnight to release the drug. The mixture was then 
filtered with a 20 nm PTFE filter to remove the polymer. 20 μl of the solution was 
injected into the HPLC using the same eluent and flow rate as used to obtained the 
calibration curve. 
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6.3.3.10. Tamoxifen calibration curve via photoreaction and UV-Vis 
spectroscopy 
Concentrations of tamoxifen uploaded onto the nanogels were evaluated by means of 
calibration curve established using UV-Vis spectrophotometer after UV irradiation. 
Two stock solutions of tamoxifen at different concentrations were prepared 
independently by weight in MeOH. The solutions were cross-diluted to generate 5 
solutions with different concentrations ranging from 0.067 to 0.538 mM. The solutions 
were transferred into 1mL high precision quartz cells and irradiated for 4 hours with 
ultraviolet lamp (max output 254nm) placed 10cm from the quartz cells. The UV-Vis 
spectrum for each solution was then recorded and the max absorbance of the peak at λabs 
= 360nm was plotted against concentration to form a reference curve.  
𝑦 = 𝑏𝑥 + 𝑐        Equation 1 
Where y= area under the curve, x = concentration, b = slope of the curve and due to the 
curve passing through the origin c=0. 
6.3.3.11. Evaluation of tamoxifen loaded in MIP 
A solution of MIP in MeOH at 1mg/mL was transferred in high precision 1mL high 
precision quartz cell and irradiated for a maximum of 80 minutes with ultraviolet lamp 
(max output 254nm) placed 10cm from the quartz cell. The UV-Vis spectrum of the 
solution was recorded every 20 minutes. The max absorbance of the peak at λabs = 
360nm gave a value for Y in the equation in equation 1and b could be substituted from 
the slope of the calibration curve hence giving the concentration of tamoxifen present in 
the sample. 
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6.4. In vivo experiments, chapter 5 
All fish were maintained at 28.5 °C in ‘fish water’ which is a salt water solution 
comprised of sodium bicarbonate, marine salts and calcium sulphate in a ratio of 
7.5:1.8:0.84 g in 100 L of reverse osmosis (R/O) purified water. All test solutions were 
formed using fish water. Adult fish were maintained on a 14 hrs /10 hrs light dark cycle 
following standard husbandry protocols. Embryos/larvae used for in vivo nanogel 
analysis were maintained at 28.5 °C in the dark. For breeding, fish were housed in pairs 
overnight in 1 L tank equipped with a removal-mating sieve with a mesh net at the 
bottom. Embryos were collected the following morning within 2 hpf and placed in 
separate petri-dishes (n*50/dish). After identification, homozygous CreERt2 (-
Tg(3.5ubb:creERT2,my17:EGFP) males and homozygous loxP (-Tg(3.5ubb:loxP-
EGFP-loxP-mcherry) females adults were separated housed in 5 L tank, one couple per 
tank separated by a clear divisor for easier identification. All procedures were carried 
out under the Animals (Scientific Procedures) Act, 1986, and under local ethical 
guidelines (Queen Mary, University of London). 
6.4.1. Genotyping by breeding 
Female loxP adult zebrafish were crossed with a wild type zebrafish in a 1 L mating 
tank. Embryos were collected, sorted and maintained at 28°C. Each loxP adult was 
identified as homozygous if at 24 hpf the embryos of the produced clutch showed all 
over GFP fluorescence. The loxP who produced embryos who did not show GFP 
fluorescence was discarded. Male CreERt2 adult zebrafish were crossed with a wild type 
zebrafish in a 1 L mating tank. Embryos were collected, sorted and maintained at 28°C. 
CreERt2 adult was identified as homozygous if at 48 hpf the embryos of the produced 
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clutch showed GFP fluorescence in their hearts. The CreERt2 who produced embryos 
who did not show GFP fluorescence in the heart was discarded.  
6.4.2. Tamoxifen - induced switch 
Homozygous loxP female were crossed with and homozygous CreERt2 male to produce 
homozygous ubi:switch. Embryos were collected, sorted and maintained at 28°C. 
Two solutions of 5 and 10μM of tamoxifen citrate were prepared in fish water and 
sonicated. Two wells of a 6-well pate were filled with 10 mL of 5μM tamoxifen, two 
wells were filled with 10 mL of 10μM tamoxifen and the remaining two wells were 
filled with fish water and used as internal plate control. Thirty larvae at 4dpf ubi:switch 
were added in each well containing either tamoxifen solution or fish water. The plates 
were labelled and maintained at 28°C.    
6.4.3. Toxicity and visualisation studies in vivo using ubi:switch 
system 
Homozygous loxP female were crossed with and homozygous CreERt2 male to produce 
homozygous ubi:switch. Embryos were collected, sorted and maintained at 28°C. 
Four 50 mL solutions of 84.7μg/mL and 169.4μg/mL of NIP FM-P7 and MIP FM-P8 
were prepared in fish water. The solutions were sonicated and filtrated over 0.45μm 
GHP filter before transferring 2 mL of each solution in 20 wells of 24-well plates.  The 
other 4 wells of the plate were filled with fresh fish water and served as internal plate 
control. One ubi:switch embryo at 24 hpf was added in each well containing either the 
nanogels solution or fish water. The plates were labelled and maintained at 28°C.    
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6.4.4. Preparation of the fish for imaging 
An average of five fish per each tested solution were transferred into a solution of 4% 
w/v paraformaldehyde in phosphate buffered solution for 2 hours to fix the tissues. The 
fish were then mounted on microscope slides using agarose solution 1% w/v in PBS. 
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Table 1. Summary of nanogels size by distribution, intensity, volume and number. Nanogels samples 
prepared at 0.5 mg/ml in water at pH = 5.5 and filtrated on 0.45 μm filter.  







FM-P2 116.0 ± 44.9 87.28 ± 39.80  61.70 ± 16.59 0.130 
FM-P3 79.91 ± 23.39 55.23 ± 18.89 44.26 ± 12.04 0.296 
FM-P4 68.01 ± 35.48 35.35 ± 18.50 23.91 ± 7.933 0.233 
FM-P5 144.1 ± 49.86 123.3 ± 51.85 86.03 ± 28.78 0.362 
FM-P6 92.01 ± 36.13 64.98 ± 27.86 47.68 ± 14.62 0.207 
FM-P7 75.15 ± 38.38 42.23 ± 21.32 29.63 ± 9.339 0.269 
FM-P8 123.4 ± 37.94 105.5 ± 37.90 81.77 ± 23.63 0.340 
 
  
Fosca Mirata  Appendix 
 
 215 
2) UV-vis Spectra of nanogels 
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3) Non-imprinted nanogel without fluorescence functional monomer. 
 MIP/NIP MBA VCC NIPAM AIBN CM Yield 
Solubility 
in Water 
FM-P9 NIP 20% - 80% 10 % 0.5 % 68 % >1 mg/ml 
 
 
Figure 2. UV-Vis spectrum of a non-imprinted polymer prepared following the same procedure as the set 
of polymers already presented, but without the fluorescent monomer VCC, 1mg/mL in H2O 
 
Figure 3. Fluorescence emission followed irradiation at λ = 360nm of a non-imprinted polymer prepared 
following the same procedure as the set of polymers already presented, but without the fluorescent 
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4) NMR data provided by Mr. Pengfei Liu 
 
Figure 4. Nanogels based on 20% MBA and 80% NIPAM at CM1% after 48hrs polymerisation. From the 
bottom to the top: 1%, 2% and 5% of AIBN, respectively.  
The characteristic peaks of the acrylic group in the NIPAM are highlighted by a 
rectangle, while the residue peak of the MBA is indicated with an ellipse. It is clearly 
shown that after 48hrs, when 5% AIBN was employed, no MBA peaks were visible. 
This suggested the complete polymerisation of the cross-linker, confirming its faster 
kinetic.  
 
 
 
 
 
